

Epidemiologie von Long-Covid: Ein vorläufiger Bericht



Deutsche Kurzfassung zum gleichnamigen
KCE-Bericht



Endbericht

AIHTA Projektbericht Nr.: 135a | ISSN: 1993-0488 | ISSN-online: 1993-0496



HTA Austria
Austrian Institute for
Health Technology Assessment
GmbH

Epidemiologie von Long-Covid: Ein vorläufiger Bericht

Deutsche Kurzfassung zum gleichnamigen
KCE-Bericht

Projektteam

Projektleitung: Belgian Health Care Knowledge Centre (KCE)

Projektbearbeitung: Diego Castanares-Zapatero, MD PhD

Patrice Chalon MSc Biology

Koen Van den Heede RN, MSc, PhD

Deutsche Kurzfassung und Adaption für den österreichischen Kontext:

Sarah Wolf, MSc

Judit Erdös, MA

Begutachtung

Begutachtung der KCE-Übersichtsarbeits:

Sarah Wolf & Ingrid Zechmeister-Koss (AIHTA) <https://aihta.at/page/homepage/de>

Brecht Devleesschauwer (Sciensano) <https://www.sciensano.be/en>

Jean Yombi (UCLouvain) <https://uclouvain.be/en/index.html>

Nathalie Lorent (UZ Leuven) <https://www.uzleuven.be/en>

Karin Rondia (KCE)

Rik Gosselink (UZ Leuven) <https://www.uzleuven.be/en>

Interne Begutachtung der deutschen Kurzversion: Ingrid Zechmeister-Koss, Dr. rer. soc. oec., MA

Melanie Walter, PhD

Korrespondenz: sarah.wolf@aihta.at

Dieser Bericht soll folgendermaßen zitiert werden:

Wolf, S. and Erdös, J. for the Belgian Health Care Knowledge Centre (KCE). Epidemiology of long COVID: a preliminary report. Deutsche Kurzfassung zum gleichnamigen KCE-Bericht. AIHTA Projektbericht Nr. 135a; 2021. Wien: Austrian Institute for Health Technology Assessment GmbH.

Interessenskonflikt

Alle beteiligten AutorInnen erklären, dass keine Interessenskonflikte im Sinne der Uniform Requirements of Manuscripts Statement of Medical Journal Editors (www.icmje.org) bestehen.

Der Originalbericht von KCE ist unter folgendem Link zu beziehen:

https://kce.fgov.be/sites/default/files/atoms/files/2020-04HSR_Long%20COVID_Epidemiology.pdf

IMPRESSUM

Medieninhaber und Herausgeber:

HTA Austria – Austrian Institute for Health Technology Assessment GmbH

Garnisongasse 7/Top 20 | 1090 Wien – Österreich

<https://www.aihta.at/>

Für den Inhalt verantwortlich:

Priv.-Doz. Dr. phil. Claudia Wild, Geschäftsführung

Umschlagfoto: @Halfpoint– stock.adobe.com

Die **AIHTA Projektberichte** erscheinen unregelmäßig und dienen der Veröffentlichung der Forschungsergebnisse des Austrian Institute for Health Technology Assessment.

Die **AIHTA Projektberichte** erscheinen in geringer Auflage im Druck und werden über den Dokumentenserver „http://eprints.aihta.at/view/types/hta_report.html“ der Öffentlichkeit zur Verfügung gestellt.

AIHTA Projektbericht Nr.: 135a

ISSN 1993-0488

ISSN online 1993-0496

© 2021 AIHTA – Alle Rechte vorbehalten

Inhalt

Inhalt	7
Kernergebnisse	9
1 Hintergrund	11
2 Projektziel und Forschungsfragen	12
3 Methode	13
3.1 Systematische Literatursuche	13
3.2 Studienauswahl	13
3.3 Datenextraktion und Datensynthese	14
4 Ergebnisse	17
4.1 Eingeschlossene Studien	17
4.2 Berichtete Long-Covid Prävalenzen für bestimmte Nachbeobachtungszeiträume	17
4.3 Berichtete Long-Covid Prävalenzen für bestimmte Organsysteme oder Symptome	20
4.4 Sterblichkeit und Krankenhauswiederaufnahme	21
4.5 Am häufigsten berichtete Long-Covid Symptome	22
4.6 Auswirkungen auf das tägliche Leben	22
4.7 Potentielle Risikofaktoren	23
5 Diskussion	25
6 Schlussfolgerungen	31
7 Literatur	33
8 Anhang	36
8.1 Extraktionstabellen	36
8.2 KCE-Bericht	49

Abbildungsverzeichnis

Abbildung 3-1: Darstellung des Auswahlprozesses (PRISMA Flow Diagramm)	14
Abbildung 4-1: Studienergebnisse zu den Long-Covid Prävalenzen je nach Versorgungsebene während der akuten SARS-CoV-2 Infektion	19

Tabellenverzeichnis

Tabelle 3-1: Population-Exposure-Outcome-Design (PEOD) – Ein- und Ausschlusskriterien	13
Tabelle 8-1: Ergebnisse zu den Long-Covid Prävalenzen (Englisch)	36
Tabelle 8-2: Ergebnisse zu den Organ- bzw. Symptom-spezifischen Long-Covid Prävalenzen (Englisch)	40
Tabelle 8-3: Ergebnisse zu den Häufigkeiten der Symptome unter den Long-Covid Betroffenen (Englisch) .	42
Tabelle 8-4: Ergebnisse zu den Risikofaktoren von Long-Covid (Englisch)	46

Abkürzungsverzeichnis

aOR.....	Adjusted odds ratio
COVID-19	Coronavirus Disease-19
DLCO	Diffusing capacity of the lungs for carbon monoxide (Diffusionskapazität der Lunge für Kohlenmonoxid)
ED.....	Emergency department (Notaufnahme)
ICD-10	International Statistical Classification of Diseases and Related Health Problems (Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme)
ICU	Intensive care unit (Intensivstation)
IQR	Interquartile range (Interquartilsbereich)
ITU	Intensive therapy unit (Intensivtherapie-Einheit)
KCE	Belgian Health Care Knowledge Centre
m.....	Month (Monat)
MERS	Middle East Respiratory Syndrom
n	Number (Anzahl)
NICE.....	National Institute for Health and Care Excellence, United Kingdom
NIHR	National Institute for Health Research, United Kingdom
ONS	Office for National Statistics, United Kingdom
OR.....	Odds ratio
Pat.....	Patient*innen
PCR.....	Polymerase chain reaction (Polymerase-Kettenreaktion)
PHOSP-COVID	Post-hospitalisation COVID-19 study
PTSD	Post-traumatic stress disorder (Posttraumatische Belastungsstörung)
REACT-LC.....	Research into the Longer Term Effects of COVID-19 in Non-Hospitalised Individuals study
Sars-Cov-2	Severe acute respiratory syndrome coronavirus-2
UK	United Kingdom
USA	United States of America

Kernergabenisse

Aktuell verfügbare Datenlage zur Epidemiologie von Long-Covid unzureichend für konkrete Schlussfolgerungen:

Unterschiede in den Long-Covid Prävalenzen zwischen hospitalisierten und nicht-hospitalisierten Covid-19 Patient*innen und für verschiedene Nachbeobachtungszeiträume:

- 1-3 Monate nach der akuten SARS-CoV-2 Infektion: **5-36 %** der ambulant behandelten Patient*innen versus **39-72 %** der stationär behandelten Patient*innen
- 3-6 Monate danach: **2-21 %** versus **51-68 %**
- >6 Monate danach: **13-25 %** versus **bis zu 60 %**

Die am häufigsten berichteten Symptome unter den Long-Covid Patient*innen zwischen 1-3 sowie 3-6 Monaten nach der akuten SARS-CoV-2 Infektion sind:

nach 1-3 Monaten:	nach 3-6 Monate:
■ Müdigkeit/Erschöpfung (16-98 %)	■ Müdigkeit/Erschöpfung (16-78 %)
■ Kurzatmigkeit (10-93 %)	■ kognitive Beeinträchtigungen (13-55 %)
■ Kopfschmerzen (9-91 %)	■ Atemwegsprobleme (16-21 %)

Zusätzlich kam es bei manchen Long-Covid Patient*innen zu **Beeinträchtigungen bei alltäglichen Aktivitäten** und zu einer **verminderten sozialen Teilhabe** (z.B. Arbeitsunfähigkeit).

Potentielle aber nicht bestätigte Risikofaktoren, die das Auftreten von Long-Covid Symptomen begünstigen können, sind **das weibliche Geschlecht** und eine **hohe Anzahl an Symptomen während der akuten Infektionsphase**. Ein höheres Alter als Risikofaktor für Long-Covid bleibt umstritten.

Mangelhafte Qualität der eingeschlossenen Studien limitiert die Aussagekraft:

- **Keine einheitlich gültige Definition zu Long-Covid → unterschiedliche Ursachen möglich:** Fehlende Unterscheidung in den Studien zwischen Long-Covid Symptomen durch Organschäden und Symptomen unabhängig von Organschäden.
- **Unterschiede in den Patient*innen-Populationen** hinsichtlich der Diagnose der aktuellen Covid-19 Infektion (bestätigt versus vermutet), des Schweregrades der aktuellen Infektion (hospitalisiert versus nicht-hospitalisiert) und demographischer Merkmale.
- **Methodische Limitationen** hinsichtlich der Studiendesigns, den Datenerhebungen, der Stichprobengrößen, den Nachbeobachtungszeiträumen & den Loss-to Follow-up.

Aufgrund fehlender spezifischer Diagnostik von Long-Covid ist die **Abgrenzung von Long-Covid Symptomen zu ähnlichen Symptomen anderer Erkrankungen /Ursachen** (z.B. Post-Intensive Care Syndrome, Chronic-Fatigue Syndrom oder Depression als Folge der Lock-Downs) **schwierig**.

Unklar bleibt, inwieweit es sich bei **Long-Covid** um **neuartige Langzeitsymptome** (in Art und Dauer) im Vergleich zu den Langzeitsymptomen anderer schwerer (respiratorischer) Infektionserkrankungen handelt.

Weitere Forschung ist notwendig zu präzisieren **Definitionen von Long-Covid** inklusive dessen **Ursachen**, zur **Entwicklung der Symptome** im Zeitverlauf & zur **Häufigkeit** der Symptome **bei asymptomatischen Covid-19 Patient*innen**.

Empfehlungen für zukünftige Forschungsinitiativen zu Long-Covid:

- Ausreichend große, prospektive – wenn möglich – vergleichende Kohortenstudien
- Datenerhebung anhand validierter (wenn möglich objektiver) Tests an repräsentativ gewählten Teilnehmer*innen, nicht: Selbstbeobachtungen

Offenlegung möglicher Unsicherheiten in den Daten bei der Kommunikation von Long-Covid Prävalenzen erforderlich.

1 Hintergrund

Vorbemerkung

Die vorliegende deutsche Kurzfassung basiert auf einer vorläufigen Übersichtsarbeit zur Epidemiologie von Long-Covid des Belgian Health Care Knowledge Centre (KCE), dem belgischen Institut für Health Technology Assessment. Der englische Originalbericht des KCE wird als „Working Paper“ geführt und bis zur geplanten finalen Veröffentlichung im Oktober 2021 regelmäßig aktualisiert. Dies impliziert, dass sich die dargelegten Ergebnisse im Laufe der Zeit ändern können. Das AIHTA (SW, IZ) war Reviewer des ersten Updates der im Januar 2021 veröffentlichten Version von KCE [1] und brachte sich in die Datenpräsentation sowie -interpretation ein.

Darüber hinaus verfasste das AIHTA (SW, JE, MW, IZ) eine deutsche Kurzfassung des KCE-Berichts, die neben der Übersetzung der Kernergebnisse auch inhaltliche Ergänzungen umfasst. So wurden z.B Österreich-spezifische epidemiologische Daten (soweit vorhanden) hinzugefügt. Darüber hinaus wurden Diskussionsansätze des Originalberichts weiter ausgeführt bzw. neue Diskussionspunkte ergänzt.

Krankheitsbild

Nach mehr als einem Jahr der Covid-19 Pandemie gewannen auch die möglichen Langzeitfolgen einer akuten SARS-CoV-2 Infektion an Bedeutung. Immer mehr Hinweise deuten darauf hin, dass es nach der Genesung der akuten Infektion zu langanhaltenden Symptomen kommen kann bzw. Symptome nach mehreren Monaten wieder auftreten können. Diese werden vor allem unter dem Begriff Long-Covid zusammenfasst. In der Literatur sind aber auch andere Begriffe wie z.B. „Post-Covid Zustand“, „Langzeit-Covid“, „Post-Covid Syndrom“, „Post-Akute Covid-Symptome“ oder „chronisches Covid“ zu finden. Generell umfasst Long-Covid eine große Bandbreite und Vielfalt an Symptomen, darunter z.B. Kurzatmigkeit, Bluthochdruck, Müdigkeit, Geruchs- und Geschmacksstörungen oder psychische Beschwerden, wie Depressionen. In schweren Fällen können auch Organschäden z.B. am Herzen, der Lunge oder der Leber vorkommen [2, 3]. Die Long-Covid Patient*innen können unter einzelnen oder mehreren Symptomen gleichzeitig leiden, wobei sich im Laufe der Zeit auch neue Symptome entwickeln können. Erste internationalen Daten zeigten auch, dass Personen aller Altersgruppen und unabhängig vom Schweregrad der akuten SARS-CoV-2 Infektion langfristige Symptome erleiden können [4, 5].

Die genauen Ursachen und Risikofaktoren, welche zur Entwicklung von Long-Covis Symptomen führen, sind derzeit nicht bekannt. Aufgrund der großen Vielfalt unterschiedlichster Symptome, ist anzunehmen, dass mehrere Ursachen miteinander verwoben sind. Das KCE unterscheidet z.B. zwei Kategorien [6]:

- Langfristige Symptome infolge von Organschäden während der akuten Infektionsphase (z.B. Schädigungen an der Lunge nach einer längeren künstlichen Beatmung)
- Persistierende bzw. residuale Symptome ohne Nachweis von Organschäden

**deutsche Kurzfassung
einer Übersichtsarbeit
des belgischen
Forschungsinstituts
KCE
zur Epidemiologie von
Long-Covid**

**deutsche Kurzfassung
mit inhaltlichen
Ergänzungen**

**Fokus vermehrt auf
Langzeitfolgen einer
Covid-19 Erkrankung**

**Long-Covid meist
verwendete Begriff,
der zahlreiche
unterschiedliche
Symptome
zusammenfasst**

**mehrere langfristige
Symptome zeitgleich
auch bei jüngeren
Personen bzw. nach
milden Covid-19
Verläufen möglich**

**genaue Ursachen nicht
bekannt – KCE
unterscheidet
zwischen Symptomen
durch Organschäden
versus Symptomen
ohne Organschäden**

Darüber hinaus muss Long-Covid von anderen Erkrankungen differenziert gesehen werden. So ist Long-Covid beispielsweise vom „Post-Intensiv Care Syndrom“ abzugrenzen, welches ähnliche langfristige körperliche, psychische und kognitive Beeinträchtigungen bei Patient*innen, die zuvor auf einer Intensivstation behandelt wurden, beschreibt [6].

Derzeit gibt es keine international gültige Definition, ab welchem Zeitpunkt nach einer akuten SARS-CoV-2 Infektion von Long-Covid Symptomen gesprochen werden kann. Im Dezember 2020 schlug das britische Forschungsinstitut „National Institute for Health and Care Excellence“ (NICE) eine Definition für Long-Covid vor, welche alle Symptome, die nach der akuten Infektion auftreten und mit keiner anderen Ursache in Zusammenhang gebracht werden können, umfasst. Die Definition unterscheidet dabei zwischen unterschiedlichen Zeitpunkten nach Krankheitsbeginn [7]:

- „Anhaltendes symptomatisches Covid-19“: Patient*innen, die zwischen vier und 12 Wochen nach der akuten SARS-CoV-2 Infektion weiterhin Symptome haben
- „Post-Covid-19 Syndrom“: Patient*innen, die auch nach 12 Wochen weiterhin Symptome aufweisen

Dem Updatebericht des britischen Statistikinstituts (Office for National Statistics, ONS) vom April 2021 zufolge, weisen rund 14 % der Covid-19 Patient*innen Symptome für mindestens 12 Wochen nach der akuten Infektion auf. Demzufolge wurde geschätzt, dass im März 2021 mehr als eine Million Menschen der gesamten britischen Bevölkerung von anhaltenden Covid-19 Symptomen betroffen sind [8].

Für Österreich würde das bedeuten, dass bei einer Anzahl von insgesamt 647.000 registrierten Covid-19 Fällen (Stand 08.06.2021) mit ca. 90.580 Long-Covid Patient*innen, die für mindestens 12 Wochen langanhaltende Symptome aufweisen, zu rechnen ist. Aufgrund des zu erwartenden Anstiegs an zukünftigen Long-Covid Fällen sind neben den Beeinträchtigungen im alltägliche Leben für die Patient*innen und deren Familien auch gesellschaftliche Konsequenzen zu bedenken [4, 5].

Abgrenzung zu anderen Erkrankungen mit ähnlichen Symptomen

bisher keine einheitliche Definition; NICE unterscheidet zwischen anhaltenden Covid-19 Symptomen (4-12 Wochen nach akuter Phase) & Post-Covid-19 Syndrom (>12 Wochen)

**Prävalenz rund 14 % bis 12 Wochen danach
→ 1 Million Long-Covid Patient*innen (Pat.) in UK (März 2021)**

**Schätzung: ca. 90.580 Long-Covid Pat. in Österreich (Juni 2021)
→ gesellschaftliche Konsequenzen**

2 Projektziel und Forschungsfragen

Ziel des KCE-Berichts war es, einen Überblick über die Prävalenz, Symptomhäufigkeit und Risikofaktoren von Long-Covid Symptomen zu geben und die vorhandene Evidenz zusammenzufassen. Aus dem Projektziel ergaben sich die folgenden drei Forschungsfragen:

- 1) Wie hoch ist die Prävalenz von Long-Covid nach einer bestätigten oder vermuteten SARS-CoV-2 Infektion?
- 2) Mit welchen Symptomen geht Long-Covid einher und wie häufig kommen diese vor?
- 3) Was sind mögliche Risikofaktoren für die Entwicklung von Long-Covid im Vergleich zur akuten SARS-CoV-2 Infektion?

**Projektziel:
Zusammenfassung der Long-Covid Prävalenz, Symptomhäufigkeit und Risikofaktoren**

3 Methode

3.1 Systematische Literatursuche

Vom 03. Februar bis 20. Mai 2021 wurde eine systematische Suche in elf Datenbanken durchgeführt. Die in der Übersichtsarbeit präsentierten Ergebnisse basieren somit auf der zum Zeitpunkt der Erstellung des Berichts (27.05.2021) verfügbaren Evidenz zu Long-Covid. Insgesamt konnten 10.445 Hits durch die systematische Suche identifiziert werden. In einer erweiterten Handsuche wurden 19 zusätzliche potentiell relevante Artikel identifiziert.

**systematische Suche
in 11 Datenbanken
durchgeführt: 10.445
Hits**

Weitere Informationen zur genauen Suchstrategie sind in der aktuellen Version des KCE-Berichts (https://kce.fgov.be/sites/default/files/atoms/files/2020-04HSR_Long%20COVID_Epidemiology.pdf) beschrieben.

3.2 Studienauswahl

Die Auswahl relevanter Studien erfolgte in einem mehrstufigen Prozess: In einem ersten Schritt wurden die identifizierten Titel und die dazugehörigen Abstracts unter Berücksichtigung des „Population-Exposure-Outcome-Design“ (PEOD) und den vorab definierten Ausschlusskriterien gescreent (siehe Tabelle 3-1). Irrelevante Studien wurden verworfen und für die verbleibenden Studien wurde die Volltexte gesichtet. Aufgrund der Aktualität des Themas wurde dabei sowohl in Volltextdatenbanken als auch Preprint-Registern gesucht.

**mehrstufiger Prozess
für die Studienauswahl
unter
Berücksichtigung der
vorab definierten Ein-
& Ausschlusskriterien**

Tabelle 3-1: Population-Exposure-Outcome-Design (PEOD) – Ein- und Ausschlusskriterien

	Einschlusskriterien	Ausschlusskriterien
Population	Personen mit Long-Covid Symptomen, die länger als 4 Wochen nach der akuten Infektion angehalten haben (≥ 4 und >12 Wochen) <i>mit entsprechendem Nenner in den Studien berichtet*</i>	-
Exposition	Bestätigte Covid-19 Erkrankung (PCR, Antikörper) oder nicht bestätigte Covid-19 Erkrankung (aber hoher klinischer bzw. radiologischer Verdacht)	-
Outcome	<ul style="list-style-type: none">■ Allgemeine bzw. Organ-/Symptom-spezifische Prävalenzen■ Die am häufigsten berichteten Symptome unter Long-Covid Betroffenen■ Konsequenzen im Alltag■ Risikofaktoren für Long-Covid	-
Design	<ul style="list-style-type: none">■ $n \geq 250$ eingeschlossene Patient*innen■ Studien aus Europa und den USA■ Systematischer Review, Kohortenstudie, Querschnittsuntersuchung**	Fallberichte, Fallserien, Mixed-Method-Ansatz (qualitative Untersuchungen)
Sprache	Englisch, Französisch, Niederländisch, Spanisch	Andere Sprachen

Abbreviations: PCR - Polymerase chain reaction, n - number

* Für die Prävalenzen: Nenner entspricht den akuten Covid-19 Fällen. Für die Bewertung der am häufigsten berichteten Long-Covid Symptome: Nenner entspricht der Long-Covid Fälle; **Für Risikofaktoren: Studien mit adjustierten Analysen.

Die Anzahl der insgesamt 10.464 Treffer wurde nach Entfernung der Duplikate auf 6.619 reduziert, wovon insgesamt 6.577 Artikel im Zuge des Titel- und Abstract-Screenings ausgeschlossen wurden. Von den 42 gesichteten Volltexten wurden weitere 13 ausgeschlossen. Somit erfüllten 28 Studien (in 29 Publikationen) die vorab definierten Einschlusskriterien und wurden für die Analyse eingeschlossen (siehe Abbildung 3-1). Achtzehn Studien sind seit der ersten Berichtsversion vom Januar 2021 neu hinzugekommen. Eine Querschnittserhebung, die in der Berichtsversion vom Jänner 2021 eingeschlossen war, wurde in diesem ersten Update des KCE ausgeschlossen. Der Grund für den Ausschluss war, dass die Studie die angepassten Einschlusskriterien nicht mehr erfüllte (Personen mit anhaltenden Symptomen **2-3 Wochen** nach dem positiven SARS-CoV-2 Test).

**von 10.464 Hits
insgesamt 28 Studien
bzw. 29 Publikationen
eingeschlossen, davon
18 Studien seit Januar
2021 neu
dazugekommen**




Abbildung 3-1: Darstellung des Auswahlprozesses (PRISMA Flow Diagramm)

3.3 Datenextraktion und Datensynthese

Die Daten der 28 eingeschlossenen Studien wurden mit Hilfe von Datenextraktionsstabellen extrahiert. Basierend auf den vorab definierten Forschungsfragen wurde für jedes Unterkapitel eine eigene Extraktionstabelle erstellt (siehe Kapitel 8.1):

**eigene
Datenextraktions-
tabelle pro
Unterkapitel**

- Long-Covid Prävalenzen für bestimmte Nachbeobachtungszeiträume (1-3 Monate; 3-6 Monate, >6 Monate)
- Long-Covid Prävalenzen für bestimmte Organsysteme oder Symptome
- Die am häufigsten berichteten Symptome unter den Long-Covid Betroffenen
- Risikofaktoren für das Auftreten von Long-Covid Symptomen

Bei der Beantwortung der Fragestellungen wurde zwischen jenen Studien, für denen Analyse *alle Covid-19* Patient*innen herangezogen wurden, und den Studien, bei denen ausschließlich *Long-Covid* Patient*innen für die Analyse herangezogen wurden, differenziert. Letztere umfassen lediglich Patient*innen mit langanhaltenden Symptomen nach einer akuten SARS-CoV-2 Infektion und wurden demnach nicht für die Bestimmung der Long-Covid Prävalenzen herangezogen. Sie dienten der Beschreibung der am häufigsten berichteten Long-Covid Symptome.

in Abhängigkeit der berücksichtigten Pat.-Population Studien nur für bestimmte Fragestellungen herangezogen

4 Ergebnisse

4.1 Eingeschlossene Studien

Bei den 28 eingeschlossenen Studien handelte es sich um 22 Kohortenstudien [9-29] und sechs Querschnittsstudien [8, 30-35]. Vier der Kohortenstudien enthielten Kontrollgruppen mit Matching (z.B. Vergleichsgruppen zu Influenza bzw. zu anderen respiratorischen Erkrankungen oder Vergleichsgruppen aus den Jahren 2019 bzw. 2020) [9, 18, 23, 28]. Zwei Publikationen beschrieben die gleiche Studienpopulation [32, 35] und bei fünf Studien handelte es sich um Preprints, die sich noch im Review befinden [10, 13, 16, 30, 31]. Insgesamt verfolgten 15 Studien einen Nachbeobachtungszeitraum von einem bis zu drei Monaten, zehn Studien einen Zeitraum zwischen drei und sechs Monaten und drei Studien einen Zeitraum von mehr als 6 Monaten, wobei sieben Studien zwei der definierten Nachbeobachtungszeiträume verfolgten [8, 10, 15, 17, 26, 27, 30]. Die Stichprobengrößen variierten zwischen 256 und 236.379 Patient*innen. Der Großteil der eingeschlossenen Studien waren britische oder US-amerikanische Studien. Die anderen Studien waren aus unterschiedlichen europäischen Ländern, darunter Dänemark, Schweden, Norwegen, Niederlande, Belgien, Frankreich, Deutschland, die Schweiz, Italien und Spanien.

Hinsichtlich der berücksichtigten Populationen schlossen sechs Studien ausschließlich Patient*innen ein, die während der akuten SARS-CoV-2 Infektion hospitalisiert worden waren [9, 16, 25, 26, 29, 33]. Im Gegensatz dazu wurden in fünf Studien ausschließlich Patient*innen eingeschlossen, die ambulant behandelt wurden [10, 11, 17, 21, 34]. Die übrigen 18 eingeschlossenen Studien schlossen sowohl ambulant als auch stationär behandelte Patient*innen ein.

Die Mehrheit der Studien schloss Patient*innen ein, die zum Zeitpunkt der akuten Infektion Symptome aufwiesen. In drei Studien war ein kleiner Teil der Studententeilnehmer*innen Personen, die während der akuten SARS-CoV-2 Infektion asymptomatisch blieben [8, 30, 31]. In den meisten Studien wurden die Symptome von den Patient*innen selbst berichtet und mittels Telefonanrufe [11, 16, 22, 24, 25, 29, 33] oder elektronische Fragebögen [8, 10, 12-14, 17, 20, 21, 30-32, 34-36] erhoben. In sechs Studien wurden die Symptome (auch) im Rahmen einer Nachuntersuchung von einem Arzt/einer Ärztin erhoben [15, 19, 21, 25-27].

28 Studien, davon 22 Kohortenstudien & 6 Querschnittsstudien

**Stichprobengrößen:
277-236.379 Pat.**

meist britische & US-amerikanische Studien, jedoch auch aus der Schweiz & aus Deutschland

6 Studien zu hospitalisierten Pat. & 5 Studien zu ambulant behandelten Pat., 18 zu beiden Populationen

die meisten Pat. mit symptomatischen Covid-19 Verläufen

Großteil der Symptome von den Pat. selbst berichtet

4.2 Berichtete Long-Covid Prävalenzen für bestimmte Nachbeobachtungszeiträume

Studien mit Nachbeobachtungszeiträumen zwischen 1 und 3 Monaten

Neun der 28 eingeschlossenen Studien berichteten über die Long-Covid Prävalenz zwischen einem und drei Monaten nach der akuten Infektion. Dabei handelte es sich um sechs Kohortenstudien [10, 11, 15-17, 22] und drei Querschnittserhebungen [8, 30, 33]. Insgesamt waren drei der neun Studien lediglich als Preprint veröffentlicht [10, 16, 30].

9/28 Studien für Prävalenzen zwischen 1-3 Monate herangezogen

Alle neun herangezogenen Studien basierten auf selbstberichteten Symptomen, die mittels telemedizinischer Überwachung z.B. durch eine COVID-App, Telefon- oder Online-Umfragen oder bei Arztbesuchen erhoben wurden. Die akute SARS-CoV-2 Infektion galt bei allen Patient*innen dieser neun Studien mittels PCR- oder Antigentest als bestätigt. Drei der neun Studien schlossen nicht-hospitalisierte Patient*innen ein [10, 11, 17], während drei andere Studien hauptsächlich stationär behandelte Patient*innen einschlossen [15, 16, 33]. Die übrigen drei Studien schlossen ambulante Patient*innen zusammen mit einem begrenzten Anteil von hospitalisierten Patient*innen (<10 %) ein [8, 22, 30].

Insgesamt ergaben die Studien, dass unter den Covid-19 Patient*innen 5,2 bis 36 % bis zu drei Monate nach der akuten Infektion noch Symtome aufwiesen. In den Studien, die hospitalisierte Covid-19 Patient*innen einschlossen, reichten die Prävalenzen von 39 bis 71,8 % [15, 16, 33]. Für Patient*innen, die während der akuten Infektion nicht-hospitalisiert worden waren bzw. in den Studien, die lediglich zu einem geringen Anteil hospitalisierte Patient*innen eingeschlossen haben, wurden niedrigere Prävalenzen (5,2-36,1 %) berichtet [8, 10, 11, 17, 22, 30].

Studien mit Nachbeobachtungszeiträumen zwischen 3 und 6 Monaten

Elf der 28 eingeschlossenen Studien berichteten über die Long-Covid Prävalenz zwischen drei und sechs Monaten, darunter neun Kohortenstudien [10, 15, 17, 19, 21, 25-27, 29] und zwei Querschnittserhebungen [8, 30]. Von diesen neun Studien wurden fünf bereits zur Bestimmung der Prävalenz nach einem bis drei Monaten herangezogen [8, 10, 15, 17, 30]. Insgesamt waren zwei Studien lediglich als Preprint erhältlich [10, 30].

Alle herangezogenen Studien basierten auf selbstberichteten Symptomen, welche z.B. mittels Telefonanrufen, Online-Fragebögen, App-Monitoring oder bei Arztbesuchen erhoben wurden. Drei der neun Studien schlossen nur hospitalisierte Patient*innen ein [25, 26, 29] und drei weitere Studien berücksichtigten lediglich ambulant behandelte Patient*innen [10, 17, 21]. Die übrigen Studien schlossen eine gemischte Population ein (ambulante und hospitalisierte Patient*innen).

Die in den Studien berichteten Ergebnisse zu den Long-Covid Prävalenzen zwischen drei und sechs Monaten nach einer akuten SARS-CoV-2 Infektion waren sehr heterogen und reichten insgesamt von 2,3 bis 68 %. Bei den *Covid-19* Patient*innen, die während der akuten Erkrankung nicht-hospitalisiert worden waren, variierten die Prävalenzen zwischen 2,3 und 21,4 % [8, 10, 17, 21, 27, 30], wohingegen die Prävalenzen für die hospitalisierte Patient*innen-Gruppe höher ausfielen (51-68 %) [19, 25, 26].

Studien mit Nachbeobachtungszeiträumen länger als 6 Monate

Nur vier Kohortenstudien der insgesamt 28 identifizierten Studien verfolgten einen Nachbeobachtungszeitraum von mehr als sechs Monaten [21, 26, 27, 36]. Zwei von diesen drei Studien wurden bereits zur Bestimmung der Prävalenz zwischen drei und sechs Monaten herangezogen [26, 27].

Zwar scheinen sich Long-Covid Symptome im Laufe der Zeit zu verbessern (siehe Abbildung 4-1), dennoch zeigten die Studien, dass auch sechs Monate nach Beginn der akuten Infektion immer noch 12,8 bis 25 % der ambulant behandelten *Covid-19* Patient*innen zumindest ein bestehendes Symptom aufwiesen. In der Gruppe der hospitalisierten Patient*innen betrug die Prävalenz nach sechs Monaten noch bis zu 60 % [21, 26, 27, 36].

Einen detaillierteren Überblick zu den berichteten Long-Covid Prävalenzen findet sich im Anhang (Tabelle 8-1).

alle 9 Studien zu selbstberichteten Symptomen bei bestätigter Covid-19 Erkrankung

ca. 5-36 % ambulant behandelter Pat.
versus ca. 39-72 % hospitalisierter Pat.
Symptome ≤3 Monate

11/28 Studien für Prävalenzen zwischen 3-6 Monate herangezogen

alle 9 Studien mit selbstberichteten Symptomen

ca. 2-21 % ambulant behandelter Pat.
versus ca. 51-68 % hospitalisierter Pat.
Symptome 3-6 Monate

4/28 Studien für Prävalenzen >6 Monate herangezogen

ca. 13-25 % ambulant behandelter Pat.
versus ≤60 % hospitalisierter Pat.
Symptome >6 Monate

Überblick der Studienergebnisse im Anhang




Abbildung 4-1: Studienergebnisse zu den Long-Covid Prävalenzen je nach Versorgungsebene während der akuten SARS-CoV-2 Infektion

4.3 Berichtete Long-Covid Prävalenzen für bestimmte Organsysteme oder Symptome

Insgesamt konnten 14 Kohortenstudien [9, 12-14, 18-21, 23-26, 28, 29, 36] und eine Querschnittsstudie [8] für die Zusammenfassung der Organ- bzw. Symptom-spezifischen Prävalenzen herangezogen werden. Die Nachbeobachtungszeiten der 14 Studien variierten von bis zu drei bis über sechs Monate. Vier Studien berichteten Prävalenzen zu mentaler Gesundheit [14, 18, 23, 36] und fünf Studien zu Geruchs- oder Geschmacksstörungen [12, 13, 20, 24, 26]. Fünf Studien legten die Prävalenzen einzelner Symptome dar [8, 19, 25, 26, 28, 36].

Mentale Gesundheit

Die Prävalenzen der psychischen Long-Covid Symptome waren sehr heterogen. So berichtete eine Studie, dass bei *Covid-19* Patient*innen, die während der akuten SARS-CoV-2 Infektion die Notaufnahme aufgesucht hatten, einen Monat später häufig psychische Symptome festgestellt wurden (55,7 %) [14]. Eine andere Studie berichtete, dass Angstzustände bzw. Stimmungsschwankungen (vor allem Depressionen) bei 4,7 % bzw. 2 % der Patient*innen bis zu drei Monate nach Beginn der Erkrankung auftraten [18]. In einer weiteren Studie wurden Angstzustände bei 7,1 % aller *Covid-19* Patient*innen und bei 9,7 % der *intensiv-medizinisch behandelten* Patient*innen auch sechs Monate nach Krankheitsbeginn erfasst [23]. In der vierten Studie, die zu einem kleinen Teil (19 %) auch hospitalisierte Covid-19 Patient*innen berücksichtigte, wurde bei 26 % der *Covid-19* Patient*innen Depressionen mindestens sechs Monate nach der akuten Infektionsphase diagnostiziert [36].

Geruchs- oder Geschmacksstörungen

Es konnte lediglich eine Studie identifiziert werden, die sich die Häufigkeit der Geruchsstörungen innerhalb einer *Covid-19* Patient*innen-Gruppe anschaut hat. Diese Kohortenstudie ergab, dass bei 9 % der hospitalisierten Covid-19 Patient*innen auch acht Monate nach Krankheitsbeginn noch Geruchsstörungen beobachtet wurden [25]. Im Gegensatz dazu berichteten vier weitere Studien die Häufigkeit von Geruchsstörungen bei *Covid-19* Patient*innen, die bereits während der akuten Infektion unter Geruchsstörungen gelitten hatten: In drei prospektiven Kohortenstudien gaben 26 bis 42 % der ambulant behandelten Patient*innen anhaltende Geruchsstörungen ein bis drei Monate nach Krankheitsbeginn an [13, 20, 24]. In einer der drei Kohortenstudien berichteten 33,8 % der Patient*innen zusätzliche Geschmacksstörungen [13]. In der vierten Studie wurden die Geruchsstörungen ambulant behandelter Patient*innen mittels validierter Tests erhoben. In dieser Studie reduzierten sich die Prävalenzen für Geruchsstörungen von 15,3 % zwei Monate nach Krankheitsbeginn auf 4,7 % nach sechs Monaten [12].

**14/28 Studien zu
Organ- bzw. Symptom-
spezifischen Long-
Covid Prävalenzen**

**4 Studien: heterogene
Prävalenzen zu
psychischen Long-
Covid Symptomen
abhängig vom
Nachbeobachtungs-
zeitraum &
Schweregrad der
Erkrankung:
ca. 2-26 %**

**5 Studien:
Geruchsstörungen bei
hospitalisierten Pat.:
9 %**

**Geruchs- bzw.
Geschmacks-
störungen bei
ambulant behandelten
Pat.: ca. 15-42 bzw.
34 %**

**im Laufe der Zeit
abnehmend**

Einzelne Long-Covid Symptome

Fünf Studien berichteten heterogene Prävalenzen zu einzelnen Long-Covid Symptomen für unterschiedliche Patient*innen-Populationen und/oder Nachbeobachtungszeiträume:

So reichten die Prävalenzen für das Long-Covid Symptom „Müdigkeit/Erschöpfung“ von insgesamt 4 % (nach 8 Monaten) [26] bis hin zu 55 % (nach >6 Wochen) [36]. Bei hospitalisierten *Covid-19* Patient*innen variierten die Prävalenzen zwischen 44 % (nach 3 Monaten) [19] und 31 % (nach 4 Monaten) [25].

Ebenso variierten die Prävalenzen für das Long-Covid Symptom „Kurzatmigkeit“ zwischen 33,3 % (nach 3 Monaten) [19] und 16,3 % (nach 4 Monaten) [25] bei der hospitalisierten *Covid-19* Patient*innen-Gruppe.

Weitere Long-Covid Symptome wurden lediglich in einer Studie berichtet. So ergab eine Studie bei 10,9 % der *Covid-19* Patient*innen einen bestehenden Husten, bei 10,1 % bestehende Kopfschmerzen und bei 7,7 % bestehende Muskelschmerzen mindestens fünf Wochen nach Krankheitsbeginn [8]. Bei den *Covid-19* Patient*innen, die während der akuten Infektion stationär behandelt wurden, berichtete eine Studie vier Monate nach der akuten Infektion bei 17,5 % der Patient*innen auftretende Gedächtnisschwierigkeiten [25].

Darüber hinaus ergab eine Studie, dass 14 % der *Covid-19* Patient*innen vier Monate nach der akuten Infektion mindestens eine neue Art von klinischen Folgeerscheinungen vorwiesen, die eine medizinische Versorgung erforderte [28].

**heterogene
Prävalenzen zu:**

**Müdigkeit/
Erschöpfung:
ca. 4-55 % (2 Studien)**

**Kurzatmigkeit:
ca. 16-33 % (2 Studien)**

**jeweils 1 Studie:
Husten: ca. 11 %
Kopfschmerzen:
ca. 10 %
Muskelschmerzen:
ca. 8 %**

**1 Studie: 14 %
mindestens 1 neues
klinisches Symptom**

4.4 Sterblichkeit und Krankenhauswiederaufnahme

Insgesamt zwei der 28 eingeschlossenen Studien berichteten Prävalenzen zur Sterblichkeit und Krankenhauswiederaufnahme nach einer SARS-CoV-2 Infektion [9, 29]. Die Nachbeobachtungszeiträume der beiden Studien lagen zwischen vier und sechs Monaten.

Die retrospektive Kohortenstudie mit gematchten Kontrollgruppen berichtete, dass beinahe ein Drittel der hospitalisierten *Covid-19* Patient*innen erneut ins Krankenhaus eingewiesen werden musste und 12,3 % der Patient*innen nach der Entlassung starben. Diese Proportionen waren höher in den Covid-19 Fällen als in den gematchten Kontrollgruppen aus einem Pool von etwa 50 Millionen Engländer*innen, von denen die persönlichen und klinischen Merkmale aus den elektronischen Gesundheitsakten für die letzten zehn Jahre entnommen worden waren [9]. Im Vergleich dazu berichtete die zweite Studie von 20,1 % der *Covid-19* Patient*innen, die innerhalb von sechs Monaten nach der akuten SARS-CoV-2 Infektion erneut die Notaufnahme aufsuchten. Die wichtigsten Faktoren, die unabhängig voneinander mit der Rückkehr in die Notaufnahme assoziiert waren, waren anhaltendes Fieber, dermatologisches Skin-Picking-Syndrom, Herzrhythmusstörungen bzw. Herzklagen, Thoraxschmerzen und Pneumonie. Darüber hinaus ergab die Studie, dass 4,4 % der Patient*innen erneut hospitalisiert wurden und 1 % innerhalb der Nachbeobachtungszeit von sechs Monaten starben. Die Gründe dafür wurden in der Studie nicht genannt [29].

Einen detaillierteren Überblick zu den berichteten Symptom- bzw. Organ-spezifischen Long-Covid Prävalenzen findet sich in Tabelle 8-1 und Tabelle 8-2 im Anhang.

**2/28 Studien zur
Sterblichkeit &
Krankenhaus-
wiederaufnahme:**

**ca. 4-33 % der
hospitalisierten
Covid-19 Pat.
benötigten eine
Wiederaufnahme ins
Krankenhaus (Gründe
dafür nicht bekannt)**

**Überblick der
Studienergebnisse im
Anhang**

4.5 Am häufigsten berichtete Long-Covid Symptome

Insgesamt 12 der 28 eingeschlossenen Studien wurden für die Zusammenfassung der am häufigsten berichteten Symptome unter den *Long-Covid* Betroffenen herangezogen, darunter sieben Kohortenstudien [10, 11, 15, 17, 22, 25, 36] und fünf Querschnittserhebungen [30-35]. Vier der 12 Studien waren Preprints [10, 30, 31, 36].

Die am häufigsten identifizierten Symptome unter den *Long-Covid* Patient*innen bis zu drei Monate nach dem Beginn der akuten Infektion waren „Müdigkeit/Erschöpfung“ mit 16 bis 98 % [10, 11, 15, 17, 22, 30-33, 35], „Kurzatmigkeit“ mit 10 bis 93 % [10, 11, 15, 17, 22, 30-33] und „Kopfschmerzen“ mit 9 bis 91% [10, 11, 15, 17, 22, 30-32].

Zu den etwas weniger häufig berichteten Symptomen, die bei *Long-Covid* Patient*innen innerhalb der ersten drei Monate nach der akuten Infektion auftraten, zählten z.B. „Husten“ mit 10,9 bis 34% [10, 15, 22, 30, 32, 33], „Brustschmerzen“ mit 10 bis 88,5 % [10, 11, 30, 32], „Herzklopfen oder Tachykardie“ mit 6 bis 86 % [11, 17, 30-32], „Durchfall“ mit 5,3 bis 85 % [22, 31] und „kognitive Schwierigkeiten“ mit 4 bis 89 % [10, 15, 17, 30, 31].

Bei drei bis sechs Monaten Nachbeobachtungszeit gehörten „Müdigkeit/Erschöpfung“ und „Kurzatmigkeit bzw. dysfunktionale Atmung“ mit 16 bis 78 % [10, 31, 34] bzw. 16 bis 20,9 % [25, 34] zu den häufigeren Symptomen bei *Long-Covid* Patient*innen. Darüber hinaus kam es nach drei bis sechs Monaten bei 13 bis 55 % auch zu „kognitive Schwierigkeiten“ [10, 25, 31] und/oder bei 72 % zu „Unwohlsein nach Anstrengungen“ [31].

Eine Kohortenstudie identifizierte das Symptom „Müdigkeit/Erschöpfung“ als das am häufigsten berichtete Long-Covid Symptom (49 %) unter den *Long-Covid* Patient*innen mindestens sechs Monate nach der akuten Infektion [36].

Tabelle 8-3 im Anhang bietet einen detaillierteren Überblick zu den Häufigkeiten der Symptome unter den *Long-Covid* Betroffenen.

12/28 Studien zu den am häufigsten berichteten Long-Covid Symptomen:

bis 3 Monate:
Müdigkeit/
Erschöpfung: 16-98 %,
Kurzatmigkeit:
10-93 %,
Kopfschmerzen:
9-91 %

nach 3-6 Monaten:
Müdigkeit/
Erschöpfung: 16-78 %,
Kurzatmigkeit:
16-21 %,
kognitive
Schwierigkeiten:
4-89 %,
Unwohlsein nach
Anstrengung: 72 %

nach 6 Monaten:
Müdigkeit am
häufigsten: 49 %

Überblick der
Studienergebnisse im
Anhang

4.6 Auswirkungen auf das tägliche Leben

Sechs der 28 eingeschlossenen Studien zeigten, dass chronische Symptome generell einen negativen Einfluss auf die Lebensqualität, die Aktivitäten des alltäglichen Lebens oder auf die Rückkehr an den Arbeitsplatz hatten [8, 15, 25, 26, 31, 32, 35]. Hinsichtlich Long-Covid, ergab eine große nationale Umfrage des britischen Statistikinstituts (ONS), dass 61 % der *Long-Covid* Patient*innen eine gewisse Einschränkung in ihren alltäglichen Aktivitäten durch die anhaltenden oder wiederkehrenden Symptome erlebten, während 17,9 % die Einschränkungen sogar als erheblich einstuften [8]. Darüber hinaus zeigte eine belgische/niederländische Studie, dass Einschränkungen in alltäglichen Aktivitäten oder Pflegebedürftigkeit auch bei ehemaligen Covid-19 Infizierten vorkamen, die während der akuten SARS-CoV-2 Infektion nicht-hospitalisiert worden waren. Die Studie berichtete, dass 41,1 % der *Long-Covid* Patient*innen zumindest bei der Durchführung alltäglicher Aktivitäten Probleme hatten, auch wenn sie nicht pflegebedürftig waren [32, 35].

Auswirkungen auf das alltägliche Leben:

2 Studien: ca. 41-61 %
der Pat. gewisse
Einschränkungen bei
alltäglichen Aktivitäten

auch bei ehemaligen
nicht hospitalisierten
Covid-19 Pat.

In Bezug auf die Arbeitsunfähigkeit nach einer akuten SARS-CoV-2 Infektion zeigte eine große prospektive Kohortenstudie, dass ca. ein Drittel der stationär behandelten *Covid-19* Patient*innen, die vor der akuten Infektion einen Beruf ausgeübt hatten, nach sechs Monaten noch nicht wieder arbeitsfähig waren [26]. Eine weitere Studie berichtete, dass 45,2 % der *Long-Covid* Patient*innen ihr Arbeitspensum im Vergleich zu vor der Erkrankung reduzierten und 22,3 % aufgrund ihres schlechten Gesundheitszustands gar nicht berufstätig waren (z.B. krankgeschrieben oder arbeitsunfähig, entlassen, gekündigt oder nicht in der Lage eine Stelle zu finden). Insbesondere kognitive Schwierigkeiten, wie Gedächtnisstörungen (z.B. Probleme Entscheidungen zu treffen, Gesprächen zu folgen, Auto zu fahren), machten es für diese Patient*innen besonders schwierig, wieder in ihr vorheriges Leben zurückzufinden [31].

**Auswirkungen
Arbeitsfähigkeit:**

**1 Studie: ca. 45 % der
Pat. eingeschränkt
berufstätig & ca. 22 %
gar nicht berufstätig**

**kognitive
Schwierigkeiten
besonders
problematisch**

4.7 Potentielle Risikofaktoren

Zwölf der 28 eingeschlossenen Studien berichten über mögliche Risikofaktoren, die das Auftreten von Long-Covid Symptomen begünstigen könnten. Die Studienergebnisse sind jedoch sehr heterogen [9, 10, 13-15, 17, 26-30, 36]:

Das weibliche Geschlecht

Die Ergebnisse von sechs Studien deuten darauf hin, dass das weibliche Geschlecht ein Risikofaktor für die Entstehung von Long-Covid darstellen könnte. So wurde in der rezentesten Erhebung des britischen Statistikinstituts (ONS) festgestellt, dass ein höherer Prozentsatz der weiblichen Teilnehmerinnen (23,0 %) Long-Covid Symptome, die für mindestens fünf Wochen nach der akuten Infektion anhielten, berichtete - im Vergleich zu 18,7 % der männlichen Teilnehmer [8]. Ähnliches wurde von drei weiteren Studien berichtet, welche angaben, dass Männer seltener unter langanhaltenden Symptomen nach einer akuten SARS-CoV-2 Infektion litten [10, 26]. Darüber hinaus sollen Frauen auch häufiger von den Long-Covid Symptomen „psychische Probleme“ und „anhaltende Geruchs- bzw. Geschmacksstörungen“ betroffen sein [13, 14].

**12/28 Studien
berichteten mögliche
Risikofaktoren:**

**6 Studien: Frauen
möglicherweise
höheres Risiko Long-
Covid Symptome zu
entwickeln**

Im Gegensatz dazu ergab eine andere Studie keine wesentlichen geschlechtsspezifischen Unterschiede hinsichtlich des Risikos, neue klinische Zustände vier Monate nach der akuten Infektion zu entwickeln [28].

**1 Studie: keine
wesentlichen
Unterschiede
zwischen den
Geschlechtern
beobachtet**

**keine eindeutigen
Hinweise, dass ein
höheres Alter ein
Risikofaktor für Long-
Covid darstellt**

Höheres Alter und Komorbiditäten

Die Ergebnisse zu „Alter“ und „Komorbiditäten“ als mögliche Risikofaktoren fielen heterogen aus. So zeigte eine Studie, dass Patient*innen, die Long-Covid Symptome entwickelten, tendenziell älter waren [17]. Eine andere Kohortenstudie gab hingegen an, dass das Risiko für neu auftretende klinische Probleme nach einer akuten SARS-CoV-2 Infektion zwar mit dem Alter und vorbestehenden Komorbiditäten anstieg, jedoch auch jüngere Patient*innen und jene ohne Komorbiditäten - im Vergleich zu den Kontrollgruppen aus den Jahren 2019 und 2020 - ein erhöhtes Risiko für die Entwicklung neuer klinischer Probleme hatten [28].

Große Anzahl an Symptomen während der akuten SARS-CoV-2 Infektion und Komorbidität

Ebenso waren die Ergebnisse der Studien hinsichtlich der Risikofaktoren „Anzahl der Symptome während der akuten Infektion“ und „Komorbiditäten“ nicht eindeutig. Laut drei Studien haben Patient*innen, die während der akuten SARS-CoV-2 Infektion eine größere Anzahl von Symptomen vorwiesen, eine höheres Risiko Long-Covid Symptome zu entwickeln [17, 27, 30]. Im Gegensatz dazu ergab eine andere Studie, dass sich die Patient*innen-Charakteristika (Alter, Geschlecht, Komorbiditäten), sowie der Schweregrad der Erstinfektion nicht als Risikofaktoren für die Entwicklung von Long-Covid Symptomen erwiesen [15].

Sonstige potentielle Risikofaktoren

In fünf Studien wurden noch weitere mögliche Risikofaktoren genannt. So ergab eine Studie, dass beispielsweise Adipositas mit einer höheren Wahrscheinlichkeit, Long-Covid Symptome zu entwickeln, assoziiert sein könnte [10]. Eine weitere Studie deutete auf eine mögliche Assoziation zwischen dem BMI einer/s Patient*in und dem anhaltenden Symptom „Kurzatmigkeit“ sechs bis acht Monate nach der akuten SARS-CoV-2 Infektion [36]. In einer anderen Studie wurde aufgezeigt, dass Long-Covid Patient*innen mit einer höheren Wahrscheinlichkeit die Blutgruppe A hatten [30]. Eine weitere Studie deutete darauf hin, dass ein niedrigerer Ausgangswert von SARS-CoV-2 Immunglobulinen – mehrere Monate nach der akuten Infektion – mit persistierenden Symptomen verbunden sein könnte [27]. Wiederum eine andere Studie fand heraus, dass hospitalisierte Covid-19 Patient*innen mit einer psychiatrischen Krankengeschichte mit einer höheren Wahrscheinlichkeit ein Monat nach der Covid-19-bedingten Notaufnahme psychiatrische Symptome aufwiesen [14].

Einen detaillierteren Überblick zu den potentiellen Risikofaktoren von Long-Covid bietet im Tabelle 8-4 Anhang.

3 Studien: Pat. mit zahlreichen Symptomen während der akuten Infektion – möglicherweise erhöhtes Risiko für langfristige Symptome

5 Studien: Hinweise für weitere mögliche Risikofaktoren, z.B. Adipositas, Blutgruppe A

Überblick der Studienergebnisse im Anhang

5 Diskussion

Die aktuelle Datenlage zur Epidemiologie von Long-Covid ist noch stark limitiert. Die Studienergebnisse zu den Prävalenzen sind sehr heterogen. Darüber hinaus ist die aktuelle Datenlage nicht ausreichend, um eindeutige Schlussfolgerungen bezüglich den Long-Covid Risikofaktoren ziehen zu können.

Die hier präsentierte Übersichtsarbeit des KCE, bei der das AIHTA als Reviewer beteiligt war, stellt das erste Update der erstmals veröffentlichten Version vom Januar 2021 [1] dar. Seit Januar 2021 konnten zusätzliche 18 Studien [9, 10, 12, 13, 16, 19-23, 25-29, 33, 34, 36] in die aktualisierte Übersichtsarbeit eingeschlossen werden. Unter Berücksichtigung der neu hinzugekommenen Evidenz war kein wesentlicher Unterschied in den Long-Covid Prävalenzen bei *nicht-hospitalisierten Covid-19 Patient*innen* zu erkennen:

- 1-3 Monate nach der Akutinfektion: Januar: 5-36 % versus Juni: 5-36%
- 3-6 Monate nach der Akutinfektion: Januar: 2-15 % versus Juni: 2-21 %

Die am häufigsten berichteten Symptome bei *Long-Covid Patient*innen* bis zu drei Monate nach der akuten Infektion (Müdigkeit/Erschöpfung [bis zu 98 %], Kurzatmigkeit [bis zu 93 %] und Kopfschmerzen [bis zu 91 %]) blieben ebenfalls unverändert. Hinsichtlich potentieller Risikofaktoren ergab die aktuellere Datenlage neue Hinweise: Während im Januar vor allem ein höheres Alter, bestehende Komorbiditäten, Adipositas oder psychiatrische Erkrankungen als mögliche Risikofaktoren in Betracht gezogen wurden, gelten aktuell das weibliche Geschlecht und eine höhere Anzahl an Symptomen während der akuten Infektionsphase als mögliche Risikofaktoren für die Entstehung von Long-Covid Symptomen.

Zu ähnlichen Schlussfolgerungen, wie in der aktuellen Übersichtsarbeit von KCE berichtet, kam auch eine rezente Übersichtsarbeit des britischen Forschungsinstituts (National Institute for Health Research, NIHR) vom März 2021, die ebenso eine hohe Variabilität in den berichteten Prävalenzen und das Fehlen von zuverlässigen Hinweisen für Long-Covid Risikofaktoren angab [4]. Darüber hinaus wurden ähnliche Prävalenzen von einer schweizer Kohortenstudie beobachtet, die aus sprachlichen Gründen (Deutsch) nicht in die Übersichtsarbeit des KCE inkludiert worden war. Die Studie ergab, dass von insgesamt 437 befragten Personen, die zwischen dem 27.02. und 05.08.2021 eine PCR-bestätigte SARS-CoV-2 Infektion hatten, durchschnittlich 26 % an anhaltenden Symptomen sechs Monate nach der akuten Infektion litten. Die Prävalenzen waren bei den hospitalisierten *Covid-19 Patient*innen* tendenziell höher (hospitalisiert 39 % versus nicht-hospitalisiert 23 %). Im Detail berichteten 54 % der Studienteilnehmer*innen von Müdigkeit/Erschöpfung, 26 % bzw. 32 % deuteten auf Depressionen bzw. Angstzustände hin und 25 % litten unter Kurzatmigkeit [37].

Limitationen der Studienqualität

Die sehr unterschiedlichen und teils gegensätzlichen Studienergebnisse sind zum Großteil auf die limitierte Qualität der eingeschlossenen Studien zurückzuführen. Die wichtigsten Einschränkungen der Studienqualität sind im folgenden beschrieben:

aktuell: limitierte Datenlage zu Long-Covid Prävalenzen bzw. Risikofaktoren

seit Januar 2021 18 weitere Studien hinzugekommen

→ keine wesentlichen Unterschiede zu Ergebnissen der früheren Auswertung vom Januar 2021 zu erkennen

→ neue Erkenntnisse zu potentiellen Risikofaktoren

ähnliche Ergebnisse auch in Schweizer Kohortenstudie:

26 % langanhaltende Symptome nach 6 Monaten → höher bei den hospitalisierten Pat. (39 versus 23 %)

heterogene Ergebnisse teilweise durch limitierte Studienqualität zu erklären:

■ Keine einheitliche Definition von Long-Covid

In den eingeschlossenen Studien wurden heterogene Definitionen von Long-Covid herangezogen. So kann Long-Covid unterschiedliche Ursachen haben (z.B. aufgrund von Organschäden oder anhaltende Symptome ohne Organschäden) oder auch in unterschiedliche Symptomcluster unterteilt werden (z.B. Gedächtnisstörungen, Symptome der Atemwege). In den eingeschlossenen Studien wurden die Symptome unabhängig von deren möglicher Ursache berichtet, d.h. Unterscheidungen, ob Organschädigungen vorlagen oder nicht, wurde nicht gemacht. Es ist jedoch davon auszugehen, dass bestimmte in den Studien untersuchte Patient*innen-Gruppen mit Organschäden in Verbindung zu bringen sind [6]. Beispielsweise berichteten einzelne Studien von respiratorischen Langzeitfolgen, die vor allem in stationär behandelten Covid-19 Patient*innen aufgetreten waren. Zusammenfassend bedeutet das, dass insbesondere für stationär behandelte Patient*innen mögliche Organschäden die Ursache für Long-Covid Symptome sein können und ihr Risiko an Langzeitfolgen zu leiden, erhöht ist. Werden ambulant behandelte Patient*innen mit stationär behandelten Patient*innen in den Studien zusammengefasst, führt das zu einer Verzerrung der Resultate.

■ Heterogene Studienpopulationen

Abgesehen von der Unterscheidung in hospitalisierte versus nicht-hospitalisierte Patient*innen variierten die Patient*innen-Populationen hinsichtlich ihrer demografischer Variablen (z.B. Alter, Geschlecht) oder hinsichtlich ihres Gesundheitszustands.

Des Weiteren unterschieden sich die Patient*innen-Populationen bezüglich ihrer Covid-19 Diagnose. So wurden in den eingeschlossenen Studien neben Patient*innen mit einer mittels eines Tests (PCR oder Antigen) bestätigten SARS-CoV Infektion auch Patient*innen mit einem starken klinischen und/oder radiologischen Verdacht auf Covid-19 berücksichtigt. Dadurch besteht die Gefahr, dass SARS-CoV-2-negative Personen als Covid-19 Fälle gezählt wurden. In Folge dessen könnten die Covid-19 sowie auch die Long-Covid Prävalenzen überschätzt sein. Im Gegensatz dazu könnte jedoch die ausschließliche Berücksichtigung von SARS-CoV-2-positiv bestätigten Personen auch zu einer Unterschätzung der Long-Covid Prävalenzen führen, da insbesondere in der Anfangszeit der Pandemie nicht alle SARS-CoV-2 Infizierte Zugang zu einem Test hatten.

Darüber hinaus wurden in den eingeschlossenen Studien überwiegend symptomatische Covid-19 Patient*innen berücksichtigt. Durch das Außer-Acht-Lassen der asymptomatischen Fälle könnten die berichteten Long-Covid Prävalenzen jedoch unterschätzt sein, da möglicherweise auch asymptomatische Covid-19 Verläufe mit langfristigen Symptomen einhergehen können [38]. Die Datenlage bezüglich den Long-Covid Fällen bei asymptomatischen Covid-19 Infizierten ist bis dato jedoch noch sehr unsicher.

■ Stichprobengrößen und Unterschiede in Nachbeobachtungen

Obwohl lediglich Studien mit einer Stichprobengröße von mindestens 250 Fällen in die Übersichtsarbeit von KCE eingeschlossen wurden, berichteten die Studien, die für die Analyse zu den Long-Covid Risikofaktoren herangezogen wurden, über fehlende Power für die multivariaten Analysen. Darüber hinaus sind die varierenden Nachbeobachtungszeiträume eine weitere Hürde für eine korrekte Schätzung der Long-Covid Prävalenzen. Zusätzlich sind die berichteten Long-Covid Prävalenzen dadurch verzerrt, dass nicht alle Patient*innen bis zum Ende der vorgesehenen Nachbeobachtungszeit an der Studie teilnahmen.

**heterogene
Definitionen zu Long-
Covid**

**Zusammenfassen von
hospitalisierten versus
nicht-hospitalisierten
Pat.-Gruppen →
Verzerrung der
Ergebnisse**

**Unterschiede in den
Pat.-Gruppen
hinsichtlich Alter und
Geschlecht →
Verzerrung der
Ergebnisse**

**Zusammenfassen von
Pat. mit bestätigter
versus vermuteter
SARS-CoV-2 Infektion
& Außerachtlassen
von
asymptomatischen
Covid-19 Pat. →
Verzerrungspotential**

**zusätzliche
Ergebnisverzerrung
durch fehlende Power
bei Studien zu
Risikofaktoren,
unterschiedliche
Nachbeobachtungen &
Loss-to Follow-up**

■ Methodische Limitationen aufgrund des Studiendesigns und der Datenerhebung

Die meisten Studien waren in ihrer Methodik limitiert. Der Großteil der eingeschlossenen Studien sind unkontrollierte prospektive Kohortenstudien (n=16/28) bzw. Querschnittserhebungen (n=6/28). Darüber hinaus wurden auch wenige unkontrollierte retrospektive Kohortenstudien (n=2/28) für die Übersichtsarbeiten herangezogen. Alle eingeschlossenen Studien gehen demnach bereits aufgrund ihres Designs mit Limitationen einher (z.B. Fehlen einer Kontrollgruppe, retrospektive Analysen).

Darüber hinaus präsentierte die meisten Studien selbstberichtete Symptome, die mit Fehlern bei der Berichterstattung (z.B. Erinnerungslücken) einhergehen und folglich zu einer Unterschätzung (z.B. wenn bestimmte Symptome vergessen wurden) oder auch zu einer Überschätzung (z.B. wenn bestimmte Symptome übertrieben berichtet wurden) führen können. Lediglich in drei der eingeschlossenen Studien wurden die Symptome auch im Zuge von ärztlichen Untersuchungen unter Einsatz geeigneter und objektiver Messinstrumente erhoben. Diese Studien schlossen jedoch hauptsächlich Notfall- oder aus dem Krankenhaus entlassene Patient*innen ein und sind somit nicht repräsentativ für alle Patient*innen – ambulant behandelte Covid-19 Patient*innen eingeschlossen [15, 19, 25].

Ebenso ist die Art der Rekrutierung mit einem potentiellen Selektionsbias verbunden, z.B. bei Apps oder Online-Umfragen, welche zu einer nicht repräsentativen Auswahl der Studienteilnehmer*innen führen können. So könnten beispielsweise Patient*innen mit schwereren Long-Covid Symptomen nicht die Energie dafür haben, an einer Umfrage teilzunehmen oder ganz im Gegenteil, mehr Energie aufwenden, da sie aufgrund ihrer Symptome und ihrem Leidensdruck mehr gewillt sind, an diesem Thema mitzuwirken. Rekrutierungsverzerrungen wurden auch in den Studien beobachtet, die Geruchsstörungen untersuchten, da in diesen Studien lediglich die Geruchsstörungen der Patient*innen weiterverfolgt wurden, die bereits während der akuten Infektion Geruchsstörungen vorwiesen. Demzufolge ist anzunehmen, dass die berichteten Prävalenzen für Geruchsstörungen überschätzt sind.

■ Aktualität des Themas

Die berichteten Long-Covid Ergebnisse können auch unterschätzt sein, da aufgrund der Aktualität des Themas manche Long-Covid Fälle in den Umfragen unberücksichtigt geblieben sein könnten – insbesondere in früheren Zeiten der Pandemie, als nur sehr wenige Ärzt*innen über Long-Covid informiert waren. Im Gegensatz dazu könnte die mediale Aufmerksamkeit von Seiten der Long-Covid Patient*innen-Initiativen auch zu einer möglichen Überschätzung der Long-Covid Fälle geführt haben.

Interpretation der Ergebnisse

Aufgrund der limitierten Studienqualität müssen die präsentierten Ergebnisse mit Vorsicht interpretiert werden.

Beispielsweise geht aus den Studien nicht hervor, bis zu welchem Ausmaß es sich um „neue“ Langzeitfolgen handelt. Ein breites Spektrum der genannten Long-Covid Symptome sind auch nach anderen schweren Infektionserkrankungen zu erwarten. Aus diesem Grund ist es notwendig, die Häufigkeit von Long-Covid-spezifischen Langzeitfolgen mit der Häufigkeit von Langzeitfolgen anderer Coronavirus-Erkrankungen oder viraler bzw. bakterieller Infektionen zu vergleichen. Bis dato wurden die Symptome anderer schwerer Erkrankungen jedoch nicht so genau

limitierte Methodik:

**z.B. fehlende
Kontrollgruppen in
den meisten Studien,**

**retrospektive
Analysen,**

**vor allem
Selbstbeobachtungen
bzw. objektiv erhobene
Symptome lediglich
für hospitalisierte Pat.**

Rekrutierungsbias:

**Art der Rekrutierung
mittels Apps oder
online Umfragen**

**Prävalenzen zu
Geruchsstörungen
möglicherweise
überschätzt**

**Aktualität & mediale
Aufmerksamkeit des
Themas birgt
zusätzliches
Verzerrungspotential**

**wichtige Aspekte für
die Interpretation der
Ergebnisse:**

**Neuartigkeit von Long-
Covid Langzeitfolgen
im Vergleich zu
anderen
Langzeitfolgen wichtig**

und longitudinal erhoben wie für Long-Covid. Daher ist ein direkter Vergleich diesbezüglich bisher nicht möglich [39, 40].

In Bezug auf den genannten Risikofaktor „weibliches Geschlecht“ muss erwähnt werden, dass die Unterschiede in den Long-Covid Prävalenzen zwischen Frauen und Männern auch andere Gründe haben können als das biologische Geschlecht. Beispielsweise ist bekannt, dass es geschlechtsspezifische Unterschiede im Gesundheitsverhalten gibt. So berichten Frauen bei Umfragen häufiger einen schlechteren Gesundheitszustand als Männer [41]. Hinsichtlich des genannten Risikofaktors „vorliegende psychiatrische Krankengeschichte“ ist es wiederum schwierig, zu differenzieren, ob beispielsweise bei einer/m Patient*in, die/der bereits vor der akuten SARS-CoV-2 Infektion psychische Probleme hatte, die psychischen Symptome als Folge der akuten SARS-CoV-2 Infektion oder als Folge der Maßnahmen zur Eindämmung der Pandemie aufgetreten sind oder auch ohne der akuten Infektion wieder aufgetreten wären.

Bei den Ergebnissen zu den Auswirkungen von Long-Covid auf die Arbeitsfähigkeit der Patient*innen sollte berücksichtigt werden, dass die Auswirkungen teilweise auch von den zur Verfügung stehenden Unterstützungen und Sozialsystemen abhängen. So werden in unterschiedlichen Ländern verschiedene sozial-rechtliche Unterstützungen für Long-Covid Patient*innen (z.B. Arbeitslosengeld, Krankengeld oder Erwerbsunfähigkeitsurlaub, Umschulungen) angeboten. Besteht beispielsweise für eine/n Long-Covid Patient*in die Möglichkeit einer Umschulung, so könnte diese/r Patient*in trotz der bestehenden Symptome wieder arbeiten, auch wenn die Rückkehr zum vorherigen Arbeitsplatz nicht mehr möglich ist. Auch die generell schwierigen Situationen am Arbeitsmarkt oder erleichterte Kündigungsmöglichkeiten in anderen Ländern können die Zahlen zu den nicht berufstätigen Personen nach einer Covid-19 Infektion erhöhen. So stehen z.B. den Patient*innen in den USA aufgrund des anders funktionierenden Sozialsystems weniger Unterstützungsmöglichkeiten zur Verfügung als den Patient*innen in Österreich.

Methodische Limitationen der Übersichtsarbeit

Die in der Übersichtsarbeit des KCE dargelegten Ergebnisse zur Epidemiologie von Long-Covid können sich von den Ergebnissen anderer Übersichtsarbeiten unterscheiden, da KCE strenge Einschlusskriterien angewendet hat (z.B. Studien mit mindestens 250 Patient*innen, Identifikation von Risikofaktoren mittels adjustierter Analysen). Darüber hinaus wurde in der Übersichtsarbeit von KCE zwischen allgemeinen bzw. Organ-/Symptom-spezifischen Long-Covid Prävalenzen und den am häufigsten berichteten Long-Covid Symptomen unterschieden, was die Vergleichbarkeit zu den Ergebnissen anderer Studien, die diese Unterscheidung nicht gemacht haben, erschwert.

Des Weiteren muss festgehalten werden, dass in der Übersichtsarbeit von KCE keine systematische Qualitätsbewertung der eingeschlossenen Studien z.B. mittels spezieller Bewertungstools durchgeführt wurde. Es wurde jedoch des Öfteren auf die mangelhafte Qualität der eingeschlossenen Studien verwiesen, die vor allem auf die Dringlichkeit des Themas und den damit verbundenen limitierten Zeitressourcen zurückzuführen ist.

**Assoziationen
zwischen Risikofaktor
und auftretendem
Long-Covid Symptom
schwierig**

**Auswirkungen von
Long-Covid auf die
Arbeitsfähigkeit der
Pat. teilweise vom
Unterstützungs-
angebot abhängig**

**abweichende
Ergebnisse bzw.
Darstellung von
anderen
Übersichtsarbeiten
z.B. aufgrund der
strengen
Einschlusskriterien**

**keine systematische
Qualitätsbewertung
der eingeschlossenen
Studien**

Laufende Studien

Aufgrund der Aktualität und Bedeutsamkeit des Themas gibt es zahlreiche laufende Studien. Im Folgenden werden einzelne genannt:

Eine der größten laufenden Studien in Europa ist die britische “REACT Long COVID (REACT-LC) - Research into the Longer Term Effects of COVID-19 in Non-Hospitalised Individuals”-Studie, in der ca. 120.000 repräsentative Teilnehmer*innen (*rund 30.000 SARS-CoV-2 Infizierte und mindestens 90.000 SARS-CoV-2 negativ Getestete*) teilnehmen werden. Eine Long-Covid Patient*innen-Subgruppe wird regelmäßig zu ihrem Symptomstatus befragt, um die Entwicklungen ihrer anhaltenden Symptome beobachten zu können [42]. Eine weitere große laufende Studie ist die britische „Post-hospitalisation COVID-19 study (PHOSP-COVID)“ Studie, die untersucht, wie sich unterschiedliche Patient*innen-Populationen von der akuten SARS-CoV-2 Infektion erholen bzw. welche Langzeitsymptome weiterhin bestehen [43].

Im deutschsprachigen Raum werden die meisten noch laufenden Long-Covid Beobachtungsstudien in der Schweiz durchgeführt mit geplanten Stichprobengrößen zwischen 200 und 7.000 (NCT04793269, NCT04881266, NCT04581135, NCT04384029). Für Deutschland ist lediglich eine prospektive Kohortenstudie mit geplanten 500 Studienteilnehmer*innen und mit Fokus auf das Long-Covid Symptom „Müdigkeit/Erschöpfung“ in den entsprechenden Studiendatenbanken gelistet (NCT04883190). In Österreich werden aktuell an der Medizinischen Universität Wien eine Beobachtungsstudie zur Prävalenz und zum Verlauf von Riechstörungen in SARS-CoV-2 Infizierten und eine retrospektive Analyse zur Lebensqualität von Patient*innen mit unter anderem Covid-19-assoziiertem Riechverlust durchgeführt [44].

Neben einzelnen kleineren bereits abgeschlossenen Studien werden in einer großen dänischen Beobachtungsstudie (Long COVID Kids DK) auch mögliche Langzeitfolgen einer SARS-CoV-2 Infektion bei Kindern und Jugendlichen (geplant n=300.000) untersucht (NCT04786353).

zahlreiche laufende Studien:

**REACT-Studie
(n=120.000)**

**PHOSP-Studie
(n= nicht berichtet)**

4 laufende Studien in der Schweiz: (n=200 – 7.000)

**1 laufende Studie in Deutschland
(n=500) & 2 laufende Studien in Österreich
(n= nicht berichtet)**

**1 laufende Studie in Dänemark zu Long-Covid bei Kindern:
(n=300.000)**

6 Schlussfolgerungen

Die in der aktuellen Übersichtsarbeit von KCE präsentierten Studienergebnisse zeigen eine große Heterogenität hinsichtlich den Long-Covid Prävalenzen bei Erwachsenen auf. Zudem ist die vorhandene Datenlage zu mangelhaft, um konkrete Schlussfolgerungen bezüglich Risikofaktoren für Long-Covid ableiten zu können.

Weitere Forschung hinsichtlich einer genaueren Charakterisierung und Klassifizierung von Long-Covid Symptomen inklusive deren Ursachen ist erforderlich. Insbesondere sollte eine präzisere Unterscheidung zwischen Long-Covid Symptomen durch Organschäden und Symptomen unabhängig von Organschäden gemacht werden. Dadurch könnte eine bessere Charakterisierung einzelner Long-Covid Untergruppen ermöglicht und folglich Long-Covid Managementstrategien effizienter gestaltet werden.

Darüber hinaus sind weitere Daten zur Entwicklung der Long-Covid Symptome im Zeitverlauf, zu den Häufigkeiten der Long-Covid Symptome bei asymptomatisch SARS-CoV-2 Infizierten und zu den Effekten der Covid-19 Impfung auf Long-Covid notwendig.

Insgesamt wurde durch die Zusammenfassung der aktuell vorhandenen Evidenz ersichtlich, dass die beschleunigte Forschung aufgrund der Aktualität und Wichtigkeit des Themas eine verminderte Studienqualität zur Folge hat. Um die Datenqualität zukünftiger Forschungsinitiativen zu Long-Covid zu verbessern, wird die Durchführung weiterer ausreichend großer, prospektiver und – wenn möglich – vergleichender Kohortenstudien empfohlen. Beispielsweise sollten Long-Covid Patient*innen mit Menschen ohne bestätigte SARS-CoV-2 Infektion verglichen werden. Dadurch könnte aufgezeigt werden, welche Symptome auch unabhängig von einer Covid-19 Erkrankung vorkommen können bzw. ob ein Anstieg der Symptome auf Covid-19 oder mitunter auch auf die Folgewirkungen der Maßnahmen zur Pandemiebekämpfung (z.B. psychische Probleme aufgrund des langen Lowdowns) zurückzuführen ist. Ebenso sollten Long-Covid Patient*innen mit Patient*innen, die eine andere schwere (respiratorische) Infektionserkrankungen hatten, verglichen werden. Dadurch könnte ein möglicher Zuwachs der Langzeitfolgen durch Covid-19 erkenntlich gemacht werden.

Des Weiteren sollte die Datenqualität zukünftiger Studien verbessert werden, indem die Symptome vermehrt systematisch erhoben werden (z.B. mit Hilfe validierter und – wenn möglich - objektiver Tests) anstatt auf selbstberichtete Symptome zurückzugreifen.

Zu guter Letzt ist es in Zukunft wichtig, bei der Berichterstattung von Long-Covid Prävalenzen an die Öffentlichkeit auch auf die möglichen Unsicherheiten der vorhandenen Daten hinzuweisen (z.B. mögliche Über- oder Unterschätzungen der Prävalenzen aufgrund von Studienlimitationen), sowie die Prävalenzen auch im entsprechendem Kontext zu kommunizieren (z.B. auf welche Personen/Patient*innen-Gruppen beziehen sich die berichteten Prävalenzen?).

**aktuell
heterogene
Ergebnisse zu den
Prävalenzen**

**weitere Forschung
zur präziseren
Charakterisierung von
Long-Covid
Untergruppen →
effizienteres
Management,
zum Symptomverlauf,
zu asymptotischen
Covid-19 Pat & zum
Effekt der Impfung**

**beschleunigte
Forschung auf Kosten
von limitierter
Studienqualität**

**ausreichend große,
prospektive und
bevorzugt kontrollierte
Kohortenstudien...**

**...& Datenerhebung
mittels validierter &
objektiver Tools
anstatt
Selbstbeobachtungen
empfohlen**

**Offenlegung möglicher
Unsicherheiten in den
Daten wichtig**

7 Literatur

- [1] Castanares-Zapatero D., Hanquet G. and Van den Heede K. Epidemiology of long COVID: a pragmatic review of the literature. Belgian Health Care Knowledge Centre, KCE, 2021. Available from: https://kce.fgov.be/sites/default/files/atoms/files/2020-04HSR_LongCOVID_COVID%20Contributions_01022021.pdf.
- [2] What might long COVID mean for the nation's health? 2021 [cited 15/04/2021]. Available from: <https://www.health.org.uk/news-and-comment/blogs/what-might-long-covid-mean-for-the-nations-health>.
- [3] Greenhalgh T., Ladds E., Knight M. and Ravindran D. 'Long Covid': evidence, recommendations and priority research questions. 2021 [cited 15/04/2021]. Available from: <https://committees.parliament.uk/writtenevidence/12345/pdf/>.
- [4] Maxwell E., Poole R. and Oustric P. NIHR Themed Review: Living with Covid19 - Second review. 2021 [cited 16.03.2021]. Available from: <https://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review/>.
- [5] Ryan F. As the UK inches towards normality, those with long Covid must not be forgotten. 2021 [cited 15/04/2021]. Available from: <https://amp.theguardian.com/commentisfree/2021/apr/14/long-covid-uk-impact-society>.
- [6] Castanares-Zapatero D., Chalon P. and van den Heede K. Pathophysiology of Long COVID: a preliminary report. Belgian Health Care Knowledge Centre, KCE, 2021 [cited 14/06/2021]. Available from: https://kce.fgov.be/sites/default/files/atoms/files/2020-04HSR_Long%20COVID_Scientific_Report.pdf.
- [7] COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020 [cited 18.12.2020]. Available from: <https://www.nice.org.uk/guidance/ng188>.
- [8] Ayoubkhani D. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. 2021 [cited 01.04.2021]. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021/pdf>.
- [9] Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *Bmj.* 2021;372:n693. DOI: 10.1136/bmj.n693.
- [10] Bliddal S., Banasik K., Pedersen O., Nissen I., Cantwell L., Schwinn M., et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. *SciLIT.* 2021; preprint.
- [11] Cellai M. and O'Keefe J. Characterization of Prolonged COVID-19 Symptoms in an Outpatient Telemedicine Clinic. *Open Forum Infect Dis.* 2020 7(10):ofaa420.
- [12] Lechien J. R., Chiesa-Estomba C. M., Beckers E., Mustin V., Ducarme M., Journe F., et al. Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. *J Intern Med.* 2021. DOI: 10.1111/joim.13209.
- [13] Makaronidis J., Firman C., Magee C., Mok J., Balogun N., Lechner M., et al. Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: a community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in people with and without SARS-CoV-2 antibodies in London, UK. *BMC Infectious Diseases.* 2021;21(1):221. DOI: 10.1186/s12879-021-05927-w.
- [14] Mazza M., De Lorenzo R., Conte C., Poletti S., Vai B., Bollettini I., et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. *Brain Behav Immun.* 2020;89:594-600. DOI: 10.1016/j.bbi.2020.07.037.
- [15] Moreno-Pérez O., Merino E., Leon-Ramirez J. M., Andres M., Ramos J. M., Arenas-Jiménez J., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. *J Infect.* 2021;82(3):378-383. DOI: 10.1016/j.jinf.2021.01.004.

- [16] Myall K. J., Mukherjee B., Castanheira A. M., Lam J. L., Benedetti G., Mak S. M., et al. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. *Ann Am Thorac Soc.* 2021;18(5):799-806. DOI: 10.1513/AnnalsATS.202008-1002OC.
- [17] Sudre C., Murray B., Varsavsky T., Graham M., Penfold R., Bowyer R., et al. Attributes and predictors of long COVID. *Nat Med.* 2021;27(4):626-631. DOI: 10.1038/s41591-021-01292-y.
- [18] Taquet M., Luciano S., Geddes J. and Harrison P. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62354 COVID-19 cases in the USA. *The Lancet Psychiatry.* 2021;8(2):130-140. DOI: 10.1016/S2215-0366(20)30462-4.
- [19] Venturelli S., Benatti S., Casati M., Binda F., Zuglian G., Imeri G., et al. Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. *Epidemiology and Infection.* 2021;149:e32. DOI: 10.1017/S0950268821000145.
- [20] Chiesa-Estomba C. M., Lechien J. R., Radulesco T., Michel J., Sowerby L. J., Hopkins C., et al. Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. *Eur J Neurol.* 2020;27(11):2318-2321. DOI: 10.1111/ene.14440.
- [21] Havervall S., Rosell A., Phillipson M., Mangsbo S. M., Nilsson P., Hober S., et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. *Jama.* 2021;325(19):2015-2016. DOI: 10.1001/jama.2021.5612.
- [22] Nehme M., Braillard O., Alcoba G., Aebischer P., Courvoisier D., Chappuis F., et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. *Annals of Internal Medicine.* 2021;174(5):723-725. DOI: 10.7326/m20-5926 %m 33284676.
- [23] Taquet M., Geddes J., Husain M., Luciano S. and Harrison P. 6-month neurological and psychiatric outcomes in 236379 survivors of COVID-19: a retrospective cohort study using electronic health records. *The Lancet Psychiatry.* 2021;8(5):416-427. DOI: 10.1016/S2215-0366(21)00084-5.
- [24] Villarreal I. M., Morato M., Martínez-Ruiz Coello M., Navarro A., Garcia-Chillerón R., Ruiz Á., et al. Olfactory and taste disorders in healthcare workers with COVID-19 infection. *Eur Arch Otorhinolaryngol.* 2021;278(6):2123-2127. DOI: 10.1007/s00405-020-06237-8.
- [25] Morin L., Savale L., Pham T., Colle R., Figueiredo S., Harrois A., et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. *Jama.* 2021;325(15):1525-1534. DOI: 10.1001/jama.2021.3331.
- [26] Ghosn J., Piroth L., Epaulard O., Le Turnier P., Mentré F., Bachelet D., et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. *Clinical Microbiology and Infection.* 2021. DOI: 10.1016/j.cmi.2021.03.012.
- [27] Augustin M., Schommers P., Stecher M., Dewald F., Gieselmann L., Gruell H., et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. *Lancet Reg Health Eur.* 2021;6:100122. DOI: 10.1016/j.lanepe.2021.100122.
- [28] Daugherty S., Guo Y., Heath K., Dasmariñas M., Jubilo K., Samranvedhya J., et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. *Bmj.* 2021;373:n1098. DOI: 10.1136/bmj.n1098.
- [29] Romero-Duarte Á., Rivera-Izquierdo M., Guerrero-Fernández de Alba I., Pérez-Contreras M., Fernández-Martínez N. F., Ruiz-Montero R., et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. *BMC Med.* 2021;19(1):129. DOI: 10.1186/s12916-021-02003-7.
- [30] Cirulli E., Barrett K., Riffle S., Bolze A., Neveux I., Dabe S., et al. Long-term COVID-19 symptoms in a large unselected population. *medRxiv.* 2020:2020.2010.2007.20208702. DOI: 10.1101/2020.10.07.20208702.
- [31] Davis H., Assaf G., McCormick L., Wei H., Low R., Re'em Y., et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. *medRxiv.* 2020:2020.2012.2024.20248802. DOI: 10.1101/2020.12.24.20248802.

- [32] Goërtz Y., Van Herck M., Delbressine J., Vaes A., Meys R., Machado F., et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? *ERJ Open Res.* 2020;6(4):00542-02020. DOI: 10.1183/23120541.00542-2020.
- [33] Mandal S., Barnett J., Brill S. E., Brown J. S., Denneny E. K., Hare S. S., et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. *Thorax.* 2020. DOI: 10.1136/thoraxjnl-2020-215818.
- [34] Stavem K., Ghanima W., Olsen M. K., Gilboe H. M. and Einvik G. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. *Thorax.* 2020;76(4):405-407. DOI: 10.1136/thoraxjnl-2020-216377.
- [35] Vaes A., Machado F., Meys R., Delbressine J., Goertz Y. J., Van Herck M., et al. Care Dependency in Non-Hospitalized Patients with COVID-19. *Journal of Clinical Medicine.* 2020;9(9):2946.
- [36] Menges D., Ballouz T., Anagnostopoulos A., Aschmann H., Domenghino A. and Fehr J. Burden of Post-COVID-19 Syndrome and Implications for Healthcare Service Planning: A Population-based Cohort Study. 2021; preprint.
- [37] E7 Zürcher Coronavirus Kohortenstudie. Corona Immunitas: 2021 [cited 14/06/2021]. Available from: <https://www.corona-immunitas.ch/programm/studien/e7-zurcher-coronavirus-kohortenstudie/>.
- [38] Belluck P. Many 'Long Covid' Patients Had No Symptoms From Their Initial Infection. *The New York Times:* 2021 [cited 21/06/2021]. Available from: <https://www.nytimes.com/2021/03/08/health/long-covid-asymptomatic.html>.
- [39] Morroy G., Peters J. B., van Nieuwenhof M., Bor H. H. J., Hautvast J. L. A., van der Hoek W., et al. The health status of Q-fever patients after long-term follow-up. *BMC Infectious Diseases.* 2011;11(1):97. DOI: 10.1186/1471-2334-11-97.
- [40] Lam M. H., Wing Y. K., Yu M. W., Leung C. M., Ma R. C., Kong A. P., et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. *Arch Intern Med.* 2009;169(22):2142-2147. DOI: 10.1001/archinternmed.2009.384.
- [41] Boerma T., Hosseinpoor A. R., Verdes E. and Chatterji S. A global assessment of the gender gap in self-reported health with survey data from 59 countries. *BMC Public Health.* 2016;16(1):675. DOI: 10.1186/s12889-016-3352-y.
- [42] REACT Long COVID [COVID-19] [UPH]. NHS Health Research Authority: 2021 [cited 14/06/2021]. Available from: <https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/react-long-covid-covid-19-uph/>.
- [43] The Post-hospitalisation COVID-19 study (PHOSP-COVID). 2021 [cited 14/06/2021]. Available from: <https://www.phosp.org/>.
- [44] Forschungs-Projekte der MedUni Wien zu COVID-19. Medizinische Universität Wien: 2021 [cited 14/06/2021]. Available from: <https://www.meduniwien.ac.at/web/forschung/forschung-zu-covid-19/>.

8 Anhang

8.1 Extraktionstabellen

Tabelle 8-1: Ergebnisse zu den Long-Covid Prävalenzen (Englisch)

Authors	Inclusion criteria	Design and Sample Size	Outcome and timing since acute COVID-19	Study population	Duration of follow-up (months)	Prevalence	Symptom-specific prevalence	Publication status
Cellai M, US [11]	Telemedicine clinic program (regular phone calls) Confirmed infection (PCR)	Uncontrolled, prospective cohort study n= 496	Persistent self-reported symptoms 6 weeks after onset of COVID-19	Ambulatory	1-3 m	5.2% (26/496)	Not reported	Published
Cirulli E, US [30]	Participants to online survey in 2 projects. Confirmed infection (PCR)	Cross-sectional survey n= 357	Self-reported symptom lasting longer than 30 days after COVID-19 onset (from a list of 32 symptoms)	Ambulatory Hospitalised 2.5%	1-3 m ≥ 3 m	at 30 days: 36.1% (129/357) ≥ 3 months: 14.8%	Not reported	Under review
Sudre C, UK, US and Sweden [17]	Self-reporting in COVID Symptom Study App (start logging when still asymptomatic) Confirmed infection (PCR)	Uncontrolled prospective cohort study n= 4 182	Any self-reported symptom > 28 days after onset of COVID-19	Ambulatory	1-3 m ≥ 3 m	13.3% (558/4182) ≥ 3 months: 2.3%	Not reported	Published
Moreno-Pérez O, Spain [15]	Outpatient structured evaluation after hospital or emergency discharge. Confirmed infection (PCR) or seroconverted	Uncontrolled, prospective cohort study n= 277	Persistence of ≥ 1 symptom or abnormal spirometry or chest X-Ray at 10-14 weeks after onset of COVID-19	Hospitalised 66 % ICU 8.7%	1-3 m > 3 m	50.9% (141/277) ≥ 3 months: 3.8% (neurological) 6.7% (respiratory)	Not reported	Published
Mandal S, UK [33]	Phone or in-person interview of every patient after hospital discharge who had tested COVID-19 positive	Cross sectional study n= 384	Self-reported symptoms 4-6 weeks after discharge and biological, respiratory and mental assessment	Hospitalised	1-3 m	71.8% (276/384)*	Breathlessness: 53% of 384 = 204 pts. Cough: 34% of 384 = 131 pts Fatigue: 69% of 384 = 265 pts*	Published

Myall K, UK [16]	Phone interview 4 weeks after hospital discharge Confirmed infection (PCR or clinically/radiologically)	Uncontrolled, prospective cohort study n= 837	Self-reported ongoing symptom 4-6 weeks after discharge	Hospitalised ICU 54%	1-3 m	39% (325/837)	Not reported	Under review
Nehme M, Switzerland [22]	Phone call 30-45 days after diagnosis (remote follow-up care system) Confirmed infection (PCR)	Uncontrolled, prospective cohort study n= 669	Self-reported ongoing symptom 30-45 days from diagnosis	Ambulatory Hospitalised 6%	1-3 m	32% (214/669)	Not reported	Published
Office for National Statistics (ONS), UK [8]	Positive COVID-19 patients who responded to the National Coronavirus (COVID-19) Infection Survey (CIS)	Cross-sectional survey n= 21 622	Self-reported persistent symptoms at 5 weeks or \geq 12 weeks after COVID-19 onset	Ambulatory Hospitalised 7.9% to 8.6%* * among those who first had infection at least 12 weeks previously	1-3 m 3-6 m	\geq 5 weeks: 21% \geq 12 weeks: 13.7%	\geq 5 weeks: <ul style="list-style-type: none">• Fatigue 11.8%• Cough 10.9%• Headache 10.1%• Myalgia 7.7% \geq 12 weeks: <ul style="list-style-type: none">• Fatigue 8.3%• Cough 7%• Headache 7.2%• Myalgia 5.6%	Not applicable
Venturelli S, Italy [19]	Inclusion in an outpatient post-discharge multidisciplinary program after hospital or ED discharge Confirmed infection (PCR or sero-conversion) 99%	Uncontrolled retrospective observational study n= 767	Ongoing symptoms (psychological, biological, respiratory evaluations) at 12 weeks	Hospitalised 88% ICU 9.7%	3-6 m	51% (394/767)	<ul style="list-style-type: none">• Fatigue 44% (334/758)• Dyspnea 29.7% (228/767)• Post traumatic psychological disorders 30.5% (222/727)• Impaired lung function (DLCO) 19% (136/716)	Published
Morin L, France [25]	Telephone assessment 3-4 months after hospital discharge Ambulatory visit for a subset of patients with relevant symptoms	Uncontrolled prospective cohort study n= 478	Symptoms at 4 months after hospital discharge	Hospitalised	3-6 m	51% (244/478)	<ul style="list-style-type: none">• Fatigue 31.1% (131/431)• Memory difficulties 17.5% (73/416)• New-onset dyspnea in 16.3% (78/478)• Persistent paresthesia 12.1% (51/421)	Published
Bliddal S, Denmark [10]	Identification through Danish Civil Registration System on basis of positive PCR for COVID-19. Patients were invited (via the national digital postbox) to complete a questionnaire.	Uncontrolled, prospective cohort study n= 445	Persistent symptoms > 4 weeks and > 12 weeks	Ambulatory	1-3 m 3-6 m	> 4 weeks: 16 % (198*0.36/445) > 12 weeks: 11.7 % (129*0.40/445)*	Not reported	Under review

Romero-Duarte S, Spain [29]	Data retrieved from follow-up consultation (primary care and hospital specialities) and periodic telephonic reports PCR confirmed infection	Uncontrolled retrospective observational study n= 767	Self-reported symptoms at any time after hospital discharge during 6 months follow-up, hospital readmission, return to the emergency services and death	Hospitalised ICU 10.8%	3-6 m	≤ 6 months: Symptoms: 63.9%* (509/797) Return to emergency department 20% (160/97) Hospitalisation 4.4% (35/767) Death 1% (8/797)	<ul style="list-style-type: none"> • Dyspnoea 28% (223/797) • Fatigue 22.1% (176/797) • Diarrhea 10.3% (82/797) • Mental health disorders 12.2% (97/797) • Dermatological issues 9.3% (74/797) • Superinfection 7.9% (63/797) <p>Less frequent symptoms:</p> <ul style="list-style-type: none"> ◦ Smell/taste 5.3% ◦ Headache 5.3% ◦ Cardiovascular 5.8% ◦ Ophthalmological 4.6% ◦ Nephrological 4.5% ◦ Haematological 4.4% ◦ Urological 4.3% ◦ Otorhinological 3.1% ◦ Endocrine 1.5% 	Published
Havervall S, Sweden [21]	Healthcare workers participating in an online survey and regular clinical/ biological assessment	Uncontrolled prospective cohort study n= 1 395	Ongoing symptoms (at least one moderate to severe symptoms) at 8 months	Ambulatory	> 6 m	≥ 2 months: 26% (84/326) ≥ 4 months: 21.4% (69/323) ≥ 8 months: 14.9% (48/323)	<ul style="list-style-type: none"> • Anosmia 9% • Fatigue 4% • Agueusia 3.7% • Dyspnoea 1.9% • Sleeping disorders 2.2% • Headache 1.5% • Palpitations < 1% • Concentration impairment < 1% • Muscle/joint pain < 1% • Memory impairment < 1% 	Published
Ghosn J, France [26]	Patients who were hospitalised were assessed through physician visits 3 and 6 months after hospital admission	Uncontrolled prospective cohort study n= 1 137	Systematic assessment of ten persisting symptoms at 3 and 6 months	Hospitalised	3-6 m > 6 m	≥ 3 month: 68% (655/957) ≥ 6 months*: 60% (639/1068) *at 6 months, 24% with ≥ 3 symptoms	<ul style="list-style-type: none"> • Fatigue nearly 40% • Dyspnoea > 20% • Joint pain nearly 20% • Myalgia nearly 20% • Headache > 10% • Rhinorrhea 10% • Cough 10% 	Published

							<ul style="list-style-type: none"> • Sore throat <10% • Agueusia 7% • Anosmia 7% 	
Augustin M, Germany [27]	Invitation of each patient with confirmed infection (PCR) for follow-up medical visits at month 4 and 7, regardless of symptoms	Uncontrolled prospective cohort study n= 958	Assessment of long-lasting symptoms with systematic questionnaires at 4 and 7 months after symptom onset (or positive testing) Median follow-up 6.8 months	Hospitalised 2.9% ICU 0.7%	3-6 m > 6 m	At 4 months: 12.8% (123/958) At 7 months: 27.8% (123/442)	At 4 months: <ul style="list-style-type: none"> • Anosmia 12.4% (55/442) • Agueusia 11.1% (49/442) • Fatigue 9.7% (43/442) • Shortness of breath 8.6% (38/442) At 7 months*: <ul style="list-style-type: none"> • Anosmia 14.7% (52/353) • Agueusia 14.2% (50/353) • Fatigue 13.6% (48/353) • Shortness of breath 11% (39/353) <p>*Due to the a high rate of dropout, we calculated the most conservative estimate at 7 months:</p> <ul style="list-style-type: none"> ○ Anosmia 5.4% (52/958) ○ Agueusia 5.2% (50/958) ○ Fatigue 5.0% (48/958) ○ Shortness of breath 4.1 % (39/958) 	Published
Menges G, Switzerland [36]	Inclusion through contact tracing of the Department of Health, based on mandatory laboratory reporting of all individuals diagnosed with SARS-CoV-2 (PCR)	Prospective cohort study n= 431	Assessment of recovery and longlasting symptoms through electronic questionnaire at 6 to 8 months after diagnosis and assessment of fatigue, dyspnoea, depression by using appropriate scales (FAS mMRC,DASS -21)	Hospitalised 19% ICU 2.3%	> 6 m	Not fully recovered 26% (111/431) Symptoms 25% (106/431)	Fatigue 55% (233/431) <ul style="list-style-type: none"> • Dyspnoea (mMRC ≥ 1) 22% (96/431) • Symptoms of depression 26% (111/431) <u>Self-reported symptoms:</u> <ul style="list-style-type: none"> • Fatigue 12% (52/431) • Cough 10% (41/431) • Sore throat 9% (38/431) • Headache 9% (37/431) • Smell/taste disorder 5% (21/431) • Rash 0.7% (3/431) 	Under review

Abbreviations: ED - emergency department, DLCO - diffusing capacity of the lungs for carbon monoxide, ICU - intensive care unit, m month, PCR - polymerase chain reaction; * own calculations

Tabelle 8-2: Ergebnisse zu den Organ- bzw. Symptom-spezifischen Long-Covid Prävalenzen (Englisch)

Authors	Inclusion criteria	Design and Sample Size	Outcome and timing since acute COVID-19	Study population	Duration of follow-up (months)	Prevalence	Prevalence of specific symptom	Publication status
Taquet M, UK, US [18]	Data extraction from electronic database in positive COVID-19 patients (confirmed infection PCR or antigen testings 92.2%)	Retrospective observational cohort study with matched control groups n= 62 354	New-onset psychiatric disorders within 14 to 90 days after COVID-19 onset	Not mentioned	1-3 m	5.8%	<ul style="list-style-type: none"> Anxiety disorder 4.7% (adjustment disorder, generalised anxiety disorder, PTSD, panic disorder) Mood disorder 2% (depression 1.7%) Psychotic disorder 0.1% Insomnia 1.9% Dementia 0.44% 	Published
Taquet M, UK, US [23]	Data extraction from electronic database in positive COVID-19 patients Confirmed infection (ICD-10 codes U07.1)	Retrospective observational cohort study with matched control groups n= 236 379	New-onset psychiatric or neurological disorders in the 6 months after COVID-19	Hospitalised 19.6% ITU 3.8%	3-6 m	Whole COVID-19 cohort: 12.84% Patients admitted in ITU: 25.79%	<ul style="list-style-type: none"> Anxiety disorders 7.11 % Anxiety disorders 9.7 % Psychotic disorders 0.42% New insomnia 2.53% Intracranial haemorrhage 0.28% Ischaemic stroke 0.76% Parkinsonism 0.11% Dementia 0.67% 	Published
Mazza M, Italy [14]	Clinical interview and self-reported questionnaires in COVID-19 patients assessed at ED and hospitalised or not. (no information on testing)	Uncontrolled prospective observational cohort study n= 402	Mental health assessment at one month after COVID-19 onset	Hospitalised 75%	1-3 m	55.7 %	<ul style="list-style-type: none"> PTSD 28% Depression 31% Insomnia 40% Anxiety 42% Obsessive-compulsive symptoms 20% 	Published
Makaronidis J, UK [13]	Invitation of people with acute loss of smell/taste through primary care centers (recruitment via online platform). Follow-	Uncontrolled prospective cohort study n= 467	Smell/taste disorders at 4-6 weeks after COVID-19 onset	Ambulatory Hospitalised 2.3%	1-3 m	Smell* 42.2% (151/357) Taste* 33.8% (116/343) * of those who developed olfactory and	Not reported	Published

	up by a questionnaire that was sent. Serology positive in 82%					taste disorders during the acute phase		
Chiesa-Es-tomba C, France and European [20]	Identification of patients with total or partial loss of smell through database from 3 hospitals. Contact after 30 days for olfactory assessment Confirmed infection (PCR)	Uncontrolled prospective cohort study n= 751	Self-reported persistent olfactory dysfunction	Ambulatory Hospitalised (no clear % mentioned)	1-3 m	Persistent loss of smell* 37% (277/751) Partial smell recovery* 14% (107/751) *of those who developed olfactory and taste disorders during the acute phase	Not reported	Published
Villarreal I, Spain [24]	Phone interview in healthcare workers with PCR positive for COVID-19	Uncontrolled prospective cohort study n= 256	Olfactory and taste disorders at 1 month after acute infection	Ambulatory Hospitalised 3.5%	1-3 m	26% (43/161)* * of those who developed olfactory and taste disorders during the acute phase	Not reported	Published
Lechien J, Belgium and Europe [12]	Online questionnaire was completed at the end of the disease or at the hospital discharge and within the 2-month post-infection (identification through hospital databases)	Uncontrolled prospective cohort study n= 1 363	Self-reported olfactory dysfunction at 2 and 6 months (objective testing in a subset)	Hospitalised 2%	3-6 m	24.1%* (328/1363) * of those who developed olfactory and taste disorders during the acute phase	Not reported	Published
Ayoubkhani D, UK [9]	Identification through electronic health and mortality records (ICD10 codes: U07.1 and U07.2)	Retrospective cohort study with matched control groups n= 47 780	-Hospital readmission -Cause of death -Organ dysfunctions	Hospitalised	3-6 m	Not reported	<ul style="list-style-type: none"> • Hospital re-admission 29.4% • Death after discharge 12.3% • Organ dysfunctions (person years): <ul style="list-style-type: none"> ◦ Respiratory disease 539/1000 ◦ Diabetes 29/1000 ◦ Cardiovascular 66/1000 	Published
Daugherty S, US [28]	Identification through electronic health from 3 data sources within the	Retrospective cohort study with three matched comparative	Assessment of risk and relative hazards for developing clinical sequelae	Hospitalised* 8.2% ICU* 1.1%	3-6 m	14.02% with at least 1 new type of clinical sequelae that required medical care	In comparison with control groups, higher risk difference and higher hazard ratio* for several new clinical outcomes: <ul style="list-style-type: none"> • Neurological disorders 	Published

	United Health Group Clinical Discovery Database (ICD10 codes: U07.1, U07.2, B34.2, B97.29) Confirmed infection (PCR)	groups (by propensity score) n= 193 113* * Total cohort: 266 586 and 193 113 with follow-up	requiring medical care after COVID-19 in 18-65 years patients, at 4 months after acute infection (median 95 IQR 42-135)	* calculated on a total of 266 586		(27 074/193 113): <ul style="list-style-type: none"> • 10.01%: one sequela • 4.01%: > 1 new sequelae 	<ul style="list-style-type: none"> • Cardiovascular disorders • Hypercoagulability • Kidney disorders • Respiratory disorders • Mental health and neurocognitive issues 	
--	---	---	---	------------------------------------	--	--	--	--

Abbreviations: ED - emergency department, DLCO - diffusing capacity of the lungs for carbon monoxide ICD10 - International Statistical Classification of Diseases and Related Health Problems, ICU - intensive care unit ITU - intensive therapy unit, m - month, PCR - polymerase chain reaction, PTSD - post-traumatic stress disorder

Tabelle 8-3: Ergebnisse zu den Häufigkeiten der Symptome unter den Long-Covid Betroffenen (Englisch)

Authors	Inclusion criteria	Design and Sample Size	Outcome and timing since acute COVID-19	Duration of follow-up (months)	Symptoms frequency	Publication status
Cellai M, US [11]	Telemedicine clinic program (regular phone calls) Confirmed infection (PCR)	Uncontrolled prospective cohort study n= 496	Persistent self-reported symptoms 6 weeks after onset of COVID-19	1-3 m	<ul style="list-style-type: none"> • Respiratory symptoms (dyspnea, chest tightness) 88.5% • Fatigue 65% (17/26) • Headache 50% (13/26) • Gastrointestinal symptoms 34% (9/26) • Palpitations 23% (6/26) • Low grade fever 11% (3/26) • 69.2% (18/26) reported at least 4 concurrent symptoms 	Published
Cirulli E, US [30]	Participants to online survey in 2 projects Confirmed infection (PCR)	Cross-sectional survey n= 357	Self-reported symptom lasting longer than 30 days after COVID-19 onset (from a list of 32 symptoms)	1-3 m	<u>Most frequent:</u> <ul style="list-style-type: none"> • Anosmia, ageusia, • Dyspnea, chest pain • Memory loss, confusion, difficulty concentrating <u>Others:</u> <ul style="list-style-type: none"> • Decreased alertness, dizziness • Headache, insomnia • Muscle weakness • Dry cough • Tachycardia • Bone or joint pain • Fatigue 	Under review

					<ul style="list-style-type: none"> • Tingling, sensitive skin, back pain • Acid reflux, diarrhoea 	
Sudre C, UK, US and Sweden [17]	Self-reporting in Covid Symptom Study App (start logging when still asymptomatic) Confirmed infection (PCR)	Uncontrolled prospective cohort study n= 4 182	Any self-reported symptom > 28 days after onset of COVID-19	1-3 m	<ul style="list-style-type: none"> • Fatigue 97.7% • Headache 91.2% • Dyspnoea (?) • Anosmia (?) • Cardiac symptoms 6.1% • Lower respiratory symptoms (?) • Memory 4.1% • Tinnitus/earache 3.6% • Neuropathy 2% • Fever (?) • Gastroenterological symptoms (?) 	Published
Moreno-Perez O, Spain [15]	Outpatient structured evaluation after hospital or emergency discharge Confirmed infection (PCR) or seroconverted	Uncontrolled prospective cohort study n= 277	Persistence of ≥ 1 symptom or abnormal spirometry or chest X-Ray at 10-14 weeks after onset of COVID-19	1-3 m	<ul style="list-style-type: none"> • Dyspnea 17.2%* • Cough 10.6%* • Fatigue 17.6%* • Anosmia-Dysgeusia 10.8%* • Cognitive disorders 7.6%* • Headache 8.9%* • Myalgia, arthralgia 9.8%* 	Published
Goertz Y [32] and Vaes A, The Netherlands and Belgium [35]	Persistent symptoms reported in social media in patients who experienced COVID-19 Confirmed: 16% ¹ -27% ² ¹ Goertz Y et al ² Vaes A et al	Cross-sectional survey n=2 113 ¹ n=1 837 ²	Any symptoms > 3 weeks to 3 months after infection onset	1-3 m	<u>Goertz et al:</u> <ul style="list-style-type: none"> • Fatigue 87% • Dyspnoea 71% • Chest tightness 44% • Headache 38% • Muscle pain 36% • Heart palpitation 32% • Cough 29% <u>Vaes et al:</u> <ul style="list-style-type: none"> • Fatigue: 98% • Sleeping disorders 88% • Pain 87% • Increased need for care: <ul style="list-style-type: none"> - Care-dependent: 31% - Limitation in daily activities: 41.1% in the independent group 	Published

Davis H, Europe and US [31]	Persistent symptoms in people who experienced symptoms consistent with COVID-19, reported on a survey through social media and support groups Confirmed infection: 27%	Cross-sectional survey n= 3 762	Persistent symptoms >28 days	1-3 m 3-6 m	<p>1-3 months (most frequent):</p> <ul style="list-style-type: none"> • Fatigue 98% • Post exertional malaise 89% • Cognitive dysfunction 85.1% • Headache 77% • Cardiovascular symptoms 86 % • Musculoskeletal symptoms 93.6% • Sore throat 59% • Respiratory symptoms 93% • Gastrointestinal symptoms 85% • Anxiety 57.9% • Depression 47.3% • Taste and smell disorders 57.6% <p>At 6 months (most frequent):</p> <ul style="list-style-type: none"> • Fatigue 77.7% • Post exertional malaise 72.2% • Cognitive dysfunction 55.4% • Sensorimotor symptoms 55.7% • Headache 53.6% • Relapses of symptoms 85.9% 	Under review
Nehme M, Switzerland [22]	Phone call 30-45 days after diagnosis (remote follow-up care system) Confirmed infection (PCR)	Uncontrolled prospective cohort study n= 669	Self-reported ongoing symptom 30-45 days from diagnosis	1-3 m	<ul style="list-style-type: none"> • Fatigue • Dyspnea • Taste/smell disorders • Cough • Headache <p>Digestive symptoms</p>	Published
Bliddal S, Denmark [10]	Identification through Danish Civil Registration System on basis of positive PCR for COVID-19. Patients were invited (via the national digital post-box) to complete a questionnaire	Uncontrolled prospective cohort study n= 445	Persistent symptoms > 4 weeks and > 12 weeks	1-3 m 3-6 m	<p>> 4 weeks:</p> <ul style="list-style-type: none"> • Fatigue 16% • Concentration or memory difficulties 13% • Reduced sense of smell 10% • Shortness of breath 10% • Headache < 10% • Muscle/joint pain <10% • Cough/chest pain <10% • Digestive symptoms <10% 	Under review

					<p>> 12 weeks:</p> <ul style="list-style-type: none"> • Fatigue 16% • Concentration difficulties 13% • Headache < 10% • Muscle/joint pain <10% • Cough/chest pain <10% <p>Digestive symptoms <10%</p>	
Stavem K, Norway [34]	Population-based cross-sectional cohort survey n= 451 PCR confirmed infection	Identification of patients through PCR positivity and invitation to a postal survey or electronically		3-6 m	<ul style="list-style-type: none"> • Dyspnea 16% • Smell disorders 12% • Taste disorders 10% 	Published
Morin L, France [25]	Telephone assessment 3-4 months after hospital discharge Ambulatory visit for a subset of patients with relevant symptoms	Uncontrolled prospective uncontrolled cohort study n= 478	Symptoms at 4 months after hospital discharge	3-6 m	<p>Ambulatory assessment (n=177):</p> <ul style="list-style-type: none"> • Cognitive disorders 38.4% (61/159) • Dysfunctional breathing 20.9% (37/177) • Chest CT scan: <ul style="list-style-type: none"> ◦ 63% (108/171) lung abnormalities (ground glass opacities) ◦ 19% (33/171) with fibrotic lesions • DLCO 87% of predicted values (n=152) • Altered heart left ventricular contractility 9.6% (8/83) • In ICU patients (n=94): anxiety (23.4%), depression (18.1%), PTSD (7.4%) 	Published
Mandal S, UK	Phone or in-person interview of every patient after hospital dis-charge who had tested COVID-19 positive	Cross-sectional study n= 384	Self-reported symptoms 4-6 weeks after discharge and biological, respiratory and mental assessment	1-3 m	<p>For symptom frequency long COVID patients (n=276):</p> <ul style="list-style-type: none"> • Breathlessness: 204/276: 74% • Cough: 131/276: 47.5% • Fatigue: 265/276: 96%* 	Published
Menges G, Switzerland [36]	Inclusion through contact tracing of the Department of Health, based on mandatory laboratory reporting of all individuals diagnosed with SARS-CoV-2 (PCR)	Prospective cohort study n= 431	Assessment of recovery and long-lasting symptoms through electronic Questionnaire at 6 to 8 months after diagnosis and assessment of fatigue, dyspnoea, depression by using appropriate scales (FAS mMRC,DASS-21)	> 6 m	<p>Fatigue 49% (52/106)</p> <ul style="list-style-type: none"> • Cough 39% (41/106) • Sore throat 36% (38/106) • Headache 35% (37/106) • Taste/smell disorders 20% (21/106) 	Under review

Abbreviations: DLCO - diffusing capacity of the lungs for carbon monoxide, ICU - intensive care unit, m - month, PCR polymerase chain reaction; * own calculations

Tabelle 8-4: Ergebnisse zu den Risikofaktoren von Long-Covid (Englisch)

First author, country	Inclusion criteria	Outcome and timing	Risk factors (association measurement and 95%CI)	Other results
Sudre C, UK, US, Sweden [17]	Inclusion by prospective self-reporting of symptoms in the COVID Symptom Study App (start logging when still asymptomatic)	Any symptom >28 days after onset, self-reported	Adjusted analysis (age and sex), compared to "short" (<10 days) COVID, symptoms during first week of COVID (aOR ratio; 95CI): <ul style="list-style-type: none"> • Fatigue 2.83 (2.09-3.83) • Headache 2.62 (2.04-3.37) • Dyspnoea 2.36 (1.91-2.91) • Hoarse voice 2.33 (1.88-2.90) • Myalgia 2.22 (1.8-2.73) 	Main predictors: age, sex, symptoms in 1 st week (AUC 76.8%). In 70+ years: Fever 5.51 (1.75-17.36) Loss of smell 7.35 (1.58-34.22) Hoarse voice 4.03 (1.21-13.42) and comorbidities
Cirulli E, US [30]	Participants to online survey in 2 projects, with positive COVID test	Any self-reported short and long-term symptom at 30, 60, 90 days from onset (list of 32 symptoms)	Adjusted analysis at day 30 (aOR ratio; 95CI): <ul style="list-style-type: none"> • Number of initial symptoms • Dyspnoea • Pain with deep breath • Sensitive skin • Blood type A No risk factor at 60 and 90 days (in multivariate)	Comorbidities and sex were risk factors in the unadjusted analysis, not in the multivariate analysis, probably due to low sample size
Moreno-Pérez O, Spain [15]	Outpatients structured evaluation after hospital or ED discharge in patients with confirmed infection	Persistence of ≥1 symptom or abnormal spirometry or chest X-ray at 10-14 weeks after onset	Adjusted analysis, (aOR ratio; 95CI): <ul style="list-style-type: none"> • For long COVID (overall): no significant risk factor • For those with initial severe pneumonia: <ul style="list-style-type: none"> ◦ opacities of lung surface on X-rays >50% 2.87 (1.13-7.32) ◦ higher heart rate at admission 1.03 (1.01-1.06) 	Predictors of spirometry abnormalities in overall cohort: estimated glomerular filtrate, male sex, comorbidities (high Charlson index associated with lower incidence) Higher imaging score at acute disease was associated with persistence of X-ray signs in overall cohort 1.66 (1.30-2.11) and severe pneumonia patients 1.68 (1.28,2.19)
Mazza M, Italy [14]	COVID-19 patients assessed at ED and hospitalised or not; no information on testing	Mental health assessment at one month after hospital or ED discharge	Adjusted analysis (sex, previous status and hospitalisation): <ul style="list-style-type: none"> • Female sex • Previous psychiatric history 	Older age and long duration of hospitalisation were risk factors in the unadjusted analysis Hospitalisation was not a risk factor
Bliddal S, Denmark [10]	Identification through Danish Civil Registration System on basis of positive PCR for COVID-19. Pa-	Persistent symptoms > 4 weeks and > 12 weeks	Adjusted analysis (sex, age, smoking, BMI, comorbidity and time from symptom start to follow-up) for the risk of symptoms after 4 weeks (aOR ratio; 95CI): <ul style="list-style-type: none"> • Female sex 2.91 (1.32-6.39) • BMI 1.13 (1.05-1.22) 	In a subgroup of 117 women with follow-up > 4 weeks, BMI is a risk factor aOR 1.10 (1.0-1.20) Being healthcare worker was not a risk factor 1.50 (0.60-3.8)

	Tients were invited (via the national digital postbox) to complete a questionnaire			
Ayoubkhani D, UK [9]	Identification through electronic health and mortality records (ICD10 codes: U07.1 and U07.2)	Assessment of mortality, hospital readmission, organ dysfunctions > 3 months after hospital discharge	<ul style="list-style-type: none"> In COVID-19 patients, rates of all outcomes were greater in 70+ patients than in those aged less than 70. In COVID-19 patients, rates of all outcomes other than diabetes were greater in the white ethnic group than in the non-white group. After matching for baseline personal characteristics (age, sex, ethnicity, region, IMD category, and smoking status) and comorbidities, rate ratio were greater in patients less than 70 than those 70+ and in non-white ethnicity, for all outcomes. 	Greater rates of death and hospital readmission in patients admitted to ICU
Daugherty S, US [28]	Identification through electronic health from three data sources within the UnitedHealth Group Clinical Discovery Database (ICD10 codes: U07.1, U07.2, B34.2, B97.29)	Assessment of risk and relative hazards for developing clinical sequelae requiring medical care after COVID-19 in 18-65 years patients, at 4 months after acute infection	<ul style="list-style-type: none"> Risk differences were increased in older individuals, had pre-existing conditions, and were admitted to hospital because of Covid-19. Younger patients (aged ≤50), those with no pre-existing conditions, or not admitted to hospital for COVID-19 also had an increased risk of developing new clinical sequelae, in comparison to control groups- 	Risk for new clinical sequelae after acute COVID-19 rarely differed between men and women, apart from fatigue and anosmia (more commonly diagnosed in women)
Makaronidis J, UK [13]	Invitation of people with acute loss of smell/taste through primary care centers (recruitment via online platform). Serology assessment.	Smell/taste disorders at 4-6 weeks after onset	<p>Adjusted analysis (age, ethnicity, patterns of smell loss and smoking) for the risk of persistent smell loss (aOR; 95CI):</p> <ul style="list-style-type: none"> Female sex 2.46 (1.47-4.13) Presence of parosmia 2.47 (1.54-4.00) 	Age was not recognised as a risk factor 0.99 (1.01-1.03)
Ghosn J, France [26]	Patients who were hospitalised were assessed through physician visits 3 and 6 months after hospital admission.	Ongoing self-reported symptoms within a list of 10 symptoms at 3 and 6 months after hospital admission	<p>Adjusted analysis for the risk of having 3 or more symptoms at 6 months follow-up (aOR; 95CI):</p> <ul style="list-style-type: none"> Female sex 2.40 (1.75-3.30) ≥ 3 symptoms at admission 2.04 (1.45-2.89) ICU admission at the acute phase 1.55 (1.09-2.18) 	Comorbidities and age were not associated with the presence of symptoms at 6 months in univariate analysis
Romero-Duarte A, Spain [29]	Data retrieved from follow-up consultation (primary care and hospital specialities) and periodic telephonic reports	Self-reported symptoms at any time after hospital discharge at any time during 6 months follow-up, hospital readmission, return to the emergency services and death	<p>Adjusted analysis for return to emergency services (aOR, 95CI):</p> <ul style="list-style-type: none"> Persistent fever 2.23 (1.18-4.19) Thoracic pain 2.55 (1.33-4.90) Anosmia/dysgeusia 0.28 (0.10-0.74) Arrhythmia or palpitations 3.08 (1.21-7.79) 	

			<ul style="list-style-type: none"> Superinfection 1.90 (1.05-3.42) Pneumonia 7.65 (1.27-45.97) Dermatological symptoms 1.75 (1.01-3.03) <p>Adjusted analysis for hospital readmission:</p> <ul style="list-style-type: none"> Persistent fever 8.31 (2.31-29.89) Nephrological disorders 6.49 (1.50-21.14) Superinfection 3.14 (1.05-9.40) Pneumonia 11.81 (1.40-99.39) 	
Augustin M, Germany [27]	Follow-up medical visits at month 4 and 7 months after acute infection (PCR confirmed), regardless of symptoms	Assessment of long-lasting symptoms with systematic questionnaires	<p>Adjusted analysis for the risk to develop long-term symptoms (aOR, 95CI)*:</p> <ul style="list-style-type: none"> Lower baseline level of SARS-CoV-2 IgG 1.90 (1.13-3.18) Number of symptoms 1.29 (1.08-1.55) Male gender 0.59 (0.36-0.98) <p>*We observed a difference between odds ratio mentioned in the text and the tables. We are awaiting author's reply.</p>	
Menges G, Switzerland [36]	Inclusion through con-tact trac-ing of the De-partment of Health, based on mandatory la-boratory reporting of all individuals diag-nosed with SARS-CoV-2 (PCR)	Assessment of recovery and long-lasting symp-toms through elec-tronic Questionnaire at 6 to 8 months after diagnosis and as-sessment of fa-tigue, dyspnoea, depres-sion by using appropriate scales (FAS mMRC,DASS-21)	-	Association between BMI and dyspnoea still present at 6-8 months.

Abbreviations: *aOR* - adjusted odds ratio, *ICD-10* - International Statistical Classification of Diseases and Related Health Problems, *ICU* - intensive care unit, *m* - month, *PCR* - polymerase chain reaction

8.2 KCE-Bericht



Federaal Kenniscentrum voor de Gezondheidszorg
Centre Fédéral d'Expertise des Soins de Santé
Belgian Health Care Knowledge Centre

21 June 2021

COVID 19 – KCE CONTRIBUTIONS

EPIDEMIOLOGY OF LONG COVID: A PRELIMINARY REPORT

DIEGO CASTANARES-ZAPATERO, PATRICE CHALON, KOEN VAN DEN HEEDE

■ TABLE OF CONTENTS

1	DISCLAIMER.....	4
2	KEY POINTS	4
3	BACKGROUND.....	6
3.1	AWARENESS AND REPORTING.....	6
3.2	HOW TO DEFINE LONG COVID?	6
4	RESEARCH QUESTIONS	7
5	METHODS	7
5.1	STRUCTURED QUESTIONS AND SEARCH CONCEPTS	7
5.2	IDENTIFICATION OF STUDIES.....	7
5.3	SELECTION OF STUDIES.....	8
6	RESULTS	8
6.1	INCLUDED STUDIES	8
6.2	PREVALENCE ESTIMATE.....	9
6.2.1	Studies with 1 to 3 months of follow-up.....	9
6.2.2	Studies with 3 to 6 months of follow-up.....	10
6.2.3	Studies with follow-up \geq 6 months	10
6.3	PREVALENCE OF LONG COVID FOR SPECIFIC ORGAN SYSTEMS OR SYMPTOMS.....	18
6.3.1	Mental health symptoms.....	18
6.3.2	Olfactory and smell symptoms	18
6.3.3	General symptoms.....	18
6.3.4	Hospital readmission and mortality.....	19
6.4	MOST COMMON SYMPTOMS AND THEIR FREQUENCY AMONG PATIENTS WITH LONG COVID.....	23
6.5	CONSEQUENCES ON DAILY-LIFE.....	29
6.6	RISK FACTORS FOR LONG COVID	29
6.6.1	Included studies.....	29
6.6.2	Risk factors	29
7	DISCUSSION.....	35
7.1	MAIN FINDINGS	35
7.2	LIMITATIONS OF AVAILABLE EVIDENCE	35
7.3	LIMITATIONS OF THIS REVIEW	37
7.4	PERSPECTIVES.....	38
■	REFERENCES.....	39
■	APPENDICES	42
APPENDIX 1.	SEARCH STRATEGY.....	42
APPENDIX 1.1.	RESEARCH QUESTION AND PEO	42
APPENDIX 1.2.	LIST OF SOURCES SEARCHED FOR STUDIES	43

APPENDIX 1.3. FLOW DIAGRAM	44
APPENDIX 2. DETAILS OF SEARCH STRATEGY IN EACH SOURCE	45
APPENDIX 2.1. COCHRANE DATABASE OF SYSTEMATIC REVIEWS	45
APPENDIX 2.2. JBI EBP DATABASE.....	45
APPENDIX 2.3. MEDLINE	45
APPENDIX 2.4. EMBASE	46
APPENDIX 2.5. PSYCINFO	46
APPENDIX 2.6. ECONLIT.....	47
APPENDIX 2.7. OVID NURSING DATABASE	47
APPENDIX 2.8. SCILIT	48
APPENDIX 2.9. EUROPEPMC	48
APPENDIX 2.10. JOURNALS@OVID.....	48
APPENDIX 2.11. CORONACENTRAL.....	49

LIST OF FIGURES

Figure 1 – Results of studies assessing the prevalence of long COVID according to the level of care during the acute phase	11
--	----

LIST OF TABLES

Table 1 – Results on long COVID prevalence	12
Table 2 – Results on prevalences of long COVID for specific organ systems or symptoms	20
Table 3 – Frequency of symptoms among long COVID patients.....	25
Table 4 – Results on risk factors for long COVID in the selected studies.....	31

LIST OF ABBREVIATIONS

ABBREVIATION	DEFINITION
aOR	Adjusted odds ratio
COVID-19	Coronavirus Disease-19
DASS 21	Depression Anxiety and Stress Scale 21
DLCO	Diffusing capacity for carbon dioxide
FAS	Fatigue assessment score
ICU	Intensive care unit
IQR	Interquartile range
ITU	Intensive therapy unit
mMRC	modified medical research council
OR	Odds ratio
PCR	Polymerase chain reaction
SARS-Cov-2	Severe acute respiratory syndrome coronavirus-2

1 DISCLAIMER

The current work is based on the available evidence at the moment of writing the report (27/05/2021). There are still major evidence gaps, as studies are ongoing and science requires time to build up. A part of the available literature is not peer-reviewed and hence not necessarily conforms to the high-quality standards for scientific research. This document should be considered as a working paper that will be updated when the final report is published (October-November 2021). This implies that some findings may change over time.

2 KEY POINTS

- Available evidence on the prevalence of long COVID remains limited and insufficient to formulate sound conclusions. Synthesising the information is challenging since studies are highly heterogeneous and the reported prevalences vary substantially.
- There is still no clear widely accepted definition of long COVID. Long COVID encompasses distinct phenotypes (or clusters of symptoms) that can broadly vary and evolve over time. As such, people may experience different patterns of symptoms that could have multiple causes. In specific patient groups (e.g. patients that have been hospitalised in the acute phase), it is important to distinguish those related with permanent organ impairment from those not related with organ damage.
- Reported prevalences differ according to the targeted population and follow-up time:
 - In studies in which (almost) all included patients were not hospitalised during the acute phase, it is estimated that, between 5 and 36% of them still have symptoms within the first 3 months after the onset of the COVID-19. However, in studies in which almost all patients have been hospitalised, higher prevalences are reported (between 39 and 72%).
 - Beyond 3 months, studies that predominantly included patients who have not been hospitalised, about 2-21% of them still have symptoms. For those studies including mostly patients that were hospitalised during the acute phase, the reported prevalence is higher and ranges between 51 and 68%.
 - Studies with long follow-up are sparse. It appears that symptoms improve over time but at 6 months of follow-up, about 13 to 25% of patients who were not hospitalised may still have at least one symptom. Higher rates reaching 60% have nonetheless been reported in patients who have been hospitalised.
 - Current evidence does not precisely allow to distinguish between the prevalence of symptoms following organ damage and symptoms unrelated to organ damage. Since the appearance of symptoms can besides COVID-19 have other non-mutual exclusive underlying causes (hospital stay, post-intensive care syndrome), the prevalence of long COVID might be overestimated.
- In the first three months, the most commonly reported persistent symptoms in the group of long COVID patients are fatigue (up to 98%), dyspnoea (up to 93%) and headache (up to 91%). Beyond 3 months, the most frequent symptoms were fatigue (up to 78%), cognitive disorders (up to 55%) and respiratory symptoms such as dyspnoea or dysfunctional breathing (up to 21%). Taste and olfactory dysfunction improve over time but may persist in the long run for a minority of patients. The type of symptoms does not seem to differ between patients who were hospitalised versus those who were not hospitalised during the acute phase. In addition to the symptoms, an impact on activities of daily life and (social) functioning is reported.
- The risk factors to develop long COVID are still unclear. Studies that aimed to identify risk factors are limited and considerably heterogeneous. Up to now, there is no study with large and sufficiently long follow-up. There are indications in those who were not hospitalised that a higher number of symptoms at the acute phase of the disease may be a risk factor for developing long COVID. The contribution of age (as a risk factor) is still controversial but long COVID seems to be prevalent across all age categories.

- The risk for being hospitalised and the risk for developing new clinical issues involving multiple organ systems requiring medical care is increased in the aftermath of COVID-19, in both groups of patients who were hospitalised or not during the acute phase of infection. Long COVID is reported regardless of the initial severity of COVID-19 and even in patients who remained initially asymptomatic.
- The current findings are based on studies presenting substantial limitations: (1)The absence of a homogeneous definition of long COVID with clear clinical criteria does not allow to make an accurate diagnosis. It is not always straightforward to distinguish long COVID from other overlapping conditions, especially when permanent organ damage is lacking. (2) Included populations vary widely according to demography, level of care received during the acute infection, sample sizes. (3) Study designs are heterogeneous (time of inclusion, follow-up duration). Many of them did not include a control group and present loss to follow-up. They are prone to recruitment and recall bias. (4) There is a lack of standardised and validated measures for symptom reporting. (5) Data on long COVID patients who had an asymptomatic infection are scarce.

3 BACKGROUND

3.1 Awareness and reporting

After more than one year into the COVID-19 pandemic, evidence has surged that many symptoms can persist or appear after recovery from the acute period of illness. Those symptoms are reported after both mild or severe COVID-19. They adversely impact daily life and induce a societal burden, as the number of affected patients is increasingly growing.

Whilst many epidemiological data report that a proportion of people endure lingering symptoms after recovery from the acute disease, there is no globally accepted definition of this issue, yet. 'Long COVID' is now the most commonly used term but several terms such as 'post-COVID condition', 'long-haul COVID', 'post-COVID syndrome', 'post-acute COVID symptoms', 'post-acute sequelae' or 'chronic COVID' are found in the literature and encompass a wide range and variety of symptoms.

For the purpose of this review, we considered studies describing long-term symptoms following the acute phase of COVID-19 if they were observed at least 4 weeks after disease onset. We stratified by length of follow-up: early in the time-course of the disease (up to 12 weeks), between 3 and 6 months and after 6 months follow-up.

3.2 How to define long COVID?

Due to its wide heterogeneity of presentation, there is, currently, a lack of international consensus regarding the definition of long COVID. The World Health Organisation (WHO) is currently running a project aiming to result in an international consensus about a definition and clinical criteria for long COVID (a report is expected to be published in October- November 2021).^a

In December 2020, the National Institute for Health and Care Excellence (NICE) proposed a definition of long COVID, based on the time beyond disease onset, when signs and symptoms, not explained by an alternative diagnosis are being reported: 'ongoing symptomatic COVID-19' is used for patients who have symptoms from 4 to 12 weeks beyond acute COVID-19, whereas 'post-COVID-19 syndrome' is the term used for those still experiencing symptoms after 12 weeks.¹

Long COVID is increasingly being seen as an active and evolving medical condition bringing into play all organs. A broad spectrum of symptoms is commonly reported. People can continue to undergo single or multiple symptoms beyond the acute phase or develop new ones, or even undergo a relapsing trend.

There is substantial uncertainty about what causes long COVID and its management could vary according to related causal mechanisms. To this end, it is of utmost importance to distinguish people who have symptoms following organ damage that occurred during the hospitalisation (for example lung sequelae after prolonged mechanical ventilation) from people who undergo a mild-to-moderate disease and who were not hospitalised. For instance, the Centers for Disease Control and Prevention (CDC) proposed to make the distinction between several types of post COVID conditions and to consider the longer effects of COVID-19 hospitalisation or treatments consequences as a particular entity.² In this vein, some of these effects can include Post-Intensive-care-Syndrome that refers to a subset of patients who have been hospitalised in the intensive care unit³ and must be differentiated from long COVID.

Interestingly, Amenta et al. (2020) proposed that symptoms could be classified into several groups: (1) residual symptoms that persist after recovery from acute illness, (2) organ dysfunction persisting after initial recovery, and (3) new symptoms coming up after asymptomatic or mild infection. This classification emphasises the fact that long COVID is a multi-organ condition and that further research is required to better classify the causes and types of symptoms.⁴

Definition and symptoms classification are subject to modification in the light of a new understanding of the disease. Some studies have indeed suggested a certain level of organ impairment, even in people who undergo a mild form of the disease.⁵

^a <https://kce.fgov.be/en/needs-and-follow-up-of-long-term-covid-19-patients-ongoing-study>

4 RESEARCH QUESTIONS

The following research questions are formulated for this systematic review:

- What is the prevalence of long COVID following a confirmed or suspected COVID-19 (highly suspected clinically and/or radiologically)?
- What are the symptoms of long COVID and their frequency?
- What are the risk factors for developing long COVID compared to “short” COVID-19?

This systematic review will be updated when the final report is published (October-November 2021).

5 METHODS

We followed the KCE Process Book for conducting the search. The search was conducted from 03 February to 20 May 2021 in 11 databases. Details of the search strategy are presented in Appendix 2.

5.1 Structured questions and search concepts

The research question was transformed into a PEOD (Population-Exposure-Outcome-Design) structured search question (See Appendix 1.1). Keywords and search concepts were collected through experts' opinion, existing recent publications retrieved after preliminary literature searches, and consultation of controlled vocabularies (Medical Subject headings = MeSH; Excerpta Medica = Emtree). Considering the topic specificities, only keywords related to the problem were sought.

	Inclusion criteria	Exclusion criteria
Population	People experiencing symptoms beyond 4 weeks onward (≥ 4 weeks and > 12 weeks) with appropriate denominator reported*	
Exposure	COVID-19 confirmed (PCR, antibodies) or not (but highly suspected clinically and/or radiologically)	
Outcome	<ul style="list-style-type: none"> • Prevalence of reported symptoms (any symptoms including biological disturbances) and daily life consequences • Risk factors for long COVID 	
Design	N \geq 250 patients included Studies conducted in Europe and the USA Systemic review, Cohort study, Cross-sectional study	Case report, Case series, Mixed method (qualitative)
Language	English, French, Dutch, Spanish	Other languages

* For prevalence assessment: denominator corresponding to the percentage of acute COVID-19 cases. For risk factors assessment, percentage of long COVID.

5.2 Identification of studies

A set of bibliographical databases and registers to search was identified based on the search questions. Considering the topic specificities (recent topic), full text databases and pre-print registries were also sought (See Appendix 1.2). A search query was developed with the assistance of a medical information specialist and adapted to each database. Considering the topic specificities (recent topic, no clear concept, several synonyms), a pure keyword strategy was chosen. Search in those databases was supplemented by collecting additional references from different sources (external experts, exploratory searches in the bibliographical databases, identification of cited references and looking into the bibliography of key references). It was completed by a regular scan of more recent literature through PubMed, MedRXIV and international websites on COVID-19 (WHO, NICE, CDC, HAS).

All identified references were imported in Endnote X.8, the duplicate search results were detected based on title match using the build-in tool from EndNote, and supplemented by manual identification after sorting on Title.

The search strategy was challenged using the results of the initial pragmatic review of literature, published in January 2021^b: we checked whether the current search strategy identified the studies previously included in this review.

5.3 Selection of studies

The selection of studies followed a three-stepped process conducted by the information specialist and one researcher.

The first step of studies identification was based on title and abstract screening using the research question and human context by the information specialist: irrelevant studies that were out of scope were excluded during this screening phase and potentially relevant studies were kept.

The second step was based on title and abstract screening using the PEOD and exclusion criteria by the researcher: irrelevant studies were discarded. The full text of the retained studies was then sought.

In the third phase assessing eligibility of inclusion, we selected studies according to the PEOD criteria: we selected studies that measured the prevalence of long COVID in a population of COVID patients, the distribution of symptoms in long COVID patients and/or identified risk factors for long COVID. We limited our selection to studies reporting symptoms ≥ 4 weeks after the onset of the initial disease and conducted in Europe or the US, for better inference to the Belgian population in terms of epidemiology, risk factors such as comorbidity and health-seeking behaviour. We decided to select only studies that have included at least 250 COVID-19 cases. Data on risk factors were based on studies adjusting for potential confounding factors such as age, sex and comorbidities. Languages were restricted to English, French, Dutch, and Spanish. Seeing the urgent need for identifying evidence, critical appraisal was not undertaken in this review but will be performed in the final version of this report.

6 RESULTS

6.1 Included studies

The search through databases yielded 10 445 hits. Additionally, 19 relevant articles in the references in included studies or by scanning the current literature were added. The number of articles was reduced to 6 619 after duplicates removal and 6 577 articles were discarded, based on title and abstract screening. After assessing 42 full texts of the remaining articles for eligibility, 13 were excluded. Thereby, 29 articles met our inclusion criteria and were included in the analysis. Two articles reported on the same study.^{6, 7} Among the retrieved articles, 10 had already been identified among the 11 included in our preliminary pragmatic review in January 2021.⁶⁻¹⁵ The article that we missed¹⁶ could have been identified by a very sensitive search, but such strategy would have required to screen an unmanageable amount of references ($> 35\,500$).

A cross-sectional survey initially included in this preliminary version was discarded because the measurement of persistent symptoms was no more in accordance with the consensus on the timing of long COVID symptoms (2-3 weeks after positive testing).¹⁷ The selection of studies is summarised in the flow diagram (See Appendix 1.3).

Twenty-two studies were observational cohort studies^{8, 10, 11, 14-16, 18-33} and 7 were cross-sectional studies^{6, 7, 9, 12, 13, 34, 35} considering the frequency and the type of symptoms after COVID-19.

Eight studies included data from several countries. Five studies were from the UK, 2 studies from France, 3 from Spain, 2 from Italy, 3 from the US, 2 from Switzerland, and the remaining four studies were from Denmark, Norway, Sweden and Germany. Four studies were preprints, still under review.^{9, 13, 19, 33} By stratifying by the follow-up duration, we identified 15 studies in the 1 to 3 months period, 10 in the 3 to 6 months period and 4 with a follow-up longer than 6 months (See Table 1 and Table

^b https://kce.fgov.be/sites/default/files/atoms/files/2020-04HSR_LongCOVID_COVID%20Contributions_01022021.pdf

2). Nine studies included several points of follow-up.^{9-12, 19, 25, 29, 30} Samples sizes widely varied and ranged from 256 to 236 379 included patients.

Regarding the characteristics of the infection at the initial period, 6 studies included exclusively hospitalised patients^{18, 22, 28, 29, 32, 34}, while five studies solely reported on ambulatory patients.^{8, 11, 19, 25, 35} Other studies included a mixed population of ambulatory and hospitalised patients: three studies had a majority of hospitalised people^{10, 14, 23}, whereas 15 others comprised both patients who were hospitalised and non-hospitalised.^{6, 7, 9, 12, 13, 15, 16, 20, 21, 24, 26, 27, 30, 31, 33}

The majority of studies included patients who experienced symptoms at the time of acute infection. Three studies included a limited proportion of patients who remained asymptomatic during acute COVID-19.^{9, 12, 30} Symptoms were mostly self-reported and collected through phone calls^{8, 16, 22, 26, 28, 32, 34} or by electronic questionnaires^{6, 7, 9, 11-14, 19-21, 24, 25, 33, 35}. Six studies assessed symptoms through a medical visit follow-up.^{10, 23, 25, 28-30}

Among the retrieved studies, we made a distinction between studies for which COVID-19 patients were used as denominator from those in which only long COVID patients have been selected. The latter exclusively pick out patients with persisting symptoms and cannot be used to determine the prevalence of long COVID among COVID-19 cases. These studies that only assessed persisting symptoms in long COVID patients were only used to describe the frequency and duration of symptoms. Sample sizes of those studies ranged between 277 to 4 182 patients (See 6.4).^{6-11, 13, 19, 26, 28, 33-35}

6.2 Prevalence estimate

6.2.1 Studies with 1 to 3 months of follow-up

We found 9 studies allowing us to assess the prevalence of long COVID between 1 to 3 months: six observational cohort studies^{8, 10, 11, 19, 22, 26} and three cross-sectional surveys^{9, 12, 34} (See Table 1). Among those, two were preprint articles currently under review.^{9, 19} One study also assessed the effect of corticosteroids on lung function.²²

All studies were based on self-reported symptoms by means of telemedicine through COVID app monitoring, phone or online surveys and medical visits. COVID-19 was confirmed in each study. Two studies included patients who were asymptomatic at the acute phase.^{19, 30}

The number of patients ranged from 277 to 4 182 in epidemiological studies, whereas the survey from ONS included 21 622 participants. The majority of patients were middle-aged (mean ages ranging from 42 to 62 years). Three studies included non-hospitalised patients,^{8, 11, 19} while 3 other studies included mostly patients who have been hospitalised.^{10, 22, 34} Three studies involved ambulatory patients along with a limited proportion of hospitalised ones, below 10%.^{9, 12, 26}

Globally, studies showed that among patients who were affected by COVID-19, the proportion of those who had persistent symptoms ranged from 5.2 to 71.8% (See Table 1 and Figure 1):

- Studies that included patients who were not hospitalised at the time of first infection or studies that included a minor proportion of patients hospitalised at the acute phase, reported lower prevalences ranging from 5.2 to 36%.^{8, 9, 11, 12, 19, 25, 26}
- Studies that included patients predominantly hospitalised (even in ICU) reported higher prevalences that ranged between 39 and 71.8%.^{10, 22, 34} The study from Myall et al. reported that 39% of the patients had symptoms 4 to 6 weeks after hospital discharge, while the study from Mandal et al. reported that up to 71.8% of patients showed at least one symptom at the same follow-up time.^{22, 34} Both studies reported high proportions of patients who were hospitalised on ICU and for whom mechanical ventilation was initiated (7% in the study from Mandal et al. and 46% in the study from Myall et al.). In the study of Moreno-Perez et al., that included 66% of hospitalised patients, the reported prevalence was at a rather similar level of 36.6%, when the subgroup of patients with severe pneumonia was excluded.

Five of the included studies extended the measure prevalence also beyond 12 weeks and indicated a higher prevalence in the first 11 weeks after disease onset compared to measurements performed after 12 weeks (See 6.2.2).^{9-12, 19, 25}

6.2.2 Studies with 3 to 6 months of follow-up

Eleven studies allow to assess the prevalence of long COVID between 3 to 6 months: 9 observational cohort studies^{10, 11, 19, 23, 25, 28-30, 32}, and two cross-sectional studies^{9, 12} (See Table 1). Among these, several studies included different time-points of follow-up: six studies were already used to determine the prevalence between 1 to 3 months^{9-12, 19, 25} and two beyond 6 months.^{29, 30} Two studies were reported in preprint articles.^{9, 19}

All studies were based on self-reported symptoms by means of phone calls, online questionnaires, app monitoring. Six studies included patients in a multidisciplinary outpatient clinic^{10, 23, 25, 28, 29, 30} and 3 of them included biological, respiratory and psychological assessments by means of various tests.^{23, 28, 30} Mean ages fluctuated from 42 to 63 years. Three studies included only hospitalised patients^{28, 29, 32}, while three studies focused on ambulatory patients.^{11, 19, 25} Five studies included a mixed population (ambulatory and hospitalised patients).^{9, 10, 12, 23, 30} Among those, two studies involved a majority of hospitalised patients^{10, 23}, while the three others had less than 10% hospitalised patients.^{9, 12, 30}

Based on those included studies, the prevalence of long COVID between 3 and 6 months was highly heterogeneous and ranged from 2.3 to 68% (See Table 1 and Figure 1):

- The three studies that reported a high prevalence mainly included hospitalised patients: Venturelli et al. have estimated the presence of ongoing symptoms at 51%, after hospital or emergency room discharge.²³ A high proportion of patients were hospitalised (88%) and followed-up at multidisciplinary outpatient clinic post-discharge. Besides, Morin et al., and Ghosn et al. reported on persistent symptoms in 51²⁸ and 68%, respectively.²⁹ They included only patients with severe or critical COVID-19 at the initial phase. In both studies, the proportions of patients who required ICU admission was 29.7 and 29%, respectively.
- Prevalence was lower in studies that predominantly included non-hospitalised patients and ranged between 2.3 and 21.4%.^{9, 11, 12, 19, 25, 30}
- Five studies reported prevalences at different time points and, we noticed a decreasing trend (Figure 1): higher prevalences were reported in the first 11 weeks after disease onset compared to measurements performed 12 or more weeks after symptom onset (ranging from 2.3 to 29%).^{9-12, 19}

6.2.3 Studies with follow-up ≥ 6 months

Four observational cohort studies, allow to assess the prevalence of long COVID at more than 6 months of follow-up.^{25, 29, 30, 33}

- In one study, long-term immunological response after COVID-19 in young low-risk patients was assessed. Healthcare workers from a hospital in Denmark were followed. Blood samples were performed every 4 months to assess the presence of antibodies against SARS-CoV-2 and symptoms were obtained through an app using standardised questionnaires. A decreasing trend in prevalence was observed over time in 323 seropositive participants. At 2 and 4 months, symptoms were present in 26 and 21.4%, respectively (See Figure 1). Almost 15% reported a minimum of one symptom for at least 8 months, while only 3.4% of seronegative patients did.²⁵
- Another study prospectively followed patients with predominantly mild COVID-19 in the acute phase. At 7 months, the prevalence was 12.8%. A high rate of dropouts was mentioned (only 37% of the initial number of patients were followed). Missing patients were called and 24.2% of reached dropouts reported over the phone the presence of symptoms (without medical assessment).³⁰
- The third study focused on hospitalised patients only, with 29% of whom were admitted to the ICU in the acute phase. Sixty per cent presented at least one persistent symptom at 6 months and 24% of them had simultaneously three or more symptoms.²⁹
- At 6 to 8 months after diagnosis, a prospective cohort study assessed patients with 19 of whom hospitalisation was required (with 2.3% at ICU). Symptoms were reported by 25% of patients and 26% reported that they had not fully recovered.³³

Figure 1 – Results of studies assessing the prevalence of long COVID according to the level of care during the acute phase




Table 1 – Results on long COVID prevalence

Authors	Inclusion criteria	Design and Sample Size	Outcome and timing since acute COVID-19	Study population	Duration of follow-up (months)	Prevalence	Symptom-specific prevalence	Publication status
Cellai M⁸, US	Telemedicine clinic program (regular phone calls) Confirmed infection (PCR)	Prospective cohort study n= 496	Persistent self-reported symptoms 6 weeks after onset of COVID-19	Ambulatory	1-3 m	5.2% (26/496)	Not reported	Published
Cirulli E⁹, US	Participants to online survey in 2 projects. Confirmed infection (PCR)	Cross-sectional survey n= 357	Self-reported symptom lasting longer than 30 days after COVID-19 onset (from a list of 32 symptoms)	Hospitalised 2.5%	1-3 m ≥ 3 m	at 30 days: 36.1% (129/357) ≥ 3 months: 14.8%	Not reported	Under review
Sudre C¹¹, UK, US and Sweden	Self-reporting in Covid Symptom Study App (start logging when still asymptomatic) Confirmed infection (PCR)	Prospective cohort study n= 4 182	Any self-reported symptom > 28 days after onset of COVID-19	Ambulatory	1-3 m ≥ 3 m ≥ 3 months:	13.3% (558/4182) 2.3%	Not reported	Published
Moreno-Perez O¹⁰, Spain	Outpatient structured evaluation after hospital or emergency discharge. Confirmed infection	Prospective cohort study n= 277	Persistence of ≥ 1 symptom or abnormal spirometry or chest X-Ray at 10-14 weeks after	Hospitalised 66 % ICU 8.7%	1-3 m > 3 m	50.9% (141/277) ≥ 3 months: 3.8% (neurological)	Not reported	Published

	(PCR) or seroconverted		onset of COVID-19				6.7% (respiratory)	
Mandal S³⁴, UK	Phone or in-person interview of every patient after hospital discharge who had tested COVID-19 positive	Cross sectional study n= 384	Self-reported symptoms 4-6 weeks after discharge and biological, respiratory and mental assessment	Hospitalised	1-3 m	71.8% (276/384)	<ul style="list-style-type: none"> • Dyspnoea 53% • Cough 34% • Fatigue 69% 	Published
Myall K²², UK	Phone interview 4 weeks after hospital discharge Confirmed infection (PCR or clinically/radiologicall y)	Prospective cohort study n= 837	Self-reported ongoing symptom 4-6 weeks after discharge	Hospitalised ICU 54%	1-3 m	39% (325/837)	Not reported	Published
Nehme M²⁶, Switzerland	Phone call 30-45 days after diagnosis (remote follow-up care system) Confirmed infection (PCR)	Prospective cohort study n= 669	Self-reported ongoing symptom 30-45 days from diagnosis	Hospitalised 6%	1-3 m	32% (214/669)	Not reported	Published
Office for National Statistics (ONS)¹², UK	Positive COVID-19 patients who responded to the National Coronavirus (COVID-19) Infection Survey (CIS)	Cross sectional survey n= 21 622	Self-reported persistent symptoms at 5 weeks or ≥ 12 weeks after COVID-19 onset	Hospitalised 7.9% to 8.6%* * among those who first had infection at least 12 weeks previously	1-3 m 3-6 m	≥ 5 weeks: 21% ≥ 12 weeks: 13.7%	<ul style="list-style-type: none"> • Fatigue 11.8% • Cough 10.9% • Headache 10.1% • Myalgia 7.7% <ul style="list-style-type: none"> • Fatigue 8.3% • Cough 7% • Headache 7.2% • Myalgia 5.6% 	Not applicable

Venturelli S²³, Italy	Inclusion in an outpatient post-discharge multidisciplinary program after hospital or ED discharge	Prospective observational study n= 767	Ongoing symptoms (psychological, biological, respiratory evaluations) at 12 weeks	Hospitalised 88% ICU 9.7%	3-6 m 51% (394/767)	<ul style="list-style-type: none"> • Fatigue 44% (334/758) • Dyspnea 29.7% (228/767) • Post traumatic psychological disorders 30.5% (222/727) • Functional finding: impaired lung function (DLCO) 19% (136/716) 	Published
	Confirmed infection (PCR or seroconversion) 99%						
Morin L²⁸, France	Telephone assessment 3-4 months after hospital discharge	Prospective cohort study n= 478	Symptoms at 4 months after hospital discharge	Hospitalised	3-6 m 51% (244/478)	<ul style="list-style-type: none"> • Fatigue 31.1% (131/431) • Memory difficulties 17.5% (73/416) • New-onset dyspnea in 16.3% (78/478) • Persistent paresthesia 12.1% (51/421) 	Published
	Ambulatory visit for a subset of patients with relevant symptoms						
Bliddal S¹⁹, Denmark	Identification through Danish Civil Registration System on basis of positive PCR for COVID-19. Patients were invited (via the national digital postbox) to complete a questionnaire	Prospective cohort study n= 445	Persistent symptoms > 4 weeks and > 12 weeks	Ambulatory 3-6 m	1-3 m > 4 weeks: 16% (71/445)* > 12 weeks: 11.7% (52/445)*	<p>* Prevalence of symptoms is not reported and are based on our own calculation</p>	Not reported Under review
Romero-Duarte S³², Spain	Data retrieved from follow-up consultation (primary care and hospital specialities) and	Retrospective observational study	Self-reported symptoms at any time after hospital discharge during 6	Hospitalised patients ICU 10.8%	3-6 m ≤ 6 months: Symptoms: 63.9%* (509/797) Return to emergency	<ul style="list-style-type: none"> • Dyspnoea 28% (223/797) • Fatigue 22.1% (176/797) 	Published

	periodic telephonic reports	n= 767	months follow-up, hospital readmission, return to the emergency services and death	department 20% (160/797) Hospitalisation 4.4% (35/767) Death 1% (8/797)	<ul style="list-style-type: none"> • Diarrhea 10.3% (82/797) • Mental health disorders 12.2% (97/797) • Dermatological issues 9.3% (74/797) • Superinfection 7.9% (63/797) <p>Less frequent symptoms:</p> <ul style="list-style-type: none"> ○ Smell/taste 5.3% ○ Headache 5.3% ○ Cardiovascular 5.8% ○ Ophthalmological 4.6% ○ Nephrological 4.5% ○ Haematological 4.4% ○ Urological 4.3% ○ Otorhinological 3.1% ○ Endocrine 1.5% 	
Havervall S²⁵, Sweden	Healthcare workers participating in an online survey and regular clinical/biological assessment	Prospective cohort study n= 1 395	Ongoing symptoms (at least one moderate to severe symptoms) at 8 months	Ambulatory > 6 m ≥ 2 months: 26% (84/326) ≥ 4 months: 21.4% (69/323) ≥ 8 months: 14.9% (48/323)	<ul style="list-style-type: none"> • Anosmia 9% • Fatigue 4% • Agueusia 3.7% • Dyspnoea 1.9% • Sleeping disorders 2.2% • Headache 1.5% • Palpitations < 1% • Concentration impairment < 1% • Muscle/joint pain < 1% 	Published

								Memory impairment < 1%
Ghosn J²⁹, France	Patients who were hospitalised were assessed through physician visits 3 and 6 months after hospital admission	Prospective cohort study n= 1 137	Systematic assessment of ten persisting symptoms at 3 and 6 months	Hospitalised ICU 0.7%	3-6 m > 6 m	≥ 3 month: 68% (655/957) ≥ 6 months*: 60% (639/1068)	<ul style="list-style-type: none"> • Fatigue nearly 40% • Dyspnoea > 20% • Joint pain nearly 20% • Myalgia nearly 20% • Headache > 10% • Rhinorrhea 10% • Cough 10% • Sore throat <10% • Agueusia 7% • Anosmia 7% 	Published
Augustin M³⁰, Germany	Invitation of each patient with confirmed infection (PCR) for follow-up medical visits at month 4 and 7, regardless of symptoms	Prospective cohort study n= 958	Assessment of long-lasting symptoms with systematic questionnaire s at 4 and 7 months after symptom onset (or positive testing) Median follow-up 6.8 months	Hospitalised 2.9% 3-6 m At 7 months: 12.8% (123/958) At 4 months: 12.8% (123/958)	> 6 m	At 7 months: 12.8% (123/958) At 4 months: 12.8% (123/958)	<ul style="list-style-type: none"> • Anosmia 12.4% (55/442) • Agueusia 11.1% (49/442) • Fatigue 9.7% (43/442) • Shortness of breath 8.6% (38/442) <ul style="list-style-type: none"> • Anosmia 14.7% (52/353) • Agueusia 14.2% (50/353) • Fatigue 13.6% (48/353) • Shortness of breath 11% (39/353) 	Published

								*Due to the a high rate of dropout, we calculated the most conservative estimate at 7 months:
								<ul style="list-style-type: none"> ○ Anosmia 5.4% (52/958) ○ Ageusia 5.2% (50/958) ○ Fatigue 5.0% (48/958) ○ Shortness of breath 4.1 % (39/958)
Menges G³³, Switzerland	Inclusion through contact tracing of the Department of Health, based on mandatory laboratory reporting of all individuals diagnosed with SARS-CoV-2 (PCR)	Prospective cohort study n= 431	Assessment of recovery and long-lasting symptoms through electronic questionnaire at 6 to 8 months after diagnosis and assessment of fatigue, dyspnoea, depression by using appropriate scales (FAS mMRC,DASS -21)	Hospitalised 19% ICU 2.3%	> 6 m	Not fully recovered 26% (111/431)	Symptoms 25% (106/431)	<ul style="list-style-type: none"> ● Fatigue 55% (233/431) ● Dyspnoea (mMRC ≥ 1) 22% (96/431) ● Symptoms of depression 26% (111/431) <p><u>Self-reported symptoms:</u></p> <ul style="list-style-type: none"> ● Fatigue 12% (52/431) ● Cough 10% (41/431) ● Sore throat 9% (38/431) ● Headache 9% (37/431) ● Smell/taste disorder 5% (21/431) ● Rash 0.7% (3/431)

Legend:DASS-21: Depression Anxiety and Stress Scale 21; DLCO: Diffusing capacity for carbon dioxide; FAS: Fatigue Assessment Score; ICU: Intensive care unit; mMRC modified medical research council; PCR: Polymerase chain reaction

6.3 Prevalence of long COVID for specific organ systems or symptoms

In this section, we only describe studies reporting prevalence on specific symptoms affecting one or several particular organ systems. Results are presented in Table 1 (symptom-specific prevalence column) and Table 2. We retrieved 15 observational cohort studies^{14-16, 18, 20, 21, 23-25, 27-29, 31-33} and one cross-sectional study.¹² Among these, six had a follow-up of 3 months^{12, 14-16, 21, 24}, while seven evaluated symptoms between 3 and 6 months.^{18, 20, 23, 27, 28, 31, 32} Three studies had a follow-up beyond 6 months.^{25, 29, 33} Only one article was under review.³³

Three studies appraised mental health^{14, 15, 27} and four evaluated the olfactory or taste disorders.^{16, 20, 21, 24} Six other studies reported on general symptoms^{12, 23, 28, 29, 31, 33}, whereas two focused on mortality and hospital readmission.^{18, 32}

6.3.1 Mental health symptoms

In a large retrospective observational study, Taquet et al. reported a frequency of 5.8% of new onset psychiatric illness in the aftermath of COVID-19. Anxiety or mood disorders (mainly depression) were reported up to 3 months after the onset of COVID-19 in respectively 4.7 and 2% of patients.¹⁵ At 6 months, in a larger cohort with a hospitalisation rate of 19.6%, the same authors reported a rate of 12.84% of new-onset psychiatric or neurological illness. This rate was higher and reached 25.79% in more severe patients who had been admitted to an intensive therapy unit (ITU). Anxiety was reported in 7.11% of the total cohort and almost 10% in the more severe subgroup who needed intensive therapy. Insomnia in both groups was 2.53 and 4.24%, respectively. Psychotic disorders or brain vascular disorders, such as stroke or haemorrhage, were less frequent (below 1%).²⁷ Mental health problems were more often identified at a frequency rate of 55% one month after the onset of the disease among COVID-19 patients that had visited the emergency department (with 75% of them hospitalised) during the acute COVID-19 phase.¹⁴

6.3.2 Olfactory and smell symptoms

In three prospective cohort studies that mainly included ambulatory patients, self-reported olfactory disorders within 1 to 3 months after onset of disease varied between 26 and 42%, in those having developed anosmia or hyposmia at the acute phase of the disease.^{16, 21, 24} One of these studies reported also 33.8% of taste disorder.²¹ One prospective cohort study investigated the olfactory abnormalities through objective and validated tests. Authors reported a prevalence of 15.3% at 2 months and 4.7% at 6 months, in those who were anosmic/hyposmic during acute COVID-19.²⁰

6.3.3 General symptoms

One cross-sectional study reported on general symptoms at different time points following acute infection¹², while three observational studies assessed the prevalence of general symptoms between 3 and 6 months^{23, 28, 31}:

- In the update of the Coronavirus Infection Survey (CIS) from April 2021, the UK Office for National Statistics (ONS) reported that the most prevalent self-reported symptoms that persist at least 5 weeks after acute infection were fatigue (11.8%), cough (10.9%), headache (10.1%) and muscle pain (7.7%). The most prevalent symptoms that persisted at least 3 months were the same as those reported at 5 weeks, but prevalences were lower for all symptoms. However, ONS mentioned that those estimates must be interpreted with caution because of a low amount of participants still reporting symptoms at 12 weeks.¹²
- In the study of Venturelli et al., 767 patients discharged from hospital (88%) or emergency room underwent an assessment through a multidisciplinary follow-up clinic. About one-third of the cohort presented dyspnoea 12 weeks after discharge (See Table 1). Other symptoms were post-traumatic psychological symptoms (30.5%) and fatigue (44%).²³ Another observational study reported a prevalence of dyspnoea of 16.3% at 4 months in hospitalised patients of whom one third was admitted to ICU (See Table 1). Other reported symptoms were fatigue (31%), memory difficulties (17.5%) and paresthesia (12.1%).²⁸
- One observational cohort study that estimated the prevalence of long COVID beyond 6 months reported on the prevalence of symptoms over time among a cohort of seropositive or seronegative for SARS-CoV-2 and not hospitalised people (See Table 1).²⁵ The most prevalent symptoms at 8 months were anosmia (9%), fatigue (4%) and ageusia (3.7%). Other less frequent

symptoms included dyspnoea, sleeping disorders, headache, palpitations, concentration/memory impairment or muscle/joint pain. The prevalence of those symptoms decreased all over time. Conversely, another study that included more severe hospitalised patients, reported fatigue by a rate of about 40%. Dyspnoea, joint/muscle pain were also common.²⁹

- In a cohort comprising 19% of hospitalised patients, Menges et al. used appropriate scales (FAS, mMRC and DASS-21) to assess fatigue, dyspnoea and depression that were reported in 55, 25 and 26%, respectively. Self-reported fatigue was lower than the prevalence estimated with the FAS.³³ (See Table 1)
- Daugherty et al. retrospectively showed, in a cohort of patients who were predominantly not hospitalised, that 14% of patients had at least one new type of clinical sequelae that required medical care 4 months after COVID-19. New symptoms were identified across a wide range of organ systems including cardiovascular, respiratory, renal, haematological and mental issues.³¹

6.3.4 Hospital readmission and mortality

Two studies focused on hospital readmission and mortality^{18,32}:

- Ayoubkhani et al. conducted a large retrospective observational and matched cohort study in the UK that included 47 780 participants who were discharged from the hospital.¹⁸ They reported on the rates of hospital readmission, mortality and new-onset diseases over a mean follow-up of 140 days and compared them to control cases matched on clinical and demographic characteristics. Twenty-nine percent of COVID-19 patients were re-admitted to the hospital whereas 9.2% of matched-control patients did. Mortality rate was 12.3% in the COVID-19 group versus 1.7% in the matched-control group. Likewise, rates of new-onset multi-organ dysfunctions (respiratory or cardiometabolic) were significantly raised in COVID-19 subjects when compared to controls (See Table 2).¹⁸
- Romero-Duarte et al. reported 20.3% of patients who returned to the emergency department and 12.1% were hospitalised within 6 months after COVID-19.³²

Table 2 – Results on prevalences of long COVID for specific organ systems or symptoms

Authors	Inclusion criteria	Design and Sample Size	Outcome and timing since acute COVID-19	Study population	Duration of follow-up	Prevalence	Prevalence of specific symptom	Publication status
Taquet M, UK ¹⁵ , US	Data extraction from electronic database in positive COVID-19 patients (confirmed infection PCR or antigen testings 92.2%)	Retrospective observational cohort study n= 62 354	New-onset psychiatric disorders within 14 to 90 days after COVID-19 onset	Percentage of hospitalization not mentioned	1-3 m	5.8%	<ul style="list-style-type: none"> • Anxiety disorder 4.7% (adjustment disorder, generalised anxiety disorder, PTSD, panic disorder) • Mood disorder 2% (depression 1.7%) • Psychotic disorder 0.1% • Insomnia 1.9% • Dementia 0.44% 	Published
Taquet M ²⁷ , UK, US	Data extraction from electronic database in positive COVID-19 patients Confirmed infection (ICD-10 codes U07.1)	Retrospective observational cohort study n= 236 379	New-onset psychiatric or neurological disorders in the 6 months after COVID-19	Hospitalised 19.6% ITU 3.8%	3-6 m Patients admitted in ITU: 25.79%	Whole COVID-19 cohort: 12.84%	<ul style="list-style-type: none"> • Anxiety disorders 7.11 % • Psychotic disorders 0.42% • New insomnia 2.53% • Intracranial haemorrhage 0.28% • Ischaemic stroke 0.76% • Parkinsonism 0.11% • Dementia 0.67% 	Published
Mazza M ¹⁴ , Italy	Clinical interview and self-reported questionnaires in COVID-19 patients assessed at ED and hospitalised or not. (no information on testing)	Prospective observational cohort study n= 402	Mental health assessment at one month after COVID-19 onset	Hospitalised 75%	1-3 m	56%	<ul style="list-style-type: none"> • PTSD 28% • Depression 31% • Insomnia 40% • Anxiety 42% • Obsessive-compulsive symptoms 20% 	Published
Makaronidis J ²¹ , UK	Invitation of people with acute loss of smell/taste through primary care	Prospective cohort study	Smell/taste disorders at 4-6 weeks after	Ambulatory	1-3 m	Smell* 42.2% (151/357)	Not reported	Published

	centers (recruitment via online platform). Follow-up by a questionnaire that was sent.	n= 467	COVID-19 onset	Hospitalised 2.3%	Taste* 33.8% (116/343)			
	Serology positive in 82%				* of those who developed olfactory and taste disorders during the acute phase			
Chiesa-Estomba C²⁴, France and European	Identification of patients with total or partial loss of smell through database from 3 hospitals. Contact after 30 days for olfactory assessment via online questionnaire	Prospective cohort study n= 751	Self-reported persistent olfactory dysfunction	Ambulatory Hospitalised (no clear % mentioned)	1-3 m	Persistent loss of smell* 37% (277/751) Partial smell recovery* 14% (107/751)	Not reported	Published
	Confirmed infection (PCR)					*of those who developed olfactory and taste disorders during the acute phase		
Villarreal I¹⁶, Spain	Phone interview in healthcare workers with PCR positive for COVID-19	Prospective cohort study n= 256	Olfactory and taste disorders at 1 month after acute infection	Hospitalised 3.5%	1-3 m	26% (43/161)*	Not reported	Published
						* of those who developed olfactory and taste disorders during the acute phase		
Lechien J²⁰, Belgium and Europe	Online questionnaire was completed at the end of the disease or at the hospital discharge and within the 2-month post-infection (identification through hospital databases)	Prospective cohort study n= 1 363	Self-reported olfactory dysfunction at 2 and 6 months (objective testing in a subset)	Hospitalised 2%	3-6 m	24.1%* (328/1363)	Not reported	Published
						* of those who developed olfactory and taste disorders during the acute phase		

Ayoubkhani D ¹⁸ , UK	Identification through electronic health and mortality records (ICD10 codes: U07.1 and U07.2)	Retrospective matched cohort study n= 47 780	Over a mean follow-up of 140 days, assessment of: - Hospital readmission - Cause of death - Organ dysfunctions	Hospitalised 3-6 m	Not reported	<ul style="list-style-type: none"> • Hospital re-admission 29.4% in COVID-19 patients vs 9.2% in the control group • Death after discharge 12.3% in COVID-19 patients vs 1.7% in the control group • New-onset organ dysfunctions in COVID-19 patients versus control group: <ul style="list-style-type: none"> ○ Respiratory disease 21.5% vs 0.8% ○ Diabetes 1.1% vs 0.3% ○ Cardiovascular 2.6% vs 0.5% 	Published	
Daugherty S ³¹ , US	Identification through electronic health from 3 data sources within the United Health Group Clinical Discovery Database (ICD10 codes: U07.1, U07.2, B34.2, B97.29) Confirmed infection (PCR)	Retrospective cohort study n= 193 113* Three comparative groups matched by propensity score	Assessment of risk and relative hazards for developing clinical sequelae requiring medical care after COVID-19 in 18-65 years patients, over a follow-up of 4 months after acute infection (median 95 IQR 42-135) * Total cohort: 266 586 and 193 113 with follow-up	Hospitalised* 8.2% ICU* 1.1% * calculated on a total of 266 586	3-6 m 14.02% with at least 1 new type of clinical sequelae that required medical care (27 074/193 113):	<ul style="list-style-type: none"> • 10.01%: one sequela • 4.01%: > 1 new sequelae 	In comparison with control groups, higher risk difference and higher hazard ratio* for several new clinical outcomes*: <ul style="list-style-type: none"> • Neurological disorders • Cardiovascular disorders • Hypercoagulability • Kidney disorders • Respiratory disorders • Mental health and neurocognitive issues <p>* clinical outcomes were grouped per organ system given the high number. Results are available upon request.</p>	Published

Legend: PCR: Polymerase chain reaction; ITU: Intensive therapy unit; PTSD: Post-traumatic stress disorder

6.4 Most common symptoms and their frequency among patients with long COVID

We report the frequency of symptoms among long COVID patients through studies assessing symptoms in this subgroup. In this case, the number of long COVID patients is used as a denominator.

We obtained data on symptom frequency in long COVID patients based on 13 articles: 7 observational cohort studies^{8, 10, 11, 19, 26, 28, 33} and 6 cross-sectional surveys (See Table 3).^{6, 7, 9, 13, 34, 35} Among these studies, 9 were already been used to determine long COVID prevalence.^{8-11, 19, 26, 28, 33, 34} Two articles reported on the same study.^{6, 7} Three other studies estimated the frequency before and after 3 months.^{9, 13, 19} and three articles were preprints.^{9, 13, 19} One study included patients who were hospitalised at the acute phase of infection and another one reported on a cohort of patients who were predominantly hospitalised. Four studies included patients who were not hospitalised at the acute phase^{8, 11, 19, 35} and 6 articles included both hospitalised and non-hospitalised patients.^{6, 7, 9, 10, 13, 26} One study reported on hospitalised patients, only.³⁴ Only one article reported on symptoms frequency after 6 months.³³ Not all articles reported on the exact estimation of the frequency of the symptoms and only mentioned whether they were frequently reported or not. The frequencies from the study from Moreno-Perez et al. were calculated based on the original data included in the paper such that only long COVID patients were included in the denominator.¹⁰

We noticed that reported frequencies highly varied across studies. Furthermore, while some symptoms were reported continuously, relapsing-remitting presentation of symptoms was also described. Other frequent symptoms are systematically described below:

- The most commonly identified long-term symptoms up to 3 months of follow-up in long COVID patients were fatigue (16%-98%; 10 studies^{6-11, 13, 19, 26, 34}), dyspnoea (10-93%; 9 studies^{6, 8-11, 13, 19, 26, 34}) and headache (9-91%; 8 studies^{6, 8-11, 13, 19, 26}).
- The most commonly identified symptoms at 3 to 6 months follow up were fatigue (16-78%; 3 studies^{13, 19, 35}), cognitive disorders (13-55%, 3 studies^{13, 19, 28}), dyspnea or dysfunctional breathing (16-20.9%, 2 studies^{28, 35}) and post-exertional malaise (72%, one study¹³).
- The study from Menges et al. identified fatigue as the most frequent symptom after 6 months.³³

We did not notice substantial differences between the types of symptoms among studies with ambulatory patients and studies with hospitalised patients. However, it should be noted that a clear distinction between both groups is not easy since many studies mixed hospitalised and non-hospitalised patients.

General health

General symptoms regularly reported include fatigue, muscle weakness, headache, pain (muscular, joint or bone pain), sleep disorders and less frequently low-grade fever or skin disorders (See Table 3). Fatigue and headache were both reported in the first 3 months and beyond. Exercise tolerance (post-exertional malaise) is also part of the reported complaints, reported by the international survey of Davis et al.-preprint. This symptom was frequently reported (89%) up to 6 months after the acute phase.¹³

Respiratory

- Respiratory symptoms like dyspnoea are frequent but highly variable in the aftermath of COVID-19 (from 10 to 93% in the first three months). Frequencies were high in both cohort studies and surveys. Nevertheless, beyond 3 months, they seem less commonly reported.
- Importantly, the frequency of dyspnoea in patients with long COVID has to be distinguished from its prevalence as an organ-specific symptom following acute COVID-19 frequently associated with lung damages. For the latter, we have already reported prevalence ranging between 16 to 30% (See 6.2).^{8, 10, 11, 9-6}
- Cough is also frequently reported in the first three months after acute infection. Frequencies ranged from 10.9 to 34% in 6 studies.^{6, 9, 10, 19, 26, 34} One study reported a frequency of 39% after 6 months.³³
- Chest pain (or chest tightness) ranged from less than 10 to 88.5% in 4 studies conducted in the first 3 months.^{6, 8, 9, 19} One study reported a low prevalence of chest pain beyond 12 weeks.¹⁹

- Functional measurements of lung damage were also performed. Alteration of lung diffusion capacity was described in two studies^{23, 28} including patients who were initially hospitalised and one study reported functional alterations, mainly marked by obstructive patterns at spirometry assessment¹⁰ (See Table 2 and Table 3).

Cardiovascular

Cardiovascular symptoms such as heart palpitations or tachycardia were mainly reported in the first 3 months after COVID-19. The reported frequency among long COVID patients varied widely from 6 to 86% in 5 studies.^{6, 8, 9, 11, 13}

Gastroenterological

Gastroenterological conditions were reported in 7 studies performed in the first 3 months.^{8-11, 13, 19, 26} The reported symptomatology largely varied: diarrhoea, acid reflux, loss of appetite or nausea. Some studies did not elaborate on the type of symptoms^{11, 26} or did not mention the frequency.¹¹

Gastrointestinal symptoms varied between 5 and 85%. Moreno et al. reported diarrhoea in 5.3% of cases.¹⁰ Nehme et al. reported a low frequency beyond one month and did not go into detail of symptoms.²⁶ In the survey of Davis et al.-preprint that included 50% of people < 60 years, a frequency of 85% was reported with diarrhoea as the most prevalent symptom in the first three months after acute infection.¹³

Neurological

- Cognitive disorders are some of the most common neurological symptoms (often referred to as 'brain fog'). They were reported in 5 studies in the first 3 months (3 cohort studies^{10, 11, 19}, 2 cross-sectional studies^{9, 13}) and 3 studies with follow-up beyond 3 months (2 cohort studies^{19, 28} and 1 cross-sectional one¹³). Symptoms are disabling and vary widely (memory disorders, concentration, executive functioning difficulties).^{9-11, 13}

In the first 3 months, reported frequencies were particularly heterogeneous ranging from 4 to 85%. The highest value came from the international survey of Davis et al.-preprint.¹³

Beyond 3 months, frequencies ranged from 13 to 55%. Such cognitive problems were part of the three most frequent symptoms at 6 months in the survey of Davis et al.-preprint.¹³

- Olfactory and/or taste dysfunction are also very often identified among long COVID patients. Six studies (4 cohort studies^{10, 11, 26, 34}, 2 cross-sectional studies^{9, 13}) reported them in 10.8% to 57.6% of patients in the first three months, whereas one cross-sectional study identified them in 10% (smell dysfunction) and 12% (taste dysfunction) of the cases.³⁵ Not all studies provide the crude values. A study reported a frequency at 20% between 6 and 8 months.³³
- Other neurological symptoms include dizziness, tinnitus, visual disorders or peripheral neuropathy (See Table 3).

Mental health

Anxiety and mood disorders (depression) are the most commonly reported mental health symptoms (3 studies^{13, 28, 34}). As mentioned previously, they were longitudinally studied in two retrospective cohorts (See 6.3). Post-traumatic stress disorder (PTSD) is also part of the reported problems and was reported in two studies, in which patients required intensive care or emergency services.^{10, 28}

Table 3 – Frequency of symptoms among long COVID patients

Authors	Inclusion criteria	Design and Sample Size	Outcome and timing since acute COVID-19	Study population	Symptoms frequency	Duration of follow-up (months)	Publication status
Cellai M⁸, US	Telemedicine clinic program (regular phone calls) Confirmed infection (PCR)	Prospective cohort study n= 496	Persistent self-reported symptoms 6 weeks after onset of COVID-19	Ambulatory	<ul style="list-style-type: none"> Respiratory symptoms (dyspnea, chest tightness) 88.5% Fatigue 65% (17/26) Headache 50% (13/26) Gastrointestinal symptoms 34% (9/26) Palpitations 23% (6/26) Low grade fever 11% (3/26) 69.2% (18/26) reported at least 4 concurrent symptoms 	1-3 m	Published
Cirulli E⁹, US	Participants to online survey in 2 projects Confirmed infection (PCR)	Cross-sectional survey n= 357	Self-reported symptom lasting longer than 30 days after COVID-19 onset (from a list of 32 symptoms)	Hospitalised 2.5%	<u>Most frequent:</u> <ul style="list-style-type: none"> Anosmia, ageusia, Dyspnea, chest pain Memory loss, confusion, difficulty concentrating <u>Others:</u> <ul style="list-style-type: none"> Decreased alertness, dizziness Headache, insomnia Muscle weakness Dry cough Tachycardia Bone or joint pain Fatigue Tingling, sensitive skin, back pain Acid reflux, diarrhoea 	1-3 m	Under review
Sudre C¹¹, UK, US and Sweden	Self-reporting in Covid Symptom Study App (start logging when still asymptomatic) Confirmed infection (PCR)	Prospective cohort study n= 4 182	Any self-reported symptom > 28 days after onset of COVID-19	Ambulatory	<ul style="list-style-type: none"> Fatigue 97.7% Headache 91.2% Dyspnoea (?) Anosmia (?) Cardiac symptoms 6.1% Lower respiratory symptoms (?) Memory 4.1% Tinnitus/earache 3.6% Neuropathy 2% 	1-3 m	Published

Moreno-Perez O¹⁰, Spain	Outpatient structured evaluation after hospital or emergency discharge	Prospective cohort study n= 277	Persistence of ≥ 1 symptom or abnormal spirometry or chest X-Ray at 10-14 weeks after onset of COVID-19	Hospitalised 66 % ICU 8.7%	<ul style="list-style-type: none"> Fever (?) Gastroenterological symptoms (?) <ul style="list-style-type: none"> Dyspnea 17.2% Cough 10.6% Fatigue 17.6% Anosmia-Dysgeusia 10.8% Cognitive disorders 7.6% Headache 8.9% Myalgia, arthralgia 9.8% Functional finding: spirometry alterations 4.7% 	1-3 m	Published
Goertz Y⁶ and Vaes A⁷, The Netherlands and Belgium	Persistent symptoms reported in social media in patients who experienced COVID-19	Cross-sectional survey n=2 113 ¹ Confirmed: 16% ¹ -27% ²	Any symptoms > 3 weeks to 3 months after infection onset	Hospitalised 5%	<u>Goertz et al.:</u> <ul style="list-style-type: none"> Fatigue 87% Dyspnoea 71% Chest tightness 44% Headache 38% Muscle pain 36% Heart palpitation 32% Cough 29% <u>Vaes et al.:</u> <ul style="list-style-type: none"> Fatigue: 98% Sleeping disorders 88% Pain 87% Increased need for care: <ul style="list-style-type: none"> Care-dependent: 31% Limitation in daily activities: 41.1% in the independent group 	1-3 m	Published
Davis H¹³, Europe and US	Persistent symptoms in people who experienced symptoms consistent with COVID-19, reported on a survey through social media and support groups	Cross-sectional survey n= 3 762	Persistent symptoms >28 days	Hospitalised 8.4%	1-3 months (most frequent): <ul style="list-style-type: none"> Fatigue 98% Post exertional malaise 89% Cognitive dysfunction 85.1% Headache 77% Cardiovascular symptoms 86 % Musculoskeletal symptoms 93.6% Sore throat 59% Respiratory symptoms 93% Gastrointestinal symptoms (diarrhea, loss of appetite, abdominal pain) 85% Anxiety 57.9% Depression 47.3% 	1-3 m 3-6 m	Under review

	Confirmed infection: 27%				<ul style="list-style-type: none"> Taste and smell disorders 57.6% <p>At 6 months (most frequent):</p> <ul style="list-style-type: none"> Fatigue 77.7% Post exertional malaise 72.2% Cognitive dysfunction 55.4% Sensorimotor symptoms 55.7% Headache 53.6% <u>Relapses of symptoms 85.9%</u> 		
Nehme M²⁶, Switzerland	Phone call 30-45 days after diagnosis (remote follow-up care system)	Prospective cohort study n= 669	Self-reported ongoing symptom 30-45 days from diagnosis	Hospitalised 6%	<ul style="list-style-type: none"> Fatigue Dyspnea Taste/smell disorders Cough Headache <p>Digestive symptoms</p>	1-3 m	Published
Bliddal S¹⁹, Denmark	Identification through Danish Civil Registration System on basis of positive PCR for COVID-19. Patients were invited (via the national digital postbox) to complete a questionnaire	Prospective cohort study n= 445	Persistent symptoms > 4 weeks and > 12 weeks	Ambulatory	<p><u>> 4 weeks:</u></p> <ul style="list-style-type: none"> Fatigue 16% Concentration or memory difficulties 13% Reduced sense of smell 10% Shortness of breath 10% Headache < 10% Muscle/joint pain <10% Cough/chest pain <10% Digestive symptoms <10% <p><u>> 12 weeks:</u></p> <ul style="list-style-type: none"> Fatigue 16% Concentration difficulties 13% Headache < 10% Muscle/joint pain <10% Cough/chest pain <10% Digestive symptoms <10% 	1-3 m 3-6 m	Under review
Stavem K³⁵, Norway	Population-based cross-sectional cohort survey n= 451 PCR confirmed infection	Identification of patients through PCR positivity and invitation to a postal survey or electronically	Persistent symptoms from 1.5 to 6 months after symptom onset	Ambulatory	<ul style="list-style-type: none"> Dyspnea 16% Smell disorders 12% Taste disorders 10% 	3-6 m	Published

Morin L²⁸, France	Telephone assessment 3-4 months after hospital discharge Ambulatory visit for a subset of patients with relevant symptoms	Prospective uncontrolled cohort study n= 478	Symptoms at 4 months after hospital discharge	Hospitalised	<u>Ambulatory assessment (n=177):</u> <ul style="list-style-type: none"> • Cognitive disorders 38.4% (61/159) • Dysfunctional breathing 20.9% (37/177) • Chest CT scan: <ul style="list-style-type: none"> ◦ 63% (108/171) lung abnormalities (ground glass opacities) ◦ 19% (33/171) with fibrotic lesions • DLCO 87% of predicted values (n=152) • Altered heart left ventricular contractility 9.6% (8/83) • In ICU patients (n=94): anxiety (23.4%), depression (18.1%), PTSD (7.4%) 	3-6 m	Published
Mandal S³⁴, UK	Phone or in-person interview of every patient after hospital discharge who had tested COVID-19 positive	Cross sectional study n= 384	Self-reported symptoms 4-6 weeks after discharge and biological, respiratory and mental assessment	Hospitalised	<ul style="list-style-type: none"> • Breathlessness: 74% (204/276) • Cough: 47.5% (131/276) • Fatigue: 96% (265/276) 	1-3 m	Published
Menges G³³, Switzerland	Inclusion through contact tracing of the Department of Health, based on mandatory laboratory reporting of all individuals diagnosed with SARS-CoV-2 (PCR)	Prospective cohort study n= 431	Assessment of recovery and long-lasting symptoms through electronic questionnaire at 6 to 8 months after diagnosis and assessment of fatigue, dyspnoea, depression by using appropriate scales (FAS mMRC,DASS-21)	Hospitalised 19% ICU 2.3%	<ul style="list-style-type: none"> • Fatigue 49% (52/106) • Cough 39% (41/106) • Sore throat 36% (38/106) • Headache 35% (37/106) • Taste/smell disorders 20% (21/106) 	> 6 m	Under review

Legend: DLCO: Diffusing capacity for carbon dioxide; ICU: Intensive care unit; PCR: Polymerase chain reaction; PTSD: post-traumatic stress disorder

6.5 Consequences on daily-life

Among the studies included in the review, seven studies showed that the burden of persisting symptoms has an impact on the quality of life, daily life activities or the return to work.^{6, 7, 10, 12, 13, 28, 29}

- In the large national survey conducted by ONS, an evaluation of the impact of long COVID on daily-life activities has newly been added. It is estimated that 61% of patients with long COVID experienced at least some limitation to their daily-life activities and 17.9% reported important limitations.¹²
- Moreno-Perez et al. observed that the impact of COVID-19 on quality of life was significantly more frequent in patients with chronic symptoms compared to those without chronic symptoms (66.9% versus 43.2%).¹⁰
- In the cohort study of Morin et al. conducted in hospital discharged patients, authors found an alteration of the quality of life, evaluated through the 36-Item Short-Form Health Survey questionnaire. Many patients scored lower on several domains of quality of health.²⁸
- In another large prospective cohort study that included patients who had been hospitalised, about one-third of those who had a professional occupation had not resumed work after 6 months.²⁹
- Davis et al. reported that 45.2% of patients who experienced long COVID reduced their work schedule compared to pre-illness and 22.3% were not working at the time of the survey due to a bad health state (being on sickness- or disability leave, being fired, quitting or being unable to find a job). They showed that cognitive problems including memory disorders negatively impacted their daily life (making decisions, following conversations, remembering medications, driving, cooking, watching children,...).¹³
- In a survey conducted in Belgium and The Netherlands, authors reported limitations in daily activities or care-dependency in the ambulatory setting. The level of care dependency was assessed with the Care Dependency Scale tool. The need for assistance significantly increased after the infection (7.7% vs 52.4%) when compared with life before. Of importance, 41.1% of the patients who were not dependent after infection reported to be at least to a limited extent dependent on others in the performance of daily activities.^{6, 7}

6.6 Risk factors for long COVID

6.6.1 Included studies

Among the studies included in the review, eleven cohort studies^{9, 10, 11, 14, 18, 19, 21, 29-32} aimed at measuring the association between potential risk factor and long COVID (or specific symptoms of long COVID) and are presented in Table 4.

Six cohort studies assessed the risk factors for long COVID per se^{9-11, 19, 29, 30}, while one cohort study was limited to the psychiatric symptoms of long COVID¹⁴ and another cohort study focused on olfactory disorders.²¹ Three cohort studies reported on the mortality, hospital/emergency admission or organ dysfunction following COVID-19.^{18, 31, 32}

Eight studies reported adjusted odds ratio^{9-11, 14, 19, 21, 30, 32} and two studies provided risk ratio or risk difference.¹⁸ Symptoms were self-reported and collected either through a COVID app to monitor patients¹¹, an online survey^{9, 21} or through a search in electronic medical records.^{18, 31, 32} Two studies were based on medical visit follow-up.^{10, 14} Two studies were still under review.^{9, 19}

6.6.2 Risk factors

- Evidence regarding risk factors for long COVID is very sparse and studies that aimed at determining them are limited and considerably heterogeneous. Results are presented in Table 4. Moreover, there is no study with large follow-up, yet.
 - In the update of April 2021, the survey from UK ONS found that a higher percentage of female (23.0%) than male (18.7%) participants reported symptoms that persisted for at least 5 weeks.¹² However, there was a degree of uncertainty over this finding (wide confidence

intervals). Two studies showed that males were less likely to experience long-term symptoms^{30, 33} and, similarly, two others found that the female gender was associated with long COVID.^{19, 29} The female gender is also associated with the likelihood of mental health issues and persistent smell/taste disorders (See below).^{14, 21} Finally, regarding the risk for new clinical conditions 4 months after acute infection, a large retrospective study in the US showed that excess of risk rarely differed according to gender (anosmia, fatigue were commonly diagnosed in women whereas myocarditis, hypercoagulability, deep vein thrombosis, kidney injury, sleep apnea were more commonly diagnosed in men).³¹

- Obesity may be associated with the likelihood of long COVID according to one study under review.¹⁹ Another study showed an association between BMI and dyspnoea still present at 6-8 months.³³
- Another pre-print article identified that patients with long COVID were more likely to have blood type A.⁹
- Long COVID patients are also more likely to have experienced a higher number of symptoms in the acute phase of the COVID, according to three studies.^{9, 11, 30} The presence of symptoms such as fatigue, headache, dyspnoea, pain with a deep breath, sensitive skin, hoarse voice and myalgia (viral symptoms) in the acute phase of the disease were recognised as risk factors for developing long COVID, in two studies.^{9, 11} One of those found that three variables - number of symptoms in the first week, age and sex - allowed to distinguish individuals with long COVID from those with short duration in a sample of patients from three countries (AUC 77%).¹¹ One study showed an association between long COVID and the severity of symptoms during infection.³³ Conversely, Moreno-Perez et al. found, in the adjusted analysis, that baseline characteristics (age, sex, comorbidities) and severity of initial infection did not behave as predictor factors. In their analysis, clinical signs of severity (based on chest X-ray and heart rate) at the initial visit to the emergency department were predictive of long COVID, in those presenting with severe pneumonia.¹⁰ Another study showed that patients who presented symptoms such as thoracic pain, persistent fever or pneumonia were more likely to undergo hospital or emergency service admission.³²
- A lower baseline level of SARS-CoV-2 immunoglobulins (several months after acute infection) was associated with persistent symptoms in one study.³⁰
- One study showed that patients who developed long COVID tended to be older.¹¹ However, age remains somewhat controversial regarding long-term symptoms. Ayoubkhani et al. compared a large cohort of individuals discharged from hospital after COVID-19 with matched control subjects (electronic health records from the general population). The rate ratio for mortality, hospital readmission and organ dysfunctions were greater in patients less than 70 compared to those 70 or older.¹⁸ Daugherty et al. showed that the risk for new-onset clinical issues increased with age and pre-existing comorbidities but younger patients and those without comorbidities had also an increased risk of developing new clinical sequelae, in comparison to control groups.³¹ The April Update from UK ONS showed that people aged 35 to 49 years have the greatest prevalence of symptoms at 5 weeks followed by those aged 50 to 69 years and 25 to 34 years.
- One cohort study on the psychiatric symptoms of long COVID found that female patients or those with a previous psychiatric history were more likely to present psychiatric symptoms one month after hospitalisation or an emergency department visit for COVID-19.¹⁴
- The cohort study on the olfactory dysfunction evidenced, after adjustment for confounding factors, that female sex and presence of parosmia were associated with unresolved smell loss at 4 weeks of follow-up.²¹

Table 4 – Results on risk factors for long COVID in the selected studies

First author, country	Inclusion criteria	Outcome and timing	Risk factors (association measurement and 95%CI)	Other results
Sudre C ¹¹ , UK, US, Sweden	Inclusion by prospective self-reporting of symptoms in the COVID Symptom Study App (start logging when still asymptomatic)	Any symptom >28 days after onset, self-reported	Adjusted analysis (age and sex), compared to "short" (<10 days) COVID, symptoms during first week of COVID (aOR ratio; 95CI): <ul style="list-style-type: none"> • Fatigue 2.83 (2.09-3.83) • Headache 2.62 (2.04-3.37) • Dyspnoea 2.36 (1.91-2.91) • Hoarse voice 2.33 (1.88-2.90) • Myalgia 2.22 (1.8-2.73) 	Main predictors: age, sex, symptoms in 1 st week (AUC 76.8%). In 70+ years (aOR ratio; 95CI): Fever 5.51 (1.75-17.36) Loss of smell 7.35 (1.58-34.22) Hoarse voice 4.03 (1.21-13.42) and comorbidities
Cirulli E ⁹ , US	Participants to online survey in 2 projects, with positive COVID test	Any self-reported short and long-term symptom at 30, 60, 90 days from onset (list of 32 symptoms)	Adjusted analysis at day 30 (aOR ratio; 95CI): <ul style="list-style-type: none"> • Number of initial symptoms • Dyspnoea • Pain with deep breath • Sensitive skin • Blood type A 	Comorbidities and sex were risk factors in the unadjusted analysis, not in the multivariate analysis, probably due to low sample size
Moreno-Perez O ¹⁰ , Spain	Outpatients structured evaluation after hospital or ED discharge in patients with confirmed infection	Persistence of ≥1 symptom or abnormal spirometry or chest X-ray at 10-14 weeks after onset	No risk factor at 60 and 90 days (in multivariate) Adjusted analysis, (aOR ratio; 95CI): <ul style="list-style-type: none"> • For long COVID (overall): no significant risk factor • For those with initial severe pneumonia: <ul style="list-style-type: none"> ◦ opacities of lung surface on X-rays >50% 2.87 (1.13-7.32) ◦ higher heart rate at admission 1.03 (1.01-1.06) 	Predictors of spirometry abnormalities in overall cohort: estimated glomerular filtrate, male sex, comorbidities (high Charlson index associated with lower incidence) Higher imaging score at acute disease was associated with persistence of X-ray signs in overall cohort aOR (95CI): 1.66 (1.30-2.11) and severe

				pneumonia patients 1.68 (1.28,2.19)
Mazza M¹⁴, Italy	COVID-19 patients assessed at ED and hospitalised or not; no information on testing	Mental health assessment at one month after hospital or ED discharge	Adjusted analysis (sex, previous status and hospitalisation): <ul style="list-style-type: none"> • Female sex • Previous psychiatric history 	Older age and long duration of hospitalisation were risk factors in the unadjusted analysis Hospitalisation was not a risk factor
Bliddal S¹⁹, Denmark	Identification through Danish Civil Registration System on basis of positive PCR for COVID-19. Patients were invited (via the national digital postbox) to complete a questionnaire	Persistent symptoms > 4 weeks and > 12 weeks	Adjusted analysis (sex, age, smoking, BMI, comorbidity and time from symptom start to follow-up) for the risk of symptoms after 4 weeks (aOR ratio; 95CI): <ul style="list-style-type: none"> • Female sex 2.91 (1.32-6.39) • BMI 1.13 (1.05-1.22) 	In a subgroup of 117 women with follow-up > 4 weeks, BMI is a risk factor aOR 1.10 (1.0-1.20) Being healthcare worker was not a risk factor 1.50 (0.60-3.8)
Ayoubkhani D¹⁸, UK	Identification through electronic health and mortality records (ICD10 codes: U07.1 and U07.2)	Assessment of mortality, hospital readmission, organ dysfunctions > 3 months after hospital discharge	<ul style="list-style-type: none"> • In COVID-19 patients, rates of all outcomes were greater in 70+ patients than in those aged less than 70. • In COVID-19 patients, rates of all outcomes other than diabetes were greater in the white ethnic group than in the non-white group. • After matching for baseline personal characteristics (age, sex, ethnicity, region, IMD category, and smoking status) and comorbidities, rate ratio were greater in patients less than 70 than those 70+ and in non-white ethnicity, for all outcomes. 	Greater rates of death and hospital readmission in patients admitted to ICU
Daugherty S³¹, US	Identification through electronic health from three data sources within the UnitedHealth Group Clinical Discovery Database (ICD10 codes: U07.1, U07.2, B34.2, B97.29)	Assessment of risk and relative hazards for developing clinical sequelae requiring medical care after COVID-19 in 18-65 years patients, at 4 months after acute infection	<ul style="list-style-type: none"> • Risk differences were increased in older individuals, had pre-existing conditions, and were admitted to hospital because of Covid-19. • Younger patients (aged ≤50), those with no pre-existing conditions, or not admitted to hospital for covid-19 also had an increased 	Risk for new clinical sequelae after acute covid-19 rarely differed between men and women, apart from fatigue and anosmia (more commonly diagnosed in women)

risk of developing new clinical sequelae, in comparison to control groups-				
Makaronidis J²¹, UK	Invitation of people with acute loss of smell/taste through primary care centers (recruitment via online platform). Serology assessment.	Smell/taste disorders at 4-6 weeks after onset	Adjusted analysis (age, ethnicity, patterns of smell loss and smoking) for the risk of persistent smell loss (aOR; 95CI): <ul style="list-style-type: none"> • Female sex 2.46 (1.47-4.13) • Presence of parosmia 2.47 (1.54-4.00) 	Age was not recognised as a risk factor 0.99 (1.01-1.03)
Ghosn J²⁹, France	Patients who were hospitalised were assessed through physician visits 3 and 6 months after hospital admission.	Ongoing self-reported symptoms within a list of 10 symptoms at 3 and 6 months after hospital admission	Adjusted analysis for the risk of having 3 or more symptoms at 6 months follow-up (aOR; 95CI): <ul style="list-style-type: none"> • Female sex 2.40 (1.75-3.30) • ≥ 3 symptoms at admission 2.04 (1.45-2.89) • ICU admission at the acute phase 1.55 (1.09-2.18) 	Comorbidities and age were not associated with the presence of symptoms at 6 months in univariate analysis
Romero-Duarte A³², Spain	Data retrieved from follow-up consultation (primary care and hospital specialities) and periodic telephonic reports	Self-reported symptoms at any time after hospital discharge at any time during 6 months follow-up, hospital readmission, return to the emergency services and death	Adjusted analysis for return to emergency services (aOR, 95CI): <ul style="list-style-type: none"> • Persistent fever 2.23 (1.18-4.19) • Thoracic pain 2.55 (1.33-4.90) • Anosmia/dysgeusia 0.28 (0.10-0.74) • Arrhythmia or palpitations 3.08 (1.21-7.79) • Superinfection 1.90 (1.05-3.42) • Pneumonia 7.65 (1.27-45.97) • Dermatological symptoms 1.75 (1.01-3.03) Adjusted analysis for hospital readmission: <ul style="list-style-type: none"> • Persistent fever 8.31 (2.31-29.89) • Nephrological disorders 6.49 (1.50-21.14) • Superinfection 3.14 (1.05-9.40) • Pneumonia 11.81 (1.40-99.39) 	
Augustin M³⁰, Germany	Follow-up medical visits at month 4 and 7 months after acute infection (PCR confirmed), regardless of symptoms	Assessment of long-lasting symptoms with systematic questionnaires	Adjusted analysis for the risk to develop long-term symptoms (aOR, 95CI)*: <ul style="list-style-type: none"> • Lower baseline level of SARS-CoV-2 IgG 1.90 (1.13-3.18) • Number of symptoms 1.29 (1.08-1.55) • Male gender 0.59 (0.36-0.98) 	

			*We observed a difference between odds ratio mentioned in the text and the tables. We are awaiting author's reply.
Menges G³³, Switzerland	Inclusion through contact tracing of the Department of Health, based on mandatory laboratory reporting of all individuals diagnosed with SARS-CoV-2 (PCR)	Assessment of recovery and long-lasting symptoms through electronic questionnaire at 6 to 8 months after diagnosis and assessment of fatigue, dyspnoea, depression by using appropriate scales (FAS mMRC,DASS-21)	<p><u>Adjusted analysis for not having recovered at 6 to 8 months (aOR, 95CI):</u></p> <ul style="list-style-type: none"> • Severe symptoms during acute illness 2.05 (1.27-3.34) • Comorbidities 2.08 (1.24-3.50) • Male gender 0.53 (0.33-0.85) <p><u>Adjusted analysis for fatigue at 6 to 8 months (aOR, 95CI):</u></p> <ul style="list-style-type: none"> • Age group: 18-35 ref; 40-64 0.59 (0.39-0.91); ≥ 65 0.41 (0.21-0.78) <p><u>Adjusted analysis for dyspnea at 6 to 8 months (aOR, 95CI):</u></p> <ul style="list-style-type: none"> • Male gender 0.45 (0.26-0.76) • Hospitalisation 4.17 (2.23-7.91) • BMI 1.14 (1.08-1.20) • Comorbidities 2.71 (1.38-5.36)

Legend: aOR: adjusted odds ratio; AUC: area under the curve; BMI: Body mass index; 95CI: 95% confidence interval; DASS-21: Depression Anxiety and Stress Scale 21; ED: emergency department; FAS: Fatigue Assessment Score; ICU: Intensive care unit; mMRC modified medical research Council; OR: odds ratio

7 DISCUSSION

7.1 Main findings

The current body of evidence about the epidemiology of long COVID is still limited. There is a huge variation of the reported prevalence and no data robust enough is available to determine patients at risk for developing long COVID. The largest and more robust study up to now is the survey from UK ONS that allows to conclude that at least 13.7% continue to report symptoms after 12 weeks.

Our results are in line with a recent review from the UK National Institute for Health Research (NIHR) that outlined the high variability in reported prevalence and the absence of reliable evidence for risk factors.³⁶

Since our previous preliminary report published in January 2021, results have changed in the light of newly published evidence. For patients who were not hospitalised during acute COVID-19, long COVID prevalences slightly increased for both periods ranging from 1 to 3 months and beyond. In the first preliminary report, the range of long COVID prevalence up to 3 months was 5 to 36% and remained at the level. Similarly, prevalences rates beyond 3 months ranged from 2 to 15% and ranges now from 2 to 21%. Likewise, we noticed that prevalences are higher in patients who were initially hospitalised and could still reach 68% beyond 3 months. New studies with longer follow-up durations are now available and report that prevalence is still above 10% and up to 25%. The most frequently reported symptoms did not substantially change. Finally, new studies on the potential risk factors have been published.

7.2 Limitations of available evidence

The included studies suffer from several shortcomings:

- First, the definition of long COVID is still heterogeneous and this can give rise to difficulties when trying to synthesise information:
 - There is currently emerging evidence that long COVID encompasses distinct phenotypes (or clusters of symptoms) that can overlap and evolve over time.^{11, 12} For instance, people can experience exclusively cognitive disorders, while others will present only respiratory symptoms. However, it should be noted that studies widely report on symptoms that are considered regardless of their phenotype or whether they are related to distinct causes and permanent organ damage.
 - People may indeed experience symptoms possibly related to organ damage (cf: [preliminary report on pathophysiology-May 2021](#)). For instance, pulmonary sequelae can arise after prolonged mechanical ventilation in critically-ill patients. This gives rise to many difficulties in accurate diagnosis. Current evidence does not clearly allow to distinguish between the symptoms following organ damage from those unrelated to organ damage. Both types of symptoms are included in studies regardless if this distinction.

Moreover, determining the extent to which symptoms are specifically related to COVID-19 remains challenging. According to the available evidence, the distinction between patients who suffered from organ damage because of interventions at the hospital (or a worsening of preexisting comorbidities) and another causes cannot be made. This overlap contributes to the observed heterogeneity and illustrates that long COVID relates to several conditions.

Hence, the higher prevalence of symptoms observed in patients who were hospitalised could potentially be related to higher likelihood to develop organ impairment when the disease is severe. This emphasises the fact that this particular subset of patients with long-lasting symptoms may represent a different phenotype of the long COVID entity. In this way, the entity of long COVID can partially overlap with other issues such as post-intensive care syndrome, for instance.

Other studies that were not selected in our systematic review observed a similar trend. For instance, a short survey conducted in the UK by the NIHR reported this difference according to the hospitalisation status (it was not included in the review because results were not described in detail).³⁶ Nearly a third of those who were not hospitalised experienced at least one enduring symptoms at one month and still 10% after three months. For those who were admitted to the hospital, between 50 and 89% had at least one remaining symptom after two

months.³⁶ Similarly, a study conducted in China, that was excluded from our analysis for country exclusion, showed that 76% of discharged patients reported at least one symptom at 6-month follow-up.³⁷ Another study, also excluded from our analysis for limited sample size, identified a high proportion (51.6%) of respiratory damages (diffusion capacity) after hospital discharge.³⁸

- The severity of persistent symptoms following COVID-19 may also differ. The study from Ayoukhani et al., for example, emphasised that hospital discharged patients had an increased risk of multi-organ dysfunctions.¹⁸ Daugherty et al. retrospectively showed in a cohort of patients who were predominantly not hospitalised that the risk for new clinical problems requiring medical care was also high in this group.³¹

Conversely, another recent nationwide cohort study in Denmark estimated that the risk of severe complications was low in COVID-19 who did not require hospital admission. By comparing with non-COVID-19 matched subjects, the authors showed that the risk of receiving one of 25 selected new hospital diagnoses within 6 months after infection, or the risk of initiating a new drug therapy was low. Only the risk of venous thromboembolism, receiving a hospital diagnosis of dyspnoea, initiating new drugs (bronchodilator therapy or triptans) were slightly increased. It may be noted that this study mainly focused on patients who did not experience severe COVID-19 and that the prevalence could be underestimated since they reported on symptoms that led to hospital encounter.³⁹

- The question of knowing whether and to what extent all reported symptoms are excess symptoms in comparison with other infectious diseases, could also be addressed. Similar multi-organ long-term consequences have been reported after other types of coronaviruses or other viral or bacterial infections.^{40, 41} Nevertheless, those symptoms were not so precisely and longitudinally assessed as for long COVID, and no clear conclusion can be drawn, up to now.
- In the same line, it is very difficult to ascertain that symptoms are typical for long COVID or if they would have occurred anyway. Similarly, for health conditions already existing before COVID-19 (e.g. mental health disorders), there is no possibility to distinguish a relapse that would have occurred independently of the infection or really a specific long COVID symptom. In the same vein, symptoms pre-existing before COVID-19 are not mentioned in studies. However, the UK-ONS survey included a control group of people with the same age and sex profile as those tested positive for SARS-CoV-2, but who were unlikely to have been infected. Reported symptoms were significantly height fold lower in the control group (prevalence of symptoms at 5 weeks at 2.8% and 1.7% at 12 weeks).
- Second, there are also variations across the studies regarding the targeted patient populations:
 - Study populations were markedly differed in terms of severity of the level of care at the acute phase and hospitalisation. Our analyse retrieved studies with a high proportion of hospitalisation (including ICU admission) along with studies with less than 10% hospitalisation or exclusively ambulatory patients. Moreover study populations included COVID-19 confirmed (PCR, antibodies) cases as well as non-confirmed cases (highly suspected clinically and/or radiologically; self-reported). Reporting a general prevalence is not reliable enough with such a high heterogeneity.
 - Moreover, demographic variables, health conditions and risk factors for long COVID also vary among studies. The ONS-update of April 2021 identified that prevalence was greatest among people aged 35 to 69 years, females, and those with a pre-existing activity-limiting health condition.¹² We noticed, in this review, that people who were hospitalised were likely to be older probably because older patients were more severely ill. Evidence on the female gender as a risk factor seems still limited and the impact of chronic comorbidities is poorly considered across studies.
 - Sample sizes, time of inclusion and follow-up duration of studies vary widely. Although we only selected studies with a sample size of at least 250 COVID-19 cases, the studies included for risk factors report a lack of power for multivariate analysis and state that the lack of significance should not be taken for a lack of association. It should also be noted that follow-up is more precise for hospital discharged patients since some studies proposed multidisciplinary follow-up clinics.

- Variability of time of inclusion (after infection confirmation, after onset of symptoms, after hospital discharge), follow-up duration and important loss to follow-up are hurdles to correctly estimate long COVID prevalence.
- Studies are prone to several bias. Most studies are based on self-reported symptoms and this may lead to recall biases and cause misclassification. The use of a COVID app and an online survey to recruit patients may also result in a selection bias. One study, for instance, reported an under-representation of male and elderly patients.¹¹ Besides, those with more severe illness might have been less likely to enter data in the app, and this may result in an underestimation of the prevalence.¹¹ However, it is also likely that those experiencing persistent symptoms will be more likely to participate in studies. Conversely, some studies organised a structured assessment through medical visits and through the use of appropriate and objective measurements tools. Overall, those studies mainly included emergency or hospital-discharged patients.^{10, 23, 28}

Recruitment bias was observed in studies that assessed the olfactory disorders in which only those who reported smell or taste disorders were followed-up. It is likely that prevalence was overrated.

Furthermore, the lack of control group in many studies can lead to an overestimation of prevalence.

- Due to the nascent nature of COVID-19, physicians might have underestimated and overlooked the long COVID symptoms early in the pandemic. Moreover, testing was not available at the beginning of the pandemic making difficult to associate the complaint of non-tested patients with COVID-19. Besides, since testing is often required in studies and was initially limited to hospitalised people, this can account for a selection bias for the patients infected during the first wave of the pandemic.
- Few studies report on patients who remained without symptom at the acute phase. This is a limitation and may also bias the estimation of prevalence.

7.3 Limitations of this review

This review has several limitations:

- First, due to our strict selection criteria and our distinction between prevalence of long COVID (or symptom) and symptom frequency, our conclusions may differ from other reviews that include studies from any setting, with a lower sample size, and which report risk factors identified in non-adjusted analyses as well, or studies not comparing long COVID to short COVID.
- Second, seeing the urgent need for identifying evidence, critical appraisal was not undertaken in this review and articles still under reviewing were included. The appraisal of the quality of evidence will be performed in the final version.
- Third, interpretation of results is limited by our inclusion criteria since we include only studies from Europe and US. Risk factors and comorbidities can considerably vary also within the countries that we selected.
- Data on unemployment, sick-leave or disability leave (See Consequences on daily-life) may considerably be influenced by the laws of each country and will have to be interpreted with great caution.
- We did not analyse whether our conclusion varied from the conclusions of studies with smaller sample sizes.

Limitations for the assessment of long COVID prevalence and risk factors

- **Variability in the definition of long COVID across studies:**
 - **Symptom pattern variability**
 - **Permanent organ damage as sequelae of the acute phase, or not**
 - **Severity of persistent symptoms and requirement for hospital admission**
 - **Difficulty in knowing to what extent long COVID symptoms are excess symptoms**
 - **Difficulty in accurate diagnosis (preexisting symptoms and role of comorbidities)**
- **Heterogeneity of targeted populations:**
 - **Severity and level of care of acute infection (ambulatory, hospitalisation, need for ICU admission)**
 - **Characteristics and risk factors of studied populations**
 - **Sample sizes variability**
- **Variability of study design: time of inclusion and follow-up duration and large loss to follow-up**
- **High risk of recall bias (self-reporting; no objective measurement) and lack of control group in most studies**
- **Underestimation in people who were infected during the first wave of pandemic and were not tested**
- **Few data on long COVID is available in patients who had asymptomatic infection**

7.4 Perspectives

- More research is needed on the characterisation and classification of long COVID symptoms. To this end, a distinction would have to be made between long COVID symptoms and post-COVID conditions that refers for the most part to symptoms related to organ damage (and post-intensive care syndrome) and not necessarily specific to COVID-19. This would allow a better definition and characterization of subgroups. Adequately defining long COVID would guide more efficiently the future research on treatments and the management.
- Since there is now evidence that long COVID symptoms fluctuate over time, further studies should always promote assessments at different time points.
- In order to minimise recall bias, newly conducted studies should assess symptoms during medical visits and by using appropriate and validated tools such as spirometry, cardiac echography or validated measurement scales. This approach could probably reduce the heterogeneity of reported prevalences. Since long COVID symptoms might overlap with other issues and seeing that it is not uncommon to present long-lasting symptoms after some infections, a control population should be included in the experimental design.
- Determining long COVID prevalences within each level of severity would harmonise the results.
- Research on the underlying causes of long COVID would certainly help to better classify complaints and provide new insights on how to prevent and manage it.
- Looking ahead, more research is needed on the effect of vaccination on long COVID evolution.

■ REFERENCES

1. Anonymous. COVID-19 rapid guideline: managing the long-term effects of COVID-19. Review. NICE; 2020 2020-12-18. NICE Guideline (NG188) Available from: <https://www.nice.org.uk/guidance/ng188>
2. National Center for Immunization and Respiratory Diseases (NCIRD) Division of Viral Diseases. Post-COVID Conditions [Web page]. Centers for Diseases Control and Prevention;2021 [updated 2021-04-08; cited 2021-05-21]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html>
3. Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care. 2015;19:274.
4. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: An Overview and Approach to Classification. Open forum infectious diseases. 2020;7(12):ofaa509.
5. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200-4.
6. Goertz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ open research. 2020;6(4).
7. Vaes AW, Machado FVC, Meys R, Delbressine JM, Goertz YMJ, Van Herck M, et al. Care Dependency in Non-Hospitalized Patients with COVID-19. J Clin Med. 2020;9(9).
8. Cellai M, O'Keefe JB. Characterization of Prolonged COVID-19 Symptoms in an Outpatient Telemedicine Clinic. Open forum infectious diseases. 2020;7(10):ofaa420.
9. Cirulli E, Schiabor Barrett K, Riffle S, Bolze A, Neveux I, Dabe S, et al. Long-term COVID-19 symptoms in a large unselected population. medRxiv (preprints). 2020.
10. Moreno-Perez O, Merino E, Leon-Ramirez JM, Andres M, Ramos JM, Arenas-Jimenez J, et al. Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study. The Journal of infection. 2021.
11. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-31.
12. Ayoubkhani D. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. Office for National Statistics (ONS); 2021 2021-04-01. Statistical bulletin Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021/pdf>
13. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'Em Y, et al. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. SciLit (preprints). 2020.
14. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain, behavior, and immunity. 2020;89:594-600.
15. Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The lancet. Psychiatry. 2021;8(2):130-40.
16. Villarreal IM, Morato M, Martinez-RuizCoello M, Navarro A, Garcia-Chilleron R, Ruiz A, et al. Olfactory and taste disorders in healthcare workers with COVID-19 infection. Eur Arch Otorhinolaryngol. 2020.
17. Tenforde MW, Billig Rose E, Lindsell CJ, Shapiro NI, Files DC, Gibbs KW, et al. Characteristics of Adult Outpatients and Inpatients with COVID-19 - 11 Academic Medical Centers, United States, March-May 2020. MMWR Morb Mortal Wkly Rep. 2020;69(26):841-6.

18. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T, Humberstone B, Diamond SI, et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. *BMJ.* 2021;372:n693.
19. Bliddal S, Banasik K, Pedersen OB, Nissen I, Cantwell L, Schwinn M, et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. *SciLIT* (preprints). 2021.
20. Lechien J, Chiesa-Estomba C, Beckers E, Mustin V, Ducarme M, Journe F, et al. Prevalence and 6-month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients. *J Intern Med.* 2021.
21. Makaronidis J, Firman C, Magee C, Mok J, Balogun N, Lechner M, et al. Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: A community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in people with and without SARS-CoV-2 antibodies in London, UK. *Research Square* (preprints). 2021.
22. Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, et al. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. *Ann Am Thorac Soc.* 2021;18(5):799-806.
23. Venturelli S, Benatti SV, Casati M, Binda F, Zuglian G, Imeri G, et al. Surviving COVID-19 in Bergamo Province: a post-acute outpatient re-evaluation. *Epidemiology and infection.* 2021;1-25.
24. Chiesa-Estomba CM, Lechien JR, Radulesco T, Michel J, Sowerby LJ, Hopkins C, et al. Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. *Eur J Neurol.* 2020;27(11):2318-21.
25. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. *JAMA.* 2021.
26. Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F, et al. COVID-19 Symptoms: Longitudinal Evolution and Persistence in Outpatient Settings. *Ann Intern Med.* 2020.
27. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. *Lancet Psychiatry.* 2021;8(5):416-27.
28. Writing Committee for the CSG, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. *JAMA.* 2021;325(15):1525-34.
29. Ghosn J, Piroth L, Epaulard O, Le Turnier P, Mentré F, Bachelet D, et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. *Clinical Microbiology and Infection.* 2021.
30. Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. *Lancet Reg Health Eur.* 2021;6:100122.
31. Daugherty SE, Guo Y, Heath K, Dasmarinas MC, Jubilo KG, Samranvedhya J, et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. *BMJ.* 2021;373:n1098.
32. Romero-Duarte A, Rivera-Izquierdo M, Guerrero-Fernandez de Alba I, Perez-Contreras M, Fernandez-Martinez NF, Ruiz-Montero R, et al. Sequelae, persistent symptomatology and outcomes after COVID-19 hospitalization: the ANCOHVID multicentre 6-month follow-up study. *BMC Med.* 2021;19(1):129.
33. Menges D, Ballouz T, Anagnostopoulos A, Aschmann H, Domenghino A, Fehr J, et al. Burden of Post-COVID-19 Syndrome and Implications for Healthcare Service Planning: A Population-based Cohort Study. *medRxiv* (preprints). 2021.

34. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. *Thorax*. 2020.
35. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. *Thorax*. 2020.
36. Maxwell E, Poole R, Oustric P. Living with COVID-19: A dynamic review of the evidence around ongoing Covid19 (often called Long Covid). National Institute for Health Research (NIHR) Centre for Engagement and Dissemination (NIHR CED); 2021 2021-03-16. Themed Reviews (45225) Available from: <https://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review/>
37. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270):220-32.
38. Bellan M, Soddu D, Balbo PE, Baricich A, Zeppegno P, Avanzi GC, et al. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. *JAMA Netw Open*. 2021;4(1):e2036142.
39. Lund LC, Hallas J, Nielsen H, Koch A, Mogensen SH, Brun NC, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. *Lancet Infect Dis*. 2021.
40. Morroy G, Peters JB, van Nieuwenhof M, Bor HH, Hautvast JL, van der Hoek W, et al. The health status of Q-fever patients after long-term follow-up. *BMC Infect Dis*. 2011;11:97.
41. Lam MH, Wing YK, Yu MW, Leung CM, Ma RC, Kong AP, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. *Arch Intern Med*. 2009;169(22):2142-7.

■ APPENDICES

APPENDIX 1. SEARCH STRATEGY

Appendix 1.1. Research question and PEO


Project number	2020-04 HSR
Project name	Long COVID
Research question	Which putative pathophysiological mechanisms are likely to be involved in long COVID symptoms? Which pathophysiological mechanisms have been demonstrated in patients?
<i>Structured search question(s)</i>	
P (population)	chronic covid syndrome (CCS) chronic post-COVID-19 symptoms Chronicity AND COVID continuing complication COVID-19 survivors linger Long term cardiopulmonary Long term complications of COVID-19 long term effects of COVID-19 Long term glucometabolic long term neuropsychiatric long term symptoms of COVID-19 long-COVID long coronavirus long-haulers in COVID-19 long-lasting COVID symptoms long-SARS long-term consequences of COVID-19 long-term health consequences of COVID-19 Long-Term Sequelae of COVID-19 long tail COVID persistant COVID Post-COVID-19 syndrome post- corona post corono post-viral fatigue post discharge prolonged inflammatory status recurring COVID Coronavirus Infections* / complications
E (exposure)	COVID-19 confirmed (PCR, antibodies), or not
O (outcome)	Pathophysiological mechanisms likely to explain long COVID symptoms

Appendix 1.2. List of sources searched for studies

Source (Interface)	Set	Date of the search	Limits
Cochrane Database of Systematic Reviews		2021-02-03	none
JBI EBP Database	Current to January 13, 2021*	2021-02-03	none
MEDLINE (OVID)	Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to February 01, 2021>	2021-02-03	none
Embase (Embase.com)		2021-02-04	none
PsycInfo (OVID)	2002 to January Week 4 2021	2021-02-03	none
Econlit (OVID)	1886 to January 21,2021	2021-02-03	none
Ovid Nursing	1946 to January Week 4 2021	2021-02-03	none
scilit.net/		2021-02-04	none
europepmc.org/		2021-02-04	none
Journals@Ovid Full Text	February 01, 2021	2021-02-03	none
coronacentral.ai/	longhaul	2021-02-24	none

* Edition Jan 13, 2021

Appendix 1.3. Flow diagram



APPENDIX 2. DETAILS OF SEARCH STRATEGY IN EACH SOURCE

Appendix 2.1. Cochrane Database of Systematic Reviews

Date	03/02/2021
Database	Cochrane Database of Systematic Reviews Issue 2 of 12, February 2021
Strategy	388 Cochrane Reviews matching covid* in All Text OR sars-cov* in All Text OR ncov* in All Text OR "coronavirus disease 2019" in All Text OR "severe acute respiratory syndrome coronavirus 2" in All Text - (Word variations have been searched)

Appendix 2.2. JBI EBP Database

Date	03/02/2021
Database	JBI EBP Database - <Current to January 13, 2021> (OVID)
Strategy	<ol style="list-style-type: none"> 1 covid*.mp. (71) 2 sars-cov*.mp. (5) 3 ncov*.mp. (2) 4 "coronavirus disease 2019".mp. (4) 5 "severe acute respiratory syndrome coronavirus 2".mp. (3) 6 1 or 2 or 3 or 4 or 5 (72) 7 chronic*.mp. (2569) 8 complicat*.mp. (1824) 9 continu*.mp. (2616) 10 linger*.mp. (15) 11 long*.mp. (3160) 12 ongoing.mp. (745) 13 persist*.mp. (738) 14 post*.mp. (3172) 15 prolong*.mp. (687) 16 recurr*.mp. (619) 17 sequel*.mp. (146) 18 surviv*.mp. (942) 19 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (6057) 20 6 and 19 (66)

Appendix 2.3. Medline

Date	03/02/2021
Database	Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions(R) <1946 to February 01, 2021>
Strategy	<ol style="list-style-type: none"> 1 covid*.mp. (97304) 2 sars-cov*.mp. (41886) 3 ncov*.mp. (1693) 4 "coronavirus disease 2019".mp. (18515) 5 "severe acute respiratory syndrome coronavirus 2".mp. (39642) 6 1 or 2 or 3 or 4 or 5 (103558) 7 chronic*.mp. (1444607) 8 complicat*.mp. (3277182) 9 continu*.mp. (1141060) 10 linger*.mp. (2809) 11 long*.mp. (2360519) 12 ongoing.mp. (169115) 13 persist*.mp. (496696) 14 post*.mp. (2967850)

15	prolong*.mp. (391871)
16	recurr*.mp. (730089)
17	sequel*.mp. (79502)
18	surviv*.mp. (1492823)
19	7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (10257634)
20	6 and 19 (35486)
23	((covid* or sars-cov* or ncov* or "coronavirus disease 2019" or "severe acute respiratory syndrome coronavirus 2") adj2 (chronic* or complicat* or continu* or linger* or long* or ongoing or persist* or post* or prolong* or recurr* or sequel* or surviv*).mp. (4008)

Appendix 2.4. Embase

Date	04/02/2021		
Database	Embase (Embase.com)		
Strategy	#23. (covid* OR 'sars cov*' OR ncov* OR 'coronavirus disease 2019' OR 'severe acute respiratory syndrome coronavirus 2') NEAR/2 (chronic* OR complicat* OR continu* OR linger* OR long* OR ongoing OR persist* OR post* OR prolong* OR recurr* OR sequel* OR surviv*)	3,610	5 Feb 2021
	#19. #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18	13,426,644	5 Feb 2021
	#18. surviv*	2,044,038	5 Feb 2021
	#17. sequel*	105,703	5 Feb 2021
	#16. recurr*	1,094,799	5 Feb 2021
	#15. prolong*	546,789	5 Feb 2021
	#14. post*	4,472,700	5 Feb 2021
	#13. persist*	678,567	5 Feb 2021
	#12. ongoing	310,519	5 Feb 2021
	#11. long*	3,382,297	5 Feb 2021
	#10. linger*	3,759	5 Feb 2021
	#9. continu*	1,544,748	5 Feb 2021
	#8. complicat*	3,406,441	5 Feb 2021
	#7. chronic*	2,111,426	5 Feb 2021
	#6. #1 OR #2 OR #3 OR #4 OR #5	108,451	5 Feb 2021
	#5. 'severe acute respiratory syndrome coronavirus 2'	26,313	5 Feb 2021
	#4. 'coronavirus disease 2019'	84,404	5 Feb 2021
	#3. ncov*	1,746	5 Feb 2021
	#2. 'sars cov*' OR 'covid*'	33,477	5 Feb 2021
	#1. covid*		

Appendix 2.5. PsycInfo

Date	03/02/2021		
Database	APA PsycInfo (OVID) <2002 to January Week 4 2021>		
Strategy	1 covid*.mp. (3448) 2 sars-cov*.mp. (424) 3 ncov*.mp. (30) 4 "coronavirus disease 2019".mp. (375) 5 "severe acute respiratory syndrome coronavirus 2".mp. (80) 6 1 or 2 or 3 or 4 or 5 (3493) 7 chronic*.mp. (122042) 8 complicat*.mp. (39731) 9 continu*.mp. (200140) 10 linger*.mp. (1566)		

11	long*.mp. (362201)
12	ongoing.mp. (46047)
13	persist*.mp. (66335)
14	post*.mp. (331214)
15	prolong*.mp. (23205)
16	recurr*.mp. (29631)
17	sequel*.mp. (8593)
18	surviv*.mp. (70040)
19	7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (1006943)
20	6 and 19 (1487)
22	((covid* or sars-cov* or ncov* or "coronavirus disease 2019" or "severe acute respiratory syndrome coronavirus 2") adj3 (chronic* or complicat* or continu* or linger* or long* or ongoing or persist* or post* or prolong* or recurr* or sequel* or surviv*)).mp. (216)

Appendix 2.6. EconLit

Date	03/02/2021
Database	Econlit <1886 to January 21,2021> (OVID)
Strategy	1 covid*.mp. (1190) 2 sars-cov*.mp. (35) 3 ncov*.mp. (7) 4 "coronavirus disease 2019".mp. (13) 5 "severe acute respiratory syndrome coronavirus 2".mp. (2) 6 1 or 2 or 3 or 4 or 5 (1208) 7 chronic*.mp. (3250) 8 complicat*.mp. (5581) 9 continu*.mp. (46703) 10 linger*.mp. (311) 11 long*.mp. (137530) 12 ongoing.mp. (7085) 13 persist*.mp. (26176) 14 post*.mp. (64415) 15 prolong*.mp. (1966) 16 recurr*.mp. (2551) 17 sequel*.mp. (203) 18 surviv*.mp. (13009) 19 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (271942) 20 6 and 19 (388) 21 ((covid* or sars-cov* or ncov* or "coronavirus disease 2019" or "severe acute respiratory syndrome coronavirus 2") adj5 (chronic* or complicat* or continu* or linger* or long* or ongoing or persist* or post* or prolong* or recurr* or sequel* or surviv*)).mp. (79)

Appendix 2.7. Ovid Nursing Database

Date	03/02/2021
Database	Ovid Nursing Database <1946 to January Week 4 2021>
Strategy	1 covid*.mp. (3574) 2 sars-cov*.mp. (1683) 3 ncov*.mp. (18) 4 "coronavirus disease 2019".mp. (490) 5 "severe acute respiratory syndrome coronavirus 2".mp. (192) 6 1 or 2 or 3 or 4 or 5 (3702) 7 chronic*.mp. (61219) 8 complicat*.mp. (106625) 9 continu*.mp. (80457)

-
- 10 linger*.mp. (208)
 11 long*.mp. (77301)
 12 ongoing.mp. (10190)
 13 persist*.mp. (12631)
 14 post*.mp. (117838)
 15 prolong*.mp. (10585)
 16 recurr*.mp. (14127)
 17 sequel*.mp. (3144)
 18 surviv*.mp. (27822)
 19 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (386772)
 20 6 and 19 (995)
 22 ((covid* or sars-cov* or ncov* or "coronavirus disease 2019" or "severe acute respiratory syndrome coronavirus 2") adj3 (chronic* or complicat* or continu* or linger* or long* or ongoing or persist* or post* or prolong* or recurr* or sequel* or surviv*).mp. (176)
-

Appendix 2.8. SciLit

Date	04/02/2021
Database	https://www.scilit.net/
Strategy	Long covid (all fields, lim preprint) (2416)

Appendix 2.9. EuropePMC

Date	04/02/2021
Database	europepmc.org/
Strategy	1 ("long covid") AND (SRC:"PPR") (91) 2 ("long-term covid") AND (SRC:"PPR") (41) 3 ("post covid") AND (SRC:"PPR") (750)

Appendix 2.10. Journals@OVID

Date	03/02/2021
Database	Journals@Ovid Full Text <February 01, 2021>
Strategy	1 covid*.mp. (42367) 2 sars-cov*.mp. (14758) 3 ncov*.mp. (1329) 4 "coronavirus disease 2019".mp. (10761) 5 "severe acute respiratory syndrome coronavirus 2".mp. (6991) 6 1 or 2 or 3 or 4 or 5 (45309) 7 chronic*.mp. (1597003) 8 complicat*.mp. (1559894) 9 continu*.mp. (2717400) 10 linger*.mp. (17981) 11 long*.mp. (3398881) 12 ongoing.mp. (637263) 13 persist*.mp. (1008457) 14 post*.mp. (3285408) 15 prolong*.mp. (785079) 16 recurr*.mp. (846402) 17 sequel*.mp. (159911) 18 surviv*.mp. (1431049) 19 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (6330977) 20 6 and 19 (36718) 25 (long adj2 covid*).mp. (314)

Appendix 2.11. CoronaCentral

Date	24/02/2021
Database	https://coronacentral.ai/longhaul
Strategy	"Filter" Long Haul (201)

Colophon

Title:	Epidemiology of Long COVID: a preliminary report
Authors:	Diego Castanares-Zapatero, Patrice Chalon, Koen Van den Heede
Reviewers:	Brecht Devleesschauwer (Sciensano), Jean Yombi (UCLouvain), Nathalie Lorent (UZ Leuven), Karin Rondia (KCE), Rik Gosselink (UZ Leuven) Sarah Wolf (Austrian Institute for Health Technology Assessment)
At the request of:	LUSS (Ligue des Usagers des services de santé)
Disclaimer:	This document is a rapid review of scientific literature retrieved from several publicly funded COVID-19 resource collections. The literature included in these repositories is not always peer-reviewed or externally validated. KCE synthesised the evidence in short time frames to respond to urgent questions and could therefore not follow its regular methodological procedures. This work is used to inform guidance of other governmental agencies (like Sciensano, CSS/HGR, AFMPS/FAGG and SPF/FOD).
Publication date:	21 June 2021
Legal depot:	D/2020/10.2733/16
ISSN:	2684-5830
Copyrights:	KCE reports are published under a "by/nc/nd" Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce-publications .

